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ABSTRACT 
Jenna Lee Jewell 
REGULATION OF EXOCYTOSIS BY SYNTAXIN 4-MUNC18C COMPLEXES 
Type 2 diabetes involves defects in glucose-stimulated insulin secretion 
(GSIS) from the pancreatic beta cells in combination with defects in peripheral 
(muscle and adipose) tissue glucose uptake.  Both GSIS and glucose uptake are 
regulated by Syntaxin 4 (Syn4)-Munc18c complexes.  Importantly, reports link 
obesity and Type 2 diabetes in humans with changes in protein levels of 
Munc18c and Syn4; yet the molecular mechanisms underlying this requirement 
remain unclear.  The central hypothesis proposed is that Syn4-Munc18c 
complexes are modulated by post-translational modifications and novel 
interactions.  Toward this, we found that Syn4-Munc18c complexes are regulated 
by tyrosine phosphorylation of Munc18c at Y219 in beta cells.  Munc18c tyrosine 
phosphorylation disrupts Syn4-Munc18c complexes, which leads to an increase 
in Munc18c associating with the double C2 domain protein Doc2β.  Disruption of 
Syn4-Munc18c upon tyrosine phosphorylation results in an increase in Syn4-
SNARE complex formation and GSIS from beta cells.  Similarly, tyrosine 
phosphorylation of Munc18c at Y219 and also Y521, disrupts its association with 
Syn4 in insulin-stimulated 3T3L1 adipocytes and skeletal muscle.  In vitro kinase 
assays further suggested that the insulin receptor tyrosine kinase targeted Y521 
of Munc18c.  Further investigations using 3T3L1 adipocytes and skeletal muscle 
extracts indicate that Munc18c interacts with the insulin receptor tyrosine kinase 
in an insulin-dependent manner, resulting in phosphorylation of Munc18c, 
coordinate with the timing of its dissociation from Syn4.  Finally, we found that 
stimulus-induced changes occurred also with Syn4, most notably in the islet beta 
cells.  Syn4-mediated insulin release requires F-actin remodeling to mobilize 
insulin granules to the plasma membrane.  Our studies reveal that Syn4 directly 
associates with F-actin in MIN6 beta cells, and that the disruption of this complex 
correlates with increases in glucose-stimulated insulin secretion.  Future studies 
will focus upon the potential link between Syn4, F-actin remodeling with Munc18c, 
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to further gain understanding of the requirements for Syn4-Munc18c complexes 
in insulin secretion.  In sum, given the parallels of Munc18c tyrosine 
phosphorylation in regulating Syn4-Munc18c interaction and exocytosis in beta 
cells and peripheral tissues, manipulations of this complex may have therapeutic 
potential as a strategy to treat Type 2 diabetes. 
 
Debbie C. Thurmond, Ph.D. -Chair 
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insulin release and glucose uptake: conserved roles for Munc18c and syntaxin 4.  
Am J Physiol Regul Integr Comp Physiol., 298:R517-31. 
Author Contributions:  Tables and some text were generated by Oh E.  Jewell JL 
produced the majority of text and Figures present in this chapter. 
1 
Diabetes is a condition characterized by high blood sugar (glucose) levels 
that result from defects in insulin secretion, action, or both.  There are three 
major forms of diabetes: Type 1, Type 2, and gestational diabetes.  According to 
the American Diabetes Association as of 2007, 23.6 million people in the United 
State have diabetes.  However, out of the 23.6 million it is estimated that 5.7 
million people still remain undiagnosed.  In 2006, diabetes was reported as the 
seventh leading cause of death in the United States.  Diabetes is also the leading 
source of adult blindness, nerve damage, kidney disease, and lower-limb 
amputation (3).  Type 2 diabetes represents 90-95% of all cases, and is caused 
by a combination of genetic and non-genetic factors which results in insulin 
secretion defects in the pancreas and insulin resistance in the muscle and 
adipose tissue (3).  Some of the non-genetic factors that influence Type 2 
diabetes include increasing age, obesity, and physical inactivity (3).  Type 1 
diabetes, also referred to juvenile diabetes, represents 5-10% of all cases that 
results from autoimmune destruction of the insulin-secreting beta cells, leading to 
hyperglycemia.  Gestational diabetes represents approximately 3-5% of cases, 
and occurs in pregnancies when hormones from the placenta counteract insulin 
action in the mother.  Mothers with gestational diabetes have a 63% increase in 
their risk of developing Type 2 diabetes later in life, therefore interventions could 
be extremely useful for this population (4).  Thus, by understanding the 
mechanisms involved in regulating the coordination of whole body glucose 
homeostasis we may begin to develop therapeutic strategies to prevent or treat 
patients who suffer from diabetes. 
 
1.1 COORDINATION OF WHOLE BODY GLUCOSE HOMEOSTASIS 
Circulating blood glucose levels are tightly regulated in mammals and are 
maintained at about 5 mM (~80-100 mg/dL).  Following intake of high-
carbohydrate food, blood glucose levels rise to approximately 8 mM (~120-140 
mg/dL), which under normal homeostatic circumstances induces the pancreas to 
secrete insulin from the beta cells within the Islets of Langerhans.  This release 
of insulin subsequently signals to the liver to reduce glucose output while 
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simultaneously inducing clearance of excess glucose from the blood by the 
skeletal muscle and adipose tissue.  Normally, this process restores the blood 
glucose levels to 5 mM within 2 hours after the meal.  However during 
pathological progression from normal to clinically-defined Type 2 Diabetes, there 
are clear and progressive aberrations in both insulin secretion as well as glucose 
uptake/clearance mechanisms.  Given that a significant number of proteins 
required for insulin secretion and glucose clearance are identical, alterations in 
their abundance and/or function would materially impact both mechanisms and 
increase susceptibility to aberrant glucose homeostasis.  
 
1.2 SNARE-MEDIATED EXOCYTOSIS 
The SNARE (soluble N-ethylmaleimide sensitive factor attachment protein 
receptor) core complex is composed of three proteins in a heterotrimeric 1:1:1 
ratio:  1) Syntaxin, a 35 kDa protein containing an N-terminal regulatory domain, 
a C-terminal SNARE domain, and a C-terminal transmembrane domain 
anchoring it to the plasma membrane (PM); 2) SNAP23 or SNAP25, two 
complementary isoforms that lack transmembrane domain anchors but localize to 
the PM due to palmitoylated cysteine residues; and 3) VAMP2 (also known as 
synaptobrevin), an 18 kDa protein containing a C-terminal transmembrane 
domain anchoring it to the vesicle membrane.  As depicted in Figure 1-1, the 
vesicle (v-) SNARE VAMP2 pairs with the two target PM (t-) SNAREs Syntaxin 
and SNAP23/25 forming the SNARE core complex.  Together, the three SNARE 
proteins produce a stable bundle of the four α-helices, with one α-helix from 
VAMP, one from Syntaxin, and the remaining two from SNAP23/25 [reviewed in 
(5)].  This complex is remarkably SDS-resistant once formed.  To date, 6 v-
SNARE isoforms and 11 t-SNARE isoforms have been identified in cell types 
relevant to insulin secretion and insulin action (Table 1-1).  Interestingly, the 
underlying vesicle/granule exocytosis events of insulin secretion and glucose 
uptake share numerous commonalities with those of neuronal synaptic vesicle 
exocytosis (Table 1-2).  Glucose-stimulated insulin secretion (GSIS) from the 
pancreatic beta cell and glucose uptake in the muscle and adipose are both 
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mediated by the same SNARE protein isoforms:  Syntaxin 4, SNAP23 and 
VAMP2 [reviewed in (6,7)].  Additionally, beta cells use t-SNARE isoforms 
Syntaxin 1 and SNAP25 to mediate the first-phase of insulin secretion (8).  
However, key differences exist which distinguish the specialization of events in 
each cell type (summarized in Table 1-2). 
 
1.3 INSULIN GRANULE EXOCYTOSIS 
Elevated post-prandial glucose levels trigger a signaling cascade in the 
pancreatic islet beta cells to elicit insulin release (Figure 1-2), depicted as an ~8-
step process [reviewed in (35,36)].  First, glucose entry into beta cells is 
facilitated via the plasma membrane-localized glucose transporter, GLUT2.  
GLUT2 has a relatively low affinity (KM ~30 mM) for glucose, is constitutively 
present within the plasma membrane, and does not require SNARE proteins for 
translocation and membrane localization.  Following GLUT2-facilitated uptake, 
glucose is phosphorylated by glucokinase to generate glucose-6-phosphate, 
which is subsequently metabolized via mitochondrial oxidative phosphorylation to 
effect an increase in intracellular ATP:ADP ratio (step 2).  Elevated beta cell ATP 
levels induce closure of ATP-dependent potassium channels (step 3), resulting in 
cell depolarization (step 4) and an influx of calcium ions (Ca2+) through voltage-
dependent calcium channels (step 5) to yield a net increase in the intracellular 
Ca2+ concentration ([Ca2+]i; step 6).  The increase in [Ca2+]i signals SNARE 
complex formation (step 7) to facilitate insulin release from the granules (step 8), 
although the precise mechanism(s) by which Ca2+ triggers granule fusion 
remains somewhat unresolved.  
 Insulin secretion occurs in pulsatile fashion synchronized with Ca2+ 
influxes during two major phases, and is termed ‘biphasic’.  First-phase insulin 
secretion occurs within 5-10 minutes following beta cell stimulation.  Second-
phase is less robust than first-phase, but can be sustained for several hours if 
elevated blood-glucose levels persist (37-40).  These two phases of secretion are 
thought to utilize separate pools of insulin-containing granules.  First-phase 
secretion appears to arise from plasma membrane pre-docked granules, termed
 4
             
 
 
Figure 1-1 SNARE Core Complex Formation.  Upon stimulation, 
Syntaxin (orange) adopts an ‘open’ conformation exposing its H3 domain 
(also called the SNARE domain) to associate with SNARE domains from 
VAMP2 (red) and SNAP23/25 (green) to form the four α-helical bundle 
characteristic of the SNARE core complex. 
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Table 1-1 Expression of v- and t-SNARE Isoforms in Adipose, Skeletal Muscle 
and Pancreatic β-cells 
 
 Tissue 
(Localization) 
Function References 
v-SNARE    
VAMP2/Synaptobrevin  Pancreatic ‐cells, 
adipocyte, muscle (vesicles) 
Exocytosis of insulin 
granules (‐cells), GLUT4 
vesicles at the PM 
(9‐12) 
 
VAMP3/Cellubrevin 
 
Pancreatic ‐cells, 
adipocyte, muscle (vesicles) 
Exocytosis of insulin 
granules (‐cells), GLUT4 
vesicles at the PM 
(11‐14) 
 
VAMP4  Adipocyte, muscle (TGN)   ND  (12,15) 
VAMP5/myobrevin  Adipocyte, muscle (PM)  Myogenesis  (12,16) 
VAMP7/TI‐VAMP 
 
Adipocyte (PM, endosome)  Osmotic shock‐induced 
GLUT4 translocation 
(12) 
VAMP8/Endobrevin  Pancreatic ‐cells, 
adipocyte (endosome) 
GLUT4 endocytosis, insulin 
secretion (‐cells) 
(12,17) 
t-SNARE    
Syntaxin 1A  Pancreatic ‐cells (PM)  First phase insulin 
secretion in pancreatic ‐
cells 
(18‐20) 
 
Syntaxin 2/Epimorphin  Pancreatic ‐cells, 
adipocyte (PM) 
ND  (21‐23) 
Syntaxin 3  Pancreatic ‐cells, 
adipocyte (PM) 
ND  (14,23,24) 
Syntaxin 4  Pancreatic ‐cells, 
adipocyte, muscle (PM) 
Both phases of insulin 
secretion (‐cells), GLUT4 
translocation 
(9,21,25,26) 
Syntaxin 5  Adipocyte (TGN)  GLUT4 endocytosis in 
adipocyte 
(24) 
Syntaxin 6  Adipocyte, muscle (TGN)  Putative involvement in 
GLUT4 endocytosis 
(adipocytes) 
(27‐29) 
 
Syntaxin 7  Pancreatic ‐cells, 
adipocyte (endosome)  
ND  (27,30) 
Syntaxin 8  Adipocyte (endosome)   ND  (27) 
Syntaxin 10  Muscle  ND  (31) 
Syntaxin 12  Adipocyte  ND  (27) 
Syntaxin 16  Adipocyte (TGN)  GLUT4 intracellular 
trafficking 
(28) 
SNAP23  Pancreatic ‐cells, 
adipocyte, muscle (PM) 
Exocytosis of insulin 
granules (‐cells), GLUT4 
vesicles at the PM 
(32,33) 
 
SNAP25  Pancreatic ‐cells (PM)  Exocytosis of insulin 
granules (‐cells)
(34) 
ND, not determined; N/A, not applicable; PM, plasma membrane; TGN, trans 
golgi network; ER, endoplasmic reticulum 
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Table 1-2 Comparison of Exocytosis Events of Insulin Granules, GLUT4 Vesicles 
and Synaptic Vesicles 
 
Insulin Secretion 
 
GLUT4 Vesicle 
Translocation 
 
Neurotransmitter 
Release 
 
Large secretory 
granules 
(>100 nm radius) 
Large secretory granules 
(>100 nm radius) 
Small synaptic vesicles 
(<25 nm radius) 
 
Recycling via Golgi 
complex 
 
Recycling via Golgi complex 
 
Local recycling 
 
Two secretion phases: 
1
st fast (spans 6‐10 
min); 2nd, slow and 
sustained (10 min‐hrs) 
 
Slow (5‐15 min) and sustained 
 
Fast, short‐lasting secretion 
(0.1‐6 ms) 
 
Small number of 
predocked granules 
 
Few predocked vesicles 
 
Large number of predocked 
vesicles 
 
Exocytosis targeted to 
large plasma 
membrane section 
 
Exocytosis targeted to large 
plasma membrane section 
 
Exocytosis restricted to 
synaptic active zone 
 
Complex secretory 
mixes (e.g., multiple 
peptides, 
catecholamines, 
nucleotides) 
 
Cargo proteins to integrate into 
the plasma membrane 
 
Release of one or two low‐
molecular‐weight 
compounds 
 
SNARE isoforms:  
Syntaxins 1 and 4, 
SNAP23 and SNAP25, 
VAMP2  
 
SNARE isoforms:  Syntaxin 4, 
SNAP23, VAMP2  
 
SNARE isoforms:  Syntaxin 1, 
SNAP25, VAMP2  
 
SM isoforms:  
Munc18‐1, Munc18c 
 
SM isoform:  Munc18c 
 
SM isoform:  Munc18‐1 
 
Latrunculin 
potentiates secretion 
 
Latrunculin inhibits GLUT4 
translocation 
 
Latrunculin potentiates 
secretion 
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the ‘readily releasable pool’ (RRP), while second-phase secretion is believed to 
involve release from a granule pool deeper within the cell, the ‘storage-granule 
pool,’ which presumably replenishes the RRP (41,42).  In addition, KCl and other 
non-nutrient secretagogues can induce a first-phase type release, while only fuel-
type secretagogues, such as glucose, an produce a sustained second-phase 
insulin release (43).  First and second-phase release events also differ in their 
requisite SNARE protein isoforms.  First-phase insulin release utilizes Syntaxin 
1A, Syntaxin 4, SNAP25 or SNAP23, and the v-SNARE VAMP2, whereas 
second-phase secretion is managed by Syntaxin 4, SNAP25 or SNAP23, and 
VAMP2, but specifically not Syntaxin 1A (Table 1-3). 
 
1.4 GLUT4 VESICLE TRANSLOCATION 
Approximately 80% of homeostatic glucose clearance is handled by 
skeletal muscle, with the remainder by adipose and other insulin responsive 
tissues.  Skeletal muscle glucose clearance involves transduction of the 
extracellular insulin signal into intracellular signaling events to induce 
translocation of intracellular GLUT4 vesicles to the surface of muscle cell t-tubule 
and sarcolemmal membranes.  In this process, SNARE-regulated GLUT4 vesicle 
fusion is the most distal event [reviewed in (44-46)].  Under basal conditions, 
GLUT4 protein is localized to intracellular vesicles within cells, and unlike GLUT2, 
GLUT4 has a higher affinity for glucose (KM ~4 mM).  Insulin signaling to evoke 
GLUT4-mediated glucose clearance entails at least 11 steps, as modeled in 
Figure 1-3.  The process ensues with insulin binding to extracellular α-subunits of 
the insulin receptor (IR) present on the surface of muscle cells and adipocytes 
(step 1), inducing tyrosine autophosphorylation within the IR protein and 
increased kinase activity of the IR β-subunits (step 2).  Tyrosine 
autophosphorylation of the IR fosters recruitment of IR substrates, including the 
canonical Insulin Receptor Substrate (IRS), typically through a phosphotyrosine 
binding (PTB) domain.  Once bound, substrates are themselves tyrosine-
phosphorylated (step 3).  Phosphorylated receptor substrates then serve as 
additional recruitment targets for specific proteins containing Src Homology 2  
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Figure 1-2 Glucose-Stimulated Insulin Secretion from the Islet Beta Cell.  An 
8-step model:  (1) Glucose enters the cell through the constitutively active PM 
localized GLUT2 transporter and gets metabolized, which in turn (2) increases 
the ATP:ADP ratio resulting in (3) the closure of the ATP dependent potassium 
channels (KATP).  The closure of the KATP channels leads to (4) plasma 
membrane (PM) depolarization, (5) opening of the voltage-dependent calcium 
channels (VDCC), causing calcium influx into the cell (6).  As a result, 
intracellular calcium [Ca 2+]i levels rise, and through a largely uncharacterized 
series of events, the SNARE proteins mediate (7) vesicle fusion to facilitate (8) 
insulin release.  
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(SH2) domains, including phosphatidylinositide kinase (PI3-Kinase).  Once 
recruited, PI3-Kinase is activated to catalyze the phosphorylation of 
phosphatidylinositol (4, 5) bisphosphate (PIP2) at the 3’ position, yielding 
phosphatidylinositol (3, 4, 5) trisphosphate (PIP3) (step 4).  3-Phosphoinositide-
dependent kinase-1 (PDK-1) is able to recognize the 3’ position of PIP3 with its 
PH (Pleckstrin homology) domain and is recruited to the plasma membrane 
where it is activated (step 5).  At the plasma membrane, PDK-1 phosphorylates 
and activates AKT/PKB (also known as protein kinase B, step 6) along with 
atypical PKC isoforms zeta and lambda (aPKC).  As well-defined as these initial 
signaling steps are, the identities of downstream substrates/targets of these 
serine/threonine kinases which result in GLUT4 vesicle translocation remain 
unclear, although some recent progress has been made:  Akt signals 
downstream (step 7) to AS160 (a Rab GTPase-activating protein) (63), and 
AS160 signals downstream to multiple Rab targets (step 8) (64).  Rab proteins 
have been described in GLUT4-containing vesicles (step 9), and are presumed 
to facilitate their trafficking to/docking at the plasma membrane.  However, a gap 
exists in our understanding beyond this step to link to the SNARE complex at the 
plasma membrane:  t-SNARE isoforms Syntaxin 4 and SNAP23 with the v-
SNARE VAMP2 are known to be required for GLUT4 vesicles to fuse with the 
plasma membrane (step 10) to facilitate glucose uptake into the skeletal muscle 
cell (step 11).   
Independent of insulin, exercise and muscle contraction have also been 
shown to increase glucose uptake into skeletal muscle, although far less is 
known regarding the requirements and mechanisms of SNARE proteins in this 
process.  It is clear that exercise increases the translocation of GLUT4 and 
VAMP2 to the plasma membrane of human and rat skeletal muscle (65).  VAMP3 
was also initially implicated in contraction-stimulated GLUT4 translocation, but 
subsequent studies of skeletal muscle from VAMP3 (-/-) mice failed to support 
this role (58).  With the plethora of knockout mouse models of SNARE proteins 
now available, it is anticipated that the requirements and roles for these proteins 
in exercise-stimulated glucose uptake will be forthcoming. 
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Table 1-3 Genetically-engineered Mouse Models of SNARE Protein 
Ablation/Over-expression for Studies of Glucose Homeostasis In Vivo 
 
Genotype Aberration Phenotype References 
Syntaxin     
Syntaxin 1A (‐/‐) No Syntaxin 1A expression Fewer docked granules 
during only first phase of 
insulin secretion 
(19) 
 
Syntaxin 1B (‐/‐, open) Syntaxin 1B LE expression 
only, no endogenous 
ND (47) 
Syntaxin 1A (‐/‐), Syntaxin 
1B (‐/‐, LE) 
No Syntaxin 1A or 1B, LE 
mutant expression 
ND (47) 
Syntaxin 1A Tg Beta cell specific Syntaxin 
1A over‐expression, 
decreased Munc18‐1 
expression 
Fasting hyperglycemia, 
impaired glucose tolerance 
and insulin exocytosis 
(48) 
 
Syntaxin 4 (‐/+) Reduced Syntaxin 4 and 
Munc18c expression, null 
lethal 
Insulin resistant; reduced 
GLUT4 translocation; 
defective insulin secretion 
(26,49) 
 
Syntaxin 4 Tg Increased Syn4 and 
Munc18c expression in 
pancreas, skeletal muscle 
and adipose tissues only 
Insulin sensitive; enhanced 
GLUT4 translocation and 
insulin secretion 
(25,26) 
Munc18    
Munc18‐1 (‐/‐, ‐/+) Reduced expression of 
Munc18‐1, null lethal 
ND (50,51) 
Munc18‐1 Tg  Over‐expression of 
Munc18‐1 in neuron 
ND (52) 
Munc18c Tg Over‐expression of 
Munc18c 
Insulin resistant; impaired 
insulin secretion 
(53) 
Munc18c (‐/‐) No Munc18c expression Enhanced GLUT4 uptake in 
MEF‐derived adipocytes 
(54) 
Munc18c (‐/+) Reduced Munc18c 
expression, null lethal by 
E7.5 
Insulin resistant; impaired 
insulin secretion; reduced 
GLUT4 translocation in 
skeletal muscle 
(55,56) 
VAMP    
VAMP2 (‐/‐)  No VAMP2 expression, 
lethal 
ND  (57) 
VAMP3 (‐/‐) No VAMP3 expression Normal insulin and glucose 
tolerance, and normal 
glucose uptake  
(58) 
 
VAMP8 (‐/‐) No VAMP8 expression ND  (59,60) 
SNAP25 (‐/‐, ‐/+) Reduced SNAP25 
expression, null lethal at 
birth 
ND (61) 
SNAP23 (‐/+)  Reduced SNAP23 
expression 
ND  (62) 
 
ND, not determined; Tg, transgenic; (-/-), homozygous; (-/+) heterozygous  
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Figure 1-3 Glucose Uptake Via Insulin-Stimulated GLUT4 
Translocation and Fusion in Muscle and Adipose Tissues.  An 11-step 
model:  (1) extracellular insulin binds to the β-subunit of the insulin 
receptor (IR), triggering autophosphorylation and activation of the β-
subunit kinase activity.  (2) This induces recruitment of IRS-1, and (3) 
IRS-1 recruits PI3-K.  (4) PI3-K phosphorylates PIP2 to yield PIP3.  (5) 
PIP3 recruits PDK1 to the PM, where it (6) phosphorylates and 
activates AKT.  (7) AKT phosphorylates AS160, and (8) AS160 targets 
multiple Rabs present on GLUT4 containing vesicles (9), although the 
precise mechanisms beyond this remain unclear.  (10) Vesicle fusion 
occurs via the SNARE proteins resulting in GLUT4 integration into the 
PM to facilitate (11) glucose uptake. 
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1.5 DIFFERENTIAL SNARE ISOFORM FUNCTION IN EXOCYTOSIS EVENTS 
OF GLUCOSE HOMEOSTASIS  
Insulin secreting islet beta cells and insulin-responsive muscle and 
adipose cells contain multiple isoforms of each of the SNARE proteins required 
for the distal exocytosis events occurring at the plasma membrane (Table 1-1). 
 
1.5.1 The Syntaxin Family 
 The pancreatic beta cell expresses plasma membrane-localized Syntaxin 
isoforms 1A, 2, 3 and 4, though additional non-plasma membrane Syntaxin 
isoforms are also expressed, although their function in exocytosis remains 
untested (Table 1-1).  To date, only isoforms 1A and 4 are clearly known to be 
required for insulin exocytosis (19,26), primarily from data obtained using 
knockout mouse models.  Syntaxin 1A (-/-) knockout mice show selectively 
impaired insulin release during the first phase, while islets from Syntaxin 4 
heterozygous (-/+) knockout mice display defects in both first and second phases 
of GSIS.  Furthermore, islets isolated from transgenic mice over-expressing 
Syntaxin 4 in the islet secrete approximately 30% more insulin in both phases, 
implying a positive role for Syntaxin 4 in both first- and second-phase insulin 
secretion (26).  Oddly, Syntaxin 1 over-expressing transgenic mice show insulin 
resistance with impaired insulin secretion (48).  Although the molecular basis for 
this phenotype is unclear, it has been hypothesized that stoichiometry of 
particular SNARE proteins in cells is crucial to optimal function in exocytosis.   
 In contrast to pancreatic beta cells and neuronal cells, neither muscle nor 
adipose tissues-two of the primary insulin-responsive tissues-express Syntaxin 1, 
but instead appear to rely upon Syntaxin 4 (21,23,66).  Syntaxin 4 (-/+) mice 
exhibit a blunted insulin-stimulated GLUT4 translocation and decreased glucose 
uptake into skeletal muscle (49).  Consistent with this, transgenic mice over-
expressing Syntaxin 4 in skeletal muscle tissue show a two-fold increase in 
GLUT4 translocation into the sarcolemmal and t-tubule membranes of hindlimb 
muscle (25).  Syntaxin 4 is thus the only syntaxin isoform currently known to be 
implicated in insulin-stimulated GLUT4 vesicle translocation.  Recently, GLUT4 
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was found to be expressed in the hypothalamus, suggesting that Syntaxin 4 has 
a role in the brain as well (67).  Syntaxin isoforms 2, 3, 5, 6, 7, 8 and 12 are 
reportedly expressed in adipocytes but not as critical participants in insulin-
stimulated GLUT4 vesicle exocytosis (Table 1-1). 
 
1.5.2 SNAP25, SNAP23 and SNAP29 
 SNAP25, the principal neuronal isoform, is present in the beta cell but 
absent from muscle and adipose cells (11,34).  SNAP23 is also expressed in 
beta cells, and is capable of compensating for an absence of SNAP25 (68).  
However, skeletal muscle and adipose express and utilize only SNAP23 (69-71).  
SNAP29 is also widely expressed (72), though it differs from SNAP23 and 
SNAP25 in that it binds to intracellularly-localized syntaxin isoforms in addition to 
the plasma membrane-bound syntaxins (73).  SNAP29 has not yet been reported 
to function in insulin exocytosis or GLUT4 vesicle exocytosis. 
 
1.5.3 The VAMP Family 
 There are seven currently identified VAMP isoforms, all of which are 
attached by a C-terminal transmembrane domain to vesicle/granule membranes, 
including insulin granules, synaptic vesicles, GLUT4-containing vesicles, or ER-
Golgi compartments (74).  Islet beta cells express VAMP2/synaptobrevin, 
VAMP3/cellubrevin and VAMP8, with VAMP2 as the predominate isoform 
required for GSIS (10,17,75).  Remarkably, 3T3L1 adipocytes express all VAMP 
isoforms except for VAMP1 (12), but only VAMP2, VAMP3, and VAMP7 have 
been directly linked to GLUT4 vesicle exocytosis (58,76).  In skeletal muscle, 
VAMP2, 3, 5 and 7 co-immunoprecipitate with GLUT4 vesicles, and all but 
VAMP3 translocate to the plasma membrane with GLUT4 in response to 
contraction (77).  In L6 myoblasts, VAMP7/TI-VAMP is expressed and required 
for both insulin stimulated and osmotic shock triggered-GLUT4 vesicle 
translocation (78). 
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1.6 THE SEC1/MUNC18 (SM) PROTEIN FAMILY  
 In the early 1990’s, the yeast Sec1p protein was implicated as a regulator 
of SNARE assembly and exocytosis, through its ability to directly interact with 
Syntaxin.  Homologues were subsequently identified in C. elegans (unc18), D. 
melanogaster (Rop), and mammals [reviewed in (79)].  Collectively, proteins of 
this type are referred to as ‘SM’ proteins, for Sec1/Munc18.  The mammalian 
members of this family, Munc18 proteins, are ~66-68 kDa soluble proteins with 
no apparent transmembrane domain, yet are frequently found at the plasma 
membrane through direct interaction with their cognate Syntaxins (80,81).  
Plasma membrane-associated SM proteins present in mammalian cells include 
Munc18a, Munc18b and Munc18c (also referred to as -1, -2 and -3, respectively); 
non-plasma membrane-associated mammalian SM proteins are mVps45 and 
mSly1.  Endogenous Munc18a (referred to as Munc18-1 hereafter) and Munc18b 
bind to the Syntaxin isoforms 1-3, whereas Munc18c binds with high-affinity 
solely to Syntaxin 4 (Table 1-4).   
 The regions/residues within the SM proteins that are responsible for 
syntaxin partnering specificity are still undetermined, remarkable given the 
degree of similarity that exists amongst Munc18 isoforms (Munc18b and 
Munc18c show 62% and 51% amino acid identity, respectively, to Munc18-1).  
Munc18 proteins bind with high affinity to Syntaxin at the plasma membrane (82).  
However, the Munc18 proteins are soluble and equally abundant in the cytosolic 
compartment as they are at the membrane, though cytosolic Munc18 proteins 
are not associated with syntaxins (1,81,83).  Munc18 proteins are presumed to 
localize to the plasma membrane by association with membrane-localized 
proteins, such that increased expression of Syntaxin 4 selectively attracts 
Munc18c to the plasma membrane (81).  The purpose or function of soluble 
Munc18 within the cytosolic cellular compartment is currently unknown.  Islet 
beta cells express all three isoforms, while adipocytes and skeletal muscle 
express only Munc18b and Munc18c (14,84).  Depletion studies using RNAi or 
genetic ablation of either Munc18-1 or Munc18c typically show loss of exocytic 
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function, indicative of their conserved functional importance in SNARE-mediated 
exocytosis events (50,55,56). 
 
1.7 MUNC18 AND SNARE PROTEIN MOUSE MODELS:  ALTERATIONS OF 
GLUCOSE HOMEOSTASIS 
 Reduced protein and/or mRNA levels of Syntaxin 1A, Syntaxin 4 and/or 
Munc18c have been reported in islets and skeletal muscle of diabetic and obese 
human patients (85,86).  Similarly, rodent models of obesity and diabetes, 
including the GK rat, Zucker rat, ob/ob and streptozotocin-induced diabetes 
mouse models exhibit significantly lower levels of these same SNARE isoforms 
(87-90).  In corroborating fashion, numerous knockout and transgenic mouse 
models selectively targeted for SNARE and Munc18 proteins have defects in 
glucose homeostasis (Table 1-3).  As nearly all of the classic whole-body SNARE 
and Munc18 protein homozygous knockout mice die either in embryogenesis or 
at birth, the majority of the current understanding arises from studies utilizing 
haploinsufficient mouse models.  Overall, data generally support the concept that 
Type 2 Diabetes is a polygenic disease, likely emanating from multiple 
haploinsufficiencies.  Since these are in vivo models of altered glucose 
homeostasis, effects upon whole body homeostasis as well as the tissue-specific 
effects underlying the whole body phenotypes are discussed together below. 
 
1.7.1 Syntaxin mouse models:  Mouse models of Syntaxin 1A protein over-
expression (beta cell specific transgenic), Syntaxin 4 protein over-expression 
(pancreas, skeletal muscle and adipose specific transgenic), Syntaxin 1A and/or 
Syntaxin 1B deficient and Syntaxin 4 haploinsufficient have been generated, and 
many characterized for glucose homeostatic control (Table 1.3). 
 Syntaxin 1:  Consistent with clonal cell studies and Syntaxin 1A 
ablation/interference, islets isolated from classic whole-body Syntaxin 1A 
knockout mice display impaired first-phase insulin release associated with a 
decrease in pre-docked granules as determined by total internal reflection 
fluorescence microscopy (TIRFM) and electron microscopy (EM), and show 
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normal expression levels of Munc18-1 and Munc18b (19,103).  Surprisingly, mice 
with beta-cell specific over-expression of Syntaxin 1A display fasting 
hyperglycemia, hypoinsulinemia, and impaired glucose tolerance (48).  One 
possible explanation for this disparate phenotype may be reduced Munc18-1 
levels in the Syntaxin 1A over-expressing islets, but the cause of the decreased 
Munc18-1 is unclear.   
Syntaxin 4:  Syntaxin 4 homozygous (-/-) null mice die early in 
embryogenesis, apparently due to a requirement for Syntaxin 4 in the fusion of 
the GLUT8-containing vesicle with the plasma membrane in the mouse 
blastocyst (104).  However, Syntaxin 4 heterozygous (-/+) knockout mice are 
viable and exhibit insulin resistance and impaired insulin secretion (49).  This 
insulin resistance is largely due to significantly reduced skeletal muscle glucose 
uptake and GLUT4 translocation, while the insulin secretion deficit is attributed to 
decreased first- and second-phase insulin release (26).  Notably, in addition to 
the expected 50% decrease in Syntaxin 4 protein in the Syntaxin 4 (-/+) mouse 
tissues, Munc18c protein levels were decreased in parallel, while no other protein 
levels were altered (49).  In consistent fashion, Syntaxin 4 over-expressing 
transgenic mice show a parallel upregulation of endogenous Munc18c protein 
abundance in the three tissues over-expressing the Syntaxin 4 transgene: 
adipose, skeletal muscle and pancreas (25).  Syntaxin 4 transgenic mice show 
increased insulin sensitivity, which is likely linked to their increased GLUT4 
translocation and enriched GLUT4 deposition in the sarcolemmal and t-tubule 
membranes of skeletal muscle (25).  Islets isolated from Syntaxin 4 transgenic 
mice also exhibit 30% greater GSIS during both phases (26).  These data 
corroborate studies which correlate reduced Syntaxin 4 and Munc18c protein 
levels with aberrant insulin action in human and mouse skeletal muscle (85,88).  
Collectively, these findings raise the possibility that strategies which increase 
Syntaxin 4 protein levels may coordinately protect against the development of 
insulin secretion and insulin resistance defects.  
Unlike skeletal muscle and islet cells, primary adipocytes do not exhibit 
significant changes to glucose uptake, either in the Syntaxin 4 over-expressing
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 Table 1-4 SM-Syntaxin Binding Specificities  
 
 SM Proteins Syntaxin Partner Function Reference 
M. musculus Munc18a/‐1 Syntaxin 1, 2, 3 Synaptic vesicle 
exocytosis 
(80) 
 Munc18b/‐2 Syntaxin 1, 2, 3 Apical membrane 
trafficking 
(91,92) 
 Munc18c/‐3 Syntaxin 4 GLUT4 vesicle 
exocytosis, 
insulin granule 
secretion 
(1,81,93‐95) 
 
 mSly1 Syntaxin 5, 18 ER to golgi 
transport 
(96,97) 
 mVPS45 Syntaxin 16/Tlg2p TGN transport (98,99) 
H. Sapiens Munc18a/‐2 Syntaxin 3  Primary 
neutrophil 
granule fusion 
(100) 
 
 Munc18c/‐3 Syntaxin 4 Insulin action in 
human skeletal 
muscle 
(85,100) 
 
 ND Syntaxin 1A Neuronal 
disorder 
(migraine 
predisposition) 
(101) 
 
 ND Syntaxin 7,8 Heterotypic 
fusion of late 
endosome 
(102) 
 
ND, not determined 
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transgenic mice or the Syntaxin 4 (-/+) knockout mice (25,49).  Although this 
seemingly contrasts with the earlier 3T3-L1 adipocyte studies implicating 
Syntaxin 4 in glucose uptake, it is important to note that those early studies 
utilized a dominant-negative mutant form of Syntaxin 4 to interfere with 
endogenous VAMP2 trafficking and ablate insulin-stimulated GLUT4 
translocation (9), an approach which does not necessarily reflect a requirement 
for Syntaxin 4.  As such, whether or not there is an absolute requirement for 
Syntaxin 4 in GLUT4 vesicle translocation in adipocytes, or-assuming Syntaxin 4 
is required-a minimum “threshold” Syntaxin 4 required, remain questions open for 
investigation. 
 
1.7.2 Munc18 Mouse Models:  
 SM proteins in yeast, flies, and worms have been universally 
characterized as positive and essential regulators of exocytosis events.  
Moreover, the impairment phenotypes of Munc18-1 (-/+) knockout (50,52) and 
Munc18c (-/+) knockout (55,56) mouse models indeed support a positive role for 
these SM proteins in exocytosis events in vivo (Munc18-1 and Munc18c 
homozygous knockouts are lethal).  In terms of glucose homeostasis, the 
Munc18c heterozygous knockout mouse model exhibits glucose intolerance due 
to peripheral insulin resistance coupled with deficient GSIS (55,56).  Insulin-
stimulated GLUT4 vesicle translocation in the Munc18c (-/+) hindlimb skeletal 
muscle was abolished, indicating that Munc18c deficit is likely responsible for the 
peripheral insulin resistance (55).  In terms of GSIS impairment, RNAi-mediated 
depletion of Munc18c from isolated islets or clonal beta cells in culture 
recapitulate the defective GSIS seen in the Munc18c (-/+) knockout islets (56).  In 
contrast to previously discussed studies of SM proteins as positive factors in 
exocytosis, a line of MEF-derived adipocytes from a second Munc18c (-/-) mouse 
model showed increased GLUT4 presence in plasma membrane subcellular 
fractions (54).  However, since this model consists of derived rather than primary 
cells or tissues, direct comparisons cannot be made.  With regards to the role of 
Munc18-1 in glucose homeostasis, the Munc18-1 (-/+) mice have yet to be 
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assessed for defects. However, intriguing data gained by RNAi-mediated 
depletion of Munc18-1 from clonal beta cells suggest they would likely have 
defects in GSIS that would contribute to glucose intolerance (105). 
 A transgenic mouse model of Munc18c protein over-expression in adipose, 
skeletal muscle and pancreas, akin to the Syntaxin 4 over-expression transgenic 
mouse model (Table 1-3), exhibits peripheral insulin resistance resulting from 
impaired insulin-stimulated glucose uptake and GLUT4 vesicle exocytosis, and 
decreased GSIS (53).  This in vivo phenotype fully recapitulated data from 
Munc18c protein over-expression in 3T3-L1 adipocytes, skeletal muscle and islet 
beta cells (81,93,95,106).  Notably, Munc18c transgenic mice and Munc18c (-/+) 
knockout mice have normal Syntaxin 4 protein abundance, suggesting that 
Syntaxin 4 expression directs Munc18c expression, but not vice versa (53,55). 
 The negative effect of SM protein over-expression has been demonstrated 
in Drosophila (107).  The interpretation of these data is that the overly abundant 
SM proteins bind to and sequester cognate endogenous Syntaxins, preventing 
interaction with the v-SNARE proteins, and in so doing, impair exocytosis.  
However, Munc18-1 over-expression in neuronal cells in culture enhances 
exocytosis (108), and over-expression of Munc18-1 in clonal beta cells has no 
effect upon insulin secretion [(105); Oh and Thurmond, unpublished results].  
With regards to whether SM proteins have a positive or negative role, these 
disparate results may arise from differential protein abundance and stoichiometry, 
since over-expression studies rarely control for protein expression level on a per 
cell basis.  Alternatively, the differences may be related to the different types of 
exocytosis reactions in which Munc18-1 and Munc18c reportedly participate, with 
Munc18-1 functioning in rapid vesicle release (synaptic neurotransmission and 
first-phase insulin release) and Munc18c serving in sustained second phase 
insulin release and GLUT4 vesicle exocytosis events (Table 1-2). 
 
1.7.3 VAMP and SNAP Mouse Models:  
 Of the two v-SNARE isoforms found in insulin-secreting and insulin-
responsive cell types, only VAMP3 (-/-) knockout mice have been characterized 
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for glucose homeostasis.  Though VAMP3 was initially implicated in GLUT4 
vesicle translocation in 3T3-L1 adipocytes (9,13,109) using dominant-negative 
and toxin cleavage approaches, VAMP3 null mice show normal insulin and 
glucose tolerance (58).  Insulin-stimulated glucose uptake into adipocytes is 
normal in these mice, suggesting that VAMP3 is dispensable for GLUT4 
translocation, perhaps due to compensation from VAMP2.  VAMP2 (-/+) knockout 
mice thrive while the null mice die immediately after birth (57).  Furthermore, 
calcium-triggered synaptic vesicle exocytosis in neurons of VAMP2 
haploinsufficient mice is significantly impaired, and given the numerous overlaps 
between this neuronal process and that of first-phase insulin release from the 
beta cell, it is anticipated that VAMP2 would be required for glucose homeostasis 
in vivo, provided it remains the only other v-SNARE protein in these tissue types.  
VAMP8 (-/-) knockout mice survive and have apparent defects in pancreatic 
acinar cell zymogen granule content and platelet secretion (59,60), although they 
have yet to be characterized for glucose homeostasis. 
 Although SNAP25 homozygous (-/-) knockout mice fail to thrive beyond 
birth, studies conducted using embryonic and fetal tissue have a demonstrated 
lack of evoked synaptic vesicle exocytosis (61).  While SNAP25 and SNAP23 
heterozygous (-/+) knockout mice do thrive, no characterizations of potential 
effects upon whole body glucose homeostasis or insulin release from isolated 
islets are reported to date.  
 
1.8 MUNC18-SYNTAXIN COMPLEXES: MOLECULAR MECHANISMS  
1.8.1 Protein-protein Interaction Studies-In Vitro: 
 The functional in vivo models and cell-based studies of SM and Syntaxin 
proteins indicate that SM-Syntaxin coupling is the key to understanding 
exocytosis events, and is pertinent to many diseases.  By 1999, the first 
structures of Munc18-1 bound to Syntaxin 1A were obtained, solved using 
crystallographic and NMR approaches (110-112), where Munc18-1 was seen to 
hold Syntaxin in a ‘closed’ conformation in a 1:1 stoichiometric complex, and 
interpreted as a conformation precluding Syntaxin participation in SNARE core 
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complex assembly (modeled in Figure 1-4A).  Studies of SNARE proteins in cell 
and tissue lysates support this model, along with in vitro ultracentrifugation 
studies showing the exclusion of Munc18-1/nSec1 protein from the SNARE core 
complex (113).  More recently, the Munc18c isoform has been co-crystallized 
with the N-terminal 19 residue peptide of Syntaxin 4, indicating the importance of 
this particular site for protein-protein interaction (114).  While it was initially 
argued that this interaction fostered a new conformation (modeled in Figure 1-
4B), subsequent studies in adipocytes have cast doubt on its relative importance 
in relevant exocytosis events (115). 
 A third binding mode has recently been proposed, whereby the SM protein 
associates with the four alpha-helical bundle comprised by the SNARE core 
complex (modeled as Figure 1-4C).  Support for this new binding mode comes 
from in vitro reconstitution assays using recombinant Munc18-1, Syntaxin 1A, 
SNAP-25 and VAMP2 proteins (116).  This model relies upon the hypothesis that 
Munc18-1 functions principally as a positive and necessary factor to promote 
exocytosis, consistent with the mouse model data.  The latest mechanistic 
hypothesis incorporates the SNARE binding protein Complexin (117,118).  
Complexins (CPXs), also named synaphins, were originally described in 
neuronal cells to play an essential role in Ca2+-dependent neurotransmitter 
release (119-121).  In vitro, complexins bind to assembled heterotrimeric SNARE 
complexes (122).  However the question of whether they promote or inhibit 
SNARE-regulated exocytosis is unresolved due to conflicting in vivo data (123).  
Complexins do not appear to bind individual SNARE proteins, but a recent study 
shows that CPX1 can bind to Syntaxin/SNAP25 binary complexes (124).  
Furthermore, it has been reported that Munc18-1 and CPX1 can bind 
simultaneously to the SNARE complex (125).  Complexin expression in beta cells 
was noted prior to the emergence of the current mechanistic model (126), and as 
such its linkage to the insulin exocytosis mechanism has not yet been 
determined. 
Detection of Munc18-SNARE complex association, as depicted in Figures 
1-4B and C, requires low-stringency assay conditions, where little to no detergent 
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is included (<0.1% Triton X-100).  In contrast, older titration studies performed 
under higher stringency conditions demonstrated the ability of Munc18-1 to 
displace SNAP25 and VAMP2 from Syntaxin 1 (80,127,128).  Similarly, Munc18c 
reduces the binding of SNAP23 to Syntaxin 4 in a concentration-dependent 
manner when evaluated in 1% Triton X-100 solubilized cell lysates (69), yet 
under low-stringency detergent conditions Munc18c binding to Syntaxin 4-bound 
SNARE core complexes was detected (129).  While the benefit of low-stringency 
buffers has enabled detection of the otherwise elusive transient docking complex, 
co-immunoprecipitation data obtained from cell or tissue lysates currently 
supports only Model A (Figure 1-4A).  Interestingly, a novel immunofluorescent 
approach conducted in cells supports the concept of an intermediate transition 
complex of Syntaxin 1 bound simultaneously to Munc18-1 and SNAP25, and that 
the addition of VAMP2 subsequently displaced Munc18-1 (130).  Biochemical 
validation of the formation of this and the macromolecular complexes in Models B 
and C by endogenous proteins in these cell types awaits further investigation.   
Ultrastructural analyses of Munc18-1 in complex with Syntaxin 1A (110), and 
Munc18c complexed with the N-terminal peptide of Syntaxin 4 (but not the entire 
soluble region of Syntaxin 4 protein) (114), have yielded considerable insight into 
the potential function(s) of these complexes.  Syntaxin 4 contains four cytosolic 
alpha helices:  from the N-terminus the domains are Ha, Hb, Hc, and H3, 
followed by a transmembrane domain, as determined by its homology to 
Syntaxin 1.  The C-terminal H3 domain is the canonical SNARE protein motif 
which participates in the SNARE core complex (111), and based upon homology, 
the bundled coils of Syntaxin 4 are predicted to fit into the cleft of an 
arch/crescent-shaped Munc18c (Figure 1-5A).  The Hc and H3 domains are 
connected by a flexible linker region believed to catalyze syntaxin’s transition 
from a ‘closed’ to an ‘open’ conformation, with the open form being active for 
engagement in the SNARE core complex. The N-terminal peptide of Syntaxin 4 
fits into a small pocket near the top of the overall Munc18c “crescent” shape 
(114), although the sufficiency of this region to confer binding of Syntaxin 4 to 
Munc18c has been refuted.  The minimal binding region of Syntaxin 4 needed to 
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confer to Munc18c remains unknown.  Moreover, mutations in Munc18c which 
significantly impair binding to Syntaxin 4 are situated at the apex of the crescent 
(1,2,115), distanced from the arched cleft, and in close proximity to the binding 
sites for Doc2β and the Syntaxin 4 N-terminal peptide (Figure 1-5B).  The 
significance of Doc2β is discussed in a subsequent section. 
 
1.8.2 Protein-protein Interaction Studies in Cells and Tissues-Impact of 
Post-Translational Modifications: 
 Munc18-Syntaxin complexes are regulated through post-translational 
modifications, including serine/threonine phosphorylation, tyrosine 
phosphorylation, O-linked glycosylation, and nitrosylation of either or both 
proteins.  Serine phosphorylation of Munc18-1 by protein kinase C and/or 
threonine phosphorylation by Cdk5 (cyclin-dependent kinase 5) disrupts Munc18-
Syntaxin interaction and promotes secretory granule exocytosis (131-135).  
Munc18c has been shown recently to be phosphorylated by protein kinase C, 
causing dissociation from Syntaxin 4 and increasing SNARE complex assembly 
in pancreatic acinar cells (136).  Syntaxin 1A can also be phosphorylated at 
serine by the death-associated protein kinase (DAPK), which significantly 
decreases its interaction with Munc18-1 (137).  The catalytic subunit of the 
serine/threonine phosphatase protein 2B (PP2B) has been shown to directly 
interact with Munc18c in human umbilical vein endothelial cells (HUVECs) (138). 
 While serine/threonine phosphorylation of Munc18 or Syntaxin isoforms in 
insulin-secreting or insulin-responsive cell types has yet to be demonstrated, 
both proteins can undergo tyrosine phosphorylation in a stimulus-dependent 
manner.  In clonal MIN6 beta cells, Munc18c becomes tyrosine phosphorylated 
at residue Tyr219, and as a result dissociates from Syntaxin 4 (95,139).  In 3T3-
L1 adipocytes, Munc18c residue Tyr521 was modified in response to either 
insulin or PDGF stimulations (140,141).  Interestingly, Tyr521 resides in a 
disordered region, though prediction mapping places it in close proximity to 
Tyr219 (Figure 1-5B), suggesting that this vicinity of Munc18c may be an 
important site for stimulus-induced conformational changes.  In addition, Syntaxin 
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4 becomes phosphorylated at residues Tyr115 and Tyr251 in insulin-stimulated 
3T3-L1 adipocytes (140).  Remarkably, Syntaxin 4 does not appear to undergo 
tyrosine phosphorylation in clonal beta cells (95).  Syntaxin 1A was recently 
shown to become S-nitosylated at Cys145 decreasing its binding to Munc18-1 in 
vitro (142).  Furthermore, Munc18c can be modified by O-linked glycosylation in 
3T3-L1 adipocytes under insulin-resistant conditions caused by glucosamine, 
concurrent with impaired insulin-stimulated GLUT4 translocation (143) and 
deficient Munc18c localization to the plasma membrane (144).   
 
1.8.3 Impact of Additional Binding Partners on SM-Syntaxin Interactions: 
 While in vitro studies are invaluable for detailing kinetic and binding site 
information, cellular studies have elucidated a major role for post-translational 
modifications in how the SM-syntaxin complexes associate and dissociate.  
Moreover, SM-syntaxin complex accessory proteins which are relevant to insulin 
secretion and insulin action have been identified, as discussed below. 
 
Doc2β:  As a soluble 45 kDa double C2 domain-containing protein Doc2β, is 
expressed in adipocytes and islet beta cells, and exerts positive effects upon 
GLUT4 vesicle and insulin granule exocytosis events, respectively (139,145-147).  
In islet beta cells, Doc2β protein over-expression increases GSIS by ~40%, and 
the siRNA-mediated depletion of Doc2β attenuates insulin release (146,147), 
with similar effects observed in 3T3-L1 adipocytes (145).  Doc2β can mediate 
similar outcomes in synaptic vesicle exocytosis through association of its first C2 
binding domain (C2A) with Munc18-1 (148).  In islet beta cells, the second C2 
domain (C2B) mediates its association with residues 173-255 of Munc18c, 
including the regulatory Y219 phosphorylation site (146).  Whether or not this is 
somehow linked to Doc2β association remains untested.  Doc2β effectively 
competes with Syntaxin 4 for Munc18c binding, and its endogenous association 
with Munc18c is required for GSIS.  In contrast, it has been suggested that 
Doc2β instead exerts its effects through interaction with Syntaxin 4 in a calcium-
dependent manner (147).  Although calcium was present in both beta cell studies, 
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Figure 1-4 Proposed models of Munc18c-Syntaxin 4 Interaction.  (A) 
Unstimulated state model of Munc18 holding Syntaxin in a ‘closed’ conformation 
which in turn inhibits Syntaxin from being able to participate in the SNARE 
tertiary complex, thus inhibiting exocytosis.  (B) A new model in the field derived 
from in vitro data; in stimulated state Munc18 remains bound to ‘open’ Syntaxin 
at the N-terminus allowing Syntaxin to participate in the SNARE core complex. 
(C) Munc18 interacts with the SNARE core complexes through the four α-helical 
bundle. 
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methodological differences such as use of low stringency binding conditions, use 
of calcium-chelators, and use of a transmembrane-containing insoluble syntaxin 
protein may have permitted detection of Syntaxin 4 association with Doc2β 
(145,146).  Alternatively, a very recent report shows that Doc2β interacts directly 
with the SNARE complex (149).  Thus, while there is full agreement that Doc2β  
plays a positive role in Syntaxin 4-mediated exocytosis, details of the underlying 
mechanism must await further examination. 
 
Munc13-1:  Munc13-1 is a soluble 200 kDa protein expressed in pancreatic islet 
beta cells (86,150), but not in adipocytes or skeletal muscle.  Munc13-1 is 
composed of one C1 and two C2 domains which mediate phorbol ester and 
diacylglycerol binding and phospholipid-dependent Ca2+ binding, respectively.  
Munc13-1 can pair directly with Munc18-1, Doc2β or Syntaxin 1A (148,151).  
Munc13-1 over-expression amplifies insulin secretion and is proposed to function 
in granule priming (150).  Reduced expression of Munc13-1 is observed in islets 
isolated from diabetic humans or Zucker fa/fa rats (86,150), consistent with 
glucose intolerance and the deficient insulin release characteristics of Munc13-1 
(-/+) knockout mice (152), and is therefore believed to have a required role in 
insulin exocytosis. 
 
WNK1:  A unique member of the serine/threonine kinase family, WNK1 (With No 
K (lysine)) has been linked to the inherited hypertension syndrome 
Pseudohypoaldosteronism II (153,154).  WNK1 is a soluble 230 kDa kinase 
expressed in 3T3-L1 adipocytes and islet beta cells (155,156), and is a Munc18c 
binding protein (157).  WNK1 and Munc18c associate via direct interaction of the 
N-terminal 172 residues of Munc18c (distinct from residues bound by Doc2β and 
the kinase domain of WNK1, and competitive inhibition of this complex impairs 
Syntaxin 4-mediated insulin granule exocytosis (157).  Also, WNK1-Munc18c 
complexes are found localized to the plasma membrane, though complexes are 
also found in the cytosol, a unique feature amongst Munc18c binding proteins to 
date.  There are two other unique features of this complex:  1) despite the  
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 Figure 1-5 Modeling of Munc18c-Syntaxin 4 interaction.  (A) Depicting full 
length Munc18c (green) interacting with Syntaxin 4 (orange).  The peptide 
termed 18c/pep3 (residues 460-483) is illustrated in pink and arginine 240 
shown in yellow; both have been shown to play important roles in Munc18c-
Syntaxin 4 interaction (1,2).  (B) Upper panel-Munc18c Tyr219 sits in the 
Doc2β binding region on Munc18c (blue) juxtaposed to the binding cleft for 
the N-terminus of Syntaxin 4 (red).  Lower panel-enlarged view of the boxed 
region, illustrating the close proximity between Tyr219 and Tyr521, though 
Tyr521 is not present in the crystal structure due to its location within a 
disorder region (drawn into the model with white dashed line).   
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requirement for the kinase domain of WNK1, its intrinsic kinase activity is 
apparently dispensable for interaction (i.e. Munc18c does not serve as a WNK1 
substrate); 2) siRNA-mediated WNK1 depletion does not affect insulin secretion 
from clonal beta cells nor glucose uptake into adipocytes (155), complicating 
specific designation of its role in exocytosis events pertinent to glucose 
homeostasis. 
 
80K-H:  The 80K-H protein (80 kDa) was originally identified as a PKCζ binding 
partner and is widely expressed, especially at the plasma membrane of insulin-
sensitive 3T3L1 adipocytes and L6 myotubes (158).  80K-H has been implicated 
in vesicle trafficking events via a close relationship to the protein VASAP-60 
(159), and in GLUT4 vesicle transport through its ability to interact with both 
Munc18c and PKCζ in an insulin-dependent manner (158,160).  The requirement 
of 80K-H in glucose uptake in vivo and/or primary cells and its putative role as a 
signaling link between PKCζ and Munc18c awaits further investigation. 
 
Rab3A:  Rab proteins are a large family of small GTPases responsible for the 
regulation of many membrane trafficking events and are thought to participate in 
insulin exocytosis as well as GLUT4 vesicle exocytosis through interaction with 
Munc18-Syntaxin complexes.  However, despite efforts over the past decade, 
only Rab3A, a Munc18-1 binding protein, has been identified to date (161), with 
no Munc18c binding candidate to modulate insulin action as of yet.  Rab3 null 
mice exhibit glucose intolerance coupled to ablated first-phase insulin release but 
without insulin resistance (162), consistent with its role as solely a Munc18-1 and 
not a Munc18c binding factor. 
 
Synip:  Synip (syntaxin-interacting protein) is a 62 kDa protein that was initially 
discovered as a novel Syntaxin 4-binding protein and has been implicated in the 
control of glucose transport and GLUT4 vesicle translocation in 3T3-L1 
adipocytes (163).  It binds only to the Syntaxin 4 isoform in an insulin-sensitive 
manner.  This mechanism appears to function through Synip phosphorylation at 
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Ser99 in response to activation of Akt2, and subsequent dissociation from 
Syntaxin 4 to promote GLUT4 vesicle exocytosis (164,165), although this is a 
disputed finding (166).  Synip expression in βHC-9 clonal beta cells has also 
been reported and a role for it implicated in Syntaxin 4-mediated insulin 
exocytosis using an over-expression paradigm (167).  Synip knockout mice or 
RNAi-mediated knockdown data will be required to determine if Synip is 
necessary during Syntaxin 4-based exocytosis events relevant to glucose 
homeostasis. 
 
Tomosyn and Cab45b:  Tomosyn proteins are syntaxin binding factors, with 7 
different isoforms expressed from two genes, Tomosyn-1 and Tomosyn-2 (168).  
b-Tomosyn-1 (b=big), a cytosolic protein, was identified as a Syntaxin 4-binding 
partner in 3T3-L1 adipocytes, and its over-expression inhibited GLUT4 
translocation to the plasma membrane (169).  Similarly, in beta cells depletion of 
an analogous Syntaxin 1A binding isoform of Tomosyn-1 was found to decrease 
stimulated exocytosis (170).  In contrast, depletion of a related m-tomosyn-1 
(m=medium) isoform (which also binds to Syntaxin 1A) in clonal beta cells was 
shown to increase insulin release while over-expression was inhibitory, 
suggesting that it functions as a negative regulator of insulin exocytosis (171).  
Although tomosyn-1 knockout mice exist and have enhanced synaptic 
transmission (172), the mice are not yet characterized for effects upon glucose 
homeostasis, and it remains unclear which isoforms are ablated. 
Cab45b:  was recently identified as a soluble 42 kDa calcium binding protein 
associated with Munc18b in pancreatic islet beta cells (22).  In clonal INS-1E 
beta cells, antibody-mediated interference of endogenous Cab45b or RNAi-
knockdown of Munc18b expression reduced depolarization-evoked membrane 
capacitance, implicating potential roles for each protein in insulin exocytosis. 
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1.9 Novel Roles for Munc18 and Syntaxin Proteins in Granule Mobilization 
and Pool Refilling 
 New evidence suggests that non-traditional roles exist for SM and 
syntaxin proteins in exocytosis.  Both Munc18-1 and Munc18c (-/+) knockout 
mouse models reveal the necessity of these proteins in granule localization to the 
plasma membrane (56,108).  Munc18-1-depleted clonal beta cells also exhibit 
defective docking of insulin granules to the plasma membrane (105).  Although 
this might suggest that the soluble fraction of SM proteins somehow directs 
granule mobilization through the cytoskeletal matrix, preliminary in vitro F-actin 
binding studies argue against Munc18c protein as a direct binding factor of F-
actin (Kalwat and Thurmond, unpublished results).  Syntaxin 1A can co-
immunoprecipitate with F-actin in beta cell lysates and dissociate transiently in 
response to glucose stimulation (29).  Syntaxin 4 can also associate with α-fodrin, 
an F-actin binding factor, in primary rat adipocytes (173).  Given that Syntaxin 4 
and Munc18c in particular, are required for the mobilization phase of insulin 
exocytosis, and are also responsible for the relatively long-range trafficking of 
GLUT4 vesicles in adipocytes and myocytes, future exploration regarding their 
interactions with cytoskeletal elements is required.  However, it is important to 
note that stimulus-induced actin remodeling appears to be different for exocytosis 
in beta cells than it is in adipocytes and myocytes.  Current data suggest that 
disruption of the actin cytoskeleton using agents such as Latrunculin in beta cells 
potentiates insulin exocytosis, but in adipocytes inhibits GLUT4 vesicle 
exocytosis (29,174-177). 
 
1.10 HYPOTHESIS 
Type 2 diabetes involves specific defects of glucose-stimulated insulin 
secretion from the pancreatic beta cells in addition to defects in peripheral tissue 
insulin action required for glucose uptake.  Both of these processes, insulin 
secretion and glucose uptake, are mediated by SNARE protein core complexes 
composed of Syntaxin, SNAP-23/25, and VAMP proteins.  The SNARE core 
complex is regulated by the Sec1/Munc18 (SM) family of proteins, which 
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selectively bind to their cognate Syntaxin isoforms with high affinity.  The process 
of insulin secretion utilizes multiple Munc18-Syntaxin isoform pairs, whereas 
insulin action in the peripheral tissues appears to utilize only the Munc18c-
Syntaxin 4 pair.  Importantly, recent reports have linked obesity and Type 2 
diabetes in humans with changes in protein levels and single nucleotide 
polymorphisms (SNPs) of Munc18 and Syntaxin isoforms relevant to these 
exocytotic processes, although the molecular mechanisms underlying the 
observed phenotypes remain incomplete (85,178,179).  Given the conservation 
of these proteins in two seemingly disparate processes, and the need to design 
and implement novel and more effective clinical interventions, it will be vitally 
important to delineate the mechanisms governing these conserved SNARE-
mediated exocytosis events.  Thus, the central hypothesis proposed in this thesis 
is that Syntaxin 4-Munc18c complexes are modulated by post-translational 
modifications and novel interactions.  This hypothesis was tested by using 
complementary in vitro, cell-based approaches, and animal tissue extracts to 
detail protein modifications and protein-protein interactions that impact SNARE 
core complex assembly and vesicle exocytosis mechanisms.  The rationale for 
the proposed research is that once the mechanisms regulating the function of 
Munc18c in Syntaxin 4-mediated vesicle exocytosis are established, it will 
become possible to modulate the complex for therapeutic purposes, either 
pharmacologically or through molecular based strategies. 
 
CHAPTER 2: THE TYROSINE PHOSPHORYLATION OF MUNC18C INDUCES 
A SWITCH IN BINDING SPECIFICITY FROM SYNTAXIN 4 TO DOC2β 
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2.1 INTRODUCTION 
While genetic models of Munc18c over-expression (53) and under-
expression (54,55) have both unequivocally substantiated Munc18c as a key and 
physiologically-relevant regulator of glucose homeostasis by its impact upon 
Syntaxin 4-mediated exocytosis, how it transiently interacts with Syntaxin 4 in a 
stimulus-dependent manner remains unclear.  For example, it remains to be 
resolved just what contacts of the Syntaxin molecule are sufficient to confer its 
interaction with Munc18.  There is general consensus that the N-terminal 20-30 
residues of syntaxins are important for fostering interaction with Munc18 proteins 
(97,180,181), and it is suggested that it is through this region that Munc18 
proteins remain associated with the SNARE core complex (114). However, that 
this N-terminal region of Syntaxin 4 can independently confer binding specificity 
to the Munc18c isoform, as opposed to binding Munc18a or Munc18b (Munc18a 
and Munc18b specifically bind Syntaxin isoforms 1-3) has been disputed. Thus, it 
has been suggested there are likely alternate or additional residues required to 
support and specify the association (114,115).  
 Consistent with the dissociation model put forth by Zilly et al (130), 
Munc18c-Syntaxin 4 association can be significantly reduced upon the stimulus-
induced phosphorylation of residue Y219 of Munc18c (95). We have since 
determined that a region of Munc18c containing this particular residue is 
sufficient to confer binding to the C2 domain-containing protein Doc2β, which is 
localized at the plasma membrane in islet beta cells and adipocytes (146).  
Syntaxin 4 was excluded from the Munc18c-Doc2β complex, suggesting that 
some type of “switch mechanism” occurs for transitions between Munc18c-Doc2β 
and Munc18c-Syntaxin 4 complex formation.  In the present study we have 
examined the minimal binding region of Syntaxin 4 as well as the protein-protein 
interactions amongst Munc18c and its binding partners Syntaxin 4 and Doc2β to 
test the validity of such a ‘switch mechanism.’  
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Rabbit anti-Munc18c antibody was generated as previously described (81). 
Rabbit polyclonal anti-Syntaxin 4 and N-terminal Syntaxin 4 peptide (residues 2-
23) were obtained from Chemicon (Temecula, CA).  Antibodies raised against 
SNAP-23, VAMP2, and phosphotyrosine (4G10) were obtained from Affinity 
BioReagents (Golden, CO), Synaptic Systems (Göttingen, Germany) and 
Upstate Biotechnology (Lake Placid, NY), respectively.  Rabbit polyclonal anti-
Doc2β antibody was a generous gift from Dr. Matthijs Verhage (Vrije Universiteit, 
Netherlands).  Rabbit and mouse anti-GFP antibodies were acquired from 
Abcam (Cambridge, MA) and Clontech Laboratories (Mountain View, CA), 
respectively.  Protein G plus agarose was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA). The MIN6 beta cells were a kind gift from Dr. 
John Hutton (University of Colorado Health Sciences Center).  Goat anti-mouse 
and anti-rabbit horseradish peroxidase secondary antibodies and Transfectin 
lipid reagent were acquired from Bio-Rad (Hercules, CA).  Monoclonal Flag 
antibody, radioimmunoassay grade bovine serum albumin and D-glucose were 
purchased from Sigma (St. Louis, MO).  Enhanced chemiluminescence (ECL) 
and SuperSignal West Femto reagents were obtained from Amersham 
Biosciences (Pittsburgh, PA) and Pierce (Rockford, IL), respectively.  The human 
C-peptide RIA kit was purchased from Linco Research Inc (St. Charles, MO).  
 
2.2.2 Plasmids  
The generation of pcDNA3.1-flag-Munc18c, pET28a (+)-His-Munc18c and 
pGEX-Munc18c plasmids has been previously described (81,146,157).  The 
TAP-Munc18c DNA constructs were generated by subcloning a PCR-generated 
Munc18c fragment into the XhoI and ClaI sites of the pNTAP and pCTAP shuttle 
vectors (Stratagene) for adenoviral particle production by Viraquest (North 
Liberty, IA).  The pGEX-4T1-Syntaxin 4-(1-193), -(1-112), and -(1-70) DNA 
constructs were generated by subcloning PCR-generated rat Syntaxin 4 
fragments into the SalI and XhoI restriction sites of the pGEX-4T1 expression 
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vector (GE Healthcare). The pGEX-4T1-Syntaxin 4-(1-273), -(39-273), -(118-193), 
-(71-273), and -(113-273) DNA constructs were made by subcloning PCR-
generated rat Syntaxin 4 fragments into the EcoRI and XhoI sites of the pGEX-
4T1.  The pEGFP-C2-Syntaxin 4-(118-193) DNA construct was generated by 
digesting the fragment from pGEX-4T1-Syntaxin 4-(118-193) with EcoR1 and 
XhoI and subcloning into the EcoRI and SalI sites of the pEGFP-C2 vector (BD 
Biosciences Clontech, San Jose, CA). 
 
2.2.3 Cell Culture, Transient Transfection and Secretion Assays  
MIN6 beta cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM with 25 mM glucose) supplemented with 15% fetal bovine serum, 100 
units/ml penicillin, 100 μg/ml streptomycin, 292 μg/ml L-glutamine, and 50 μM β -
mercaptoethanol as described previously (146).  MIN6 beta cells at 50-60% 
confluence were transfected with 40 μg of plasmid DNA per 10 cm2 dish using 
Transfectin (Bio-Rad) to obtain ~50% transfection efficiency.  After 48 h of 
incubation, cells were washed twice with and incubated for 2 hours in freshly 
prepared modified Krebs-Ringer bicarbonate buffer (MKRBB; 5 mM KCl, 120 mM 
NaCl, 15 mM Hepes pH 7.4, 24 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2 and 1 
mg/ml RIA-grade BSA). Cells were stimulated with 20 mM glucose or 0.1 mM 
pervanadate for the times indicated in the figures.  Cells were subsequently lysed 
in Nonidet NP-40 lysis buffer (25 mM HEPES pH 7.4, 1% NP-40, 10% glycerol, 
50 mM sodium fluoride, 10 mM sodium pyrophosphate, 137 mM sodium chloride, 
1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 
1 μg/ml pepstatin and 5 μg/ml leupeptin), and lysates were cleared by 
microcentrifugation for 10 min at 4oC for subsequent use in co-
immunoprecipitation experiments. For measurement of human C-peptide release, 
MIN6 beta cells were transiently co-transfected with each plasmid plus human 
proinsulin cDNA, (gift from Dr. Chris Newgard, Duke University), using 
Transfectin with 2 μg of each DNA per 35 mm dish of cells.  Forty-eight hours 
following transfection, cells were pre-incubated for 2 hours in MKRBB buffer and 
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stimulated with 20 mM glucose for 1 hours and buffer collected for quantitation of 
human C-peptide released.  
 CHO-K1 cell stocks were purchased from the American Type Culture 
collection (Manassas, VA) and cultured in Ham’s F-12 medium supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 292 
μg/ml L-glutamine.  At 80-90% confluence, cells were electroporated with 40 μg 
DNA as previously described (81) and incubated for 48 hours. Detergent cell 
lysates were prepared by harvesting in 1% NP40 lysis buffer and lysates cleared 
by centrifugation at 14,000 x g for 10 min at 4oC for use in co-
immunoprecipitation experiments. 
 
2.2.4 Tandem Affinity Purification (TAP)  
The InterPlay Adenoviral TAP System (Stratagene, La Jolla, CA) was 
used for precipitation of Munc18c-associated proteins from MIN6 beta cells.  
NTAP-Munc18c contained two N-terminal affinity tags:  a streptavidin binding 
peptide (SBP) and a calmodulin binding peptide (CBP), the same tags were 
present at the C-terminus of CTAP-Munc18c.  MIN6 beta cells were transduced 
using pNTAP-Munc18c or pCTAP-Munc18c CsCl-purified adenoviral particles as 
described previously (182).  Cells were harvested in the manufacturer’s lysis 
buffer containing 0.1% Triton X-100, or in this buffer containing additional 
detergent (1% Triton X-100 final concentration).  The cells were subjected to 
three successive rounds of freeze-thawing and centrifuged at 16,000 x g for 10 
min for collection of supernatant. Supernatants were incubated with streptavidin 
resin followed by washes with lysis buffer (0.1% Triton X-100) and elution. 
Eluates were then subjected to a second purification over calmodulin resin. 
Column flow-through was collected (FT).  Purified TAP-Munc18c and associated 
proteins were eluted and resolved by 12% SDS-PAGE for immunoblotting. 
 
2.2. 5 Subcellular Fractionation  
Briefly, MIN6 beta cells at 80-90% confluence were harvested into 1 ml of 
homogenization buffer (20 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 
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250 mM sucrose, 1 mM DTT and 1 mM sodium orthovanadate containing the 
protease inhibitors leupeptin (10 μg/ml), aprotinin (4 μg/ml), pepstatin (2 μg/ml) 
and PMSF (100 μM). Cells were disrupted by 10 strokes through a 27 gauge 
needle and homogenates were centrifuged at 900 x g for 10 min.  Plasma 
membrane fractions (PM) were obtained by mixing the postnuclear pellet  with 1 
ml of Buffer A (0.25 M Sucrose, 1 mM MgCl2 and 10 mM Tris-HCl, pH 7.4) and 2 
volumes of Buffer B (2 M sucrose, 1 mM MgCl2 and 10 mM Tris-HCl, pH 7.4).  
The mixture was overlaid with Buffer A and centrifuged at 113,000 x g for 1 h to 
obtain an interface containing the plasma membrane fraction.  Interface was 
collected and diluted to 2 ml with homogenization buffer for centrifugation at 
6,000 x g for 10 min, and the resulting pellet was collected as the plasma 
membrane fraction. Pellets were resuspended in 1% NP-40 lysis buffer to 
solubilize membrane proteins. 
 
2.2.6 Co-immunoprecipitation and Immunoblotting  
MIN6 beta cells were pre-incubated in MKRBB for 2 hours followed by 
glucose stimulation or treatment with 0.1 mM pervanadate. Pervanadate was 
made immediately prior to use by combining 1 mM sodium orthovanadate with 3 
mM hydrogen peroxide for 15 minutes.  Cells were subsequently lysed in 1% NP-
40 lysis buffer.  MIN6 beta cell cleared detergent lysates (2-4 mg) were combined 
with primary antibody for 2 hours at 4oC followed by a second incubation with 
protein G Plus-agarose for 2 hours.  The resultant immunoprecipitates were 
subjected to 10% or 12% SDS-PAGE followed by transfer to PVDF membranes 
for immunoblotting:  Munc18c and VAMP2 antibodies were used at 1:5,000; 
Syntaxin 4, Doc2β, SNAP-23, and 4G10 antibodies were used at 1:1,000; Flag 
and EGFP antibodies were used at 1:2,000 and 1:800, respectively.  Secondary 
antibodies conjugated to horseradish peroxidase were diluted at 1:5,000 for all 
except for phosphotyrosine, which was used at 1:2,000 for visualization by ECL 
for detection using a Chemi-Doc documentation imaging system (Bio-Rad). 
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2.2.7 Recombinant Proteins and Interaction Assays 
The pGEX fusion constructs were transformed into E. coli for expression 
of all GST fusion proteins and purified by glutathione-agarose affinity 
chromatography as described previously (163).  Recombinant fragments of 
Syntaxin 4 were obtained following thrombin cleavage and capture (Novagen).  
Recombinant His-tagged Munc18c was expressed in E. coli and purified by Ni-
NTA nickel-chelating resin (Invitrogen) under native conditions (50 mM NaH2PO4, 
0.5 M NaCl).  Eluted protein was further dialyzed overnight in 50 mM Tris pH 8.0 
supplemented with 1 mM DTT.  In vitro GST interaction assays were conducted 
by incubating GST-fusion proteins linked to sepharose beads with recombinant 
purified proteins for 2 hours at 4°C in NP-40 lysis buffer, followed by three 
stringent washes with lysis buffer, and interacting proteins eluted from the beads 
and resolved on 10% or 12% SDS-PAGE followed by transfer to PVDF 
membrane for immunoblotting.  The Syntaxin accessibility assay using GST-
VAMP2 was performed similarly but using cleared detergent cell lysates instead 
of recombinant protein. 
 
2.2.8 Surface Plasmon Resonance 
The binding kinetics for the interaction between Syntaxin 4-(1-273) and 
Syntaxin 4-(118-194) with Munc18c was determined by surface plasmon 
resonance using a BIAcore3000 instrument (Biacore AB, Uppsala, Sweden).  
Syntaxin 4-(1-273) and Syntaxin 4-(118-194) were diluted in acetate buffer at pH 
4.5 and immobilized on a CM5 sensor chip with amine coupling.  The surface 
was activated by injecting a solution containing 0.4 M N-ethyl-N’-
dimethylaminopropyl carbodimide (EDC) and 50 mM N-hydroxysuccinimide 
(NHS) for a 7 minutes flow rate of 5 μl/min (183).  Syntaxin 4 was then injected 
and the surface was subsequently blocked with 1 M ethanolamine at pH 8.5 for 7 
minutes.  The target for final immobilization levels was 1,000 resonance units 
(RUs), corresponding to approximately 1 ng of Syntaxin 4/mm2 (184).  Munc18c 
was injected over the flow cell at  30 µl/minutes for 2 minutes and allowed to 
dissociate for 3 minutes.  To determine the association (kon) and dissociation (koff) 
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rate constants, Munc18c was injected at seven concentrations (0, 1.7, 3.3, 6.7, 
13.3, 26.7, and 53.3 nM) ranging from 0 to 53.3 nM.  Between cycles, the surface 
was regenerated with 10 µl of 0.15 M acetic acid, 0.5 M NaCl.  The data was 
then fitted to a 1:1 (Langmuir) binding model using the BiaEvaluation software.  It 
was found that mass transfer was not a factor in Munc18c binding to Syntaxin 4.  
All experiments were conducted in HBS-EP running buffer (0.01 M HEPES, pH 
7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) with Munc18c storage 
buffer added to a 1:50 dilution at 25°C. 
 
2.2.9 Computer Modeling 
The three-dimensional structure of the Syntaxin 4/Munc18c complex was 
guided by the crystal structure of the Syntaxin 1A/Munc18 complex (PDB code 
1DN1) and the crystal structure of Munc18c (PDB code 2PJX).  A homology 
model of Syntaxin 4 was constructed using SwissModel based on the crystal 
structure of Syntaxin 1a.  The Syntaxin 4/Munc18c complex was constructed by 
superimposing these proteins onto their homologs in the Syntaxin 1A/Munc18 
complex.  This was carried out with the computer program PyMol.  All 
representations of three dimensional structures in the manuscript were generated 
with PyMol. 
2.2.10 Statistical Analysis 
All data are expressed as mean ± S.E.  Data were evaluated for statistical 
significance using an unpaired two-tailed Student's t test. 
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2.3 RESULTS 
2.3.1 Munc18c-Syntaxin 4 Binary Complexes Predominate in Detergent 
Lysates 
Recent studies performed in vitro report that under low-detergent 
conditions (0.1% Triton X-100) Munc18 proteins are capable of associating with 
the SNARE core complex (129,185-187).  However, under higher stringency 
conditions (1% Triton X-100), Munc18c was only able to associate with the 
SNARE complex when SNAP-23 was GST-tagged (Figure 2-1A, Lane 6), 
consistent with other similarly performed studies (129,169).  However, GST-
Munc18c pulldowns revealed a different outcome, Munc18c associated only with 
Syntaxin 4 and not the SNARE core complex (Figure 2-1B, Lane 8).  These 
results are consistent with other reports pointing to differential association of 
Munc18 proteins with the SNARE complex depending upon location of epitope 
tags and detergent stringency in binding buffers (69,80,188,189).  The Munc18-
SNARE association of endogenous proteins within cells has yet to be 
demonstrated.  MIN6 cells were harvested in 1% NP-40 membrane protein 
solubilizing buffer and cleared detergent lysates used in immunoprecipitation 
reactions with anti-Munc18c, anti-VAMP2 or an IgG control (Figure 2-2A).  Three 
independent experiments showed that Munc18c co-immunoprecipitated only with 
Syntaxin 4 and not with SNAP23 or VAMP2.   Munc18c was never seen to bind 
to Syntaxin 4 when Syntaxin 4 was complexed with other SNAREs. This was 
observed using lysates prepared from both unstimulated and glucose-stimulated 
MIN6 cells. 
 This inability to detect Munc18c association with binary (Syntaxin 4-
SNAP23) or ternary (Syntaxin 4-SNAP23-VAMP2) SNARE complexes was 
reminiscent of results from some of the original immunoprecipitation studies 
conducted using detergent cell/tissue lysates (128,188,189).  Possible reasons 
for this may be that in beta cells the Munc18c-Syntaxin 4 predominates to the 
extent that detection of the other complexes was limiting.  Alternatively, 
antibodies used in co-immunoprecipitation may have induced steric hindrance 
and disallowed association of SNAP23 or VAMP2.  A third possibility is that use 
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of 1% NP-40 detergent to solubilize endogenous membrane-associated proteins 
disrupted Munc18c-ternary SNARE complex association.  In fact, data supporting 
the existence of Munc18 binding to SNARE complexes was collected in binding 
studies utilizing 5-10 times less detergent in lysis and reaction/wash buffers than 
detergent levels used in studies reporting only Munc18c-Syntaxin binding.  
 To address the issue of antibody interference in the co-
immunoprecipitation we generated tandem affinity (TAP)-tagged Munc18c 
protein for adenoviral expression in MIN6 cells as ‘bait’ for Syntaxin 4 and 
associated SNARE proteins (Figure 2-2B).  Two versions of tagged Munc18c 
were tested, with TAP tags added to either the N- or C-terminus of Munc18c to 
randomize for potential effects due to tag location.  TAP tags consist of 
streptavidin binding peptide and calmodulin binding peptide (CBP), and input 
lysates containing the TAP-Munc18c were passed over streptavidin resin and 
subsequently calmodulin resin to yield Munc18c in the eluate, as determined by 
CBP immunoblotting (Figure 2-2B).  In addition, this system was further utilized 
to test the effect of detergent level in lysis buffers upon Munc18c binding to 
Syntaxin 4, SNAP23 and VAMP2.  TAP purification under either buffer condition 
resulted in similar yields of TAP-tagged Munc18c, as seen by immunoblotting for 
the CBP tag (Figure 2-1B, lanes 3 and 6).  Syntaxin 4 was precipitated by TAP-
Munc18c, detected by relative differences in input and flow-through (FT), and its 
strong presence in eluates.  However, TAP-tagged Munc18c precipitated ~65% 
less Syntaxin 4 protein from lysates prepared with 0.1% versus 1% NP40 
detergent.  Furthermore, neither SNAP23 nor VAMP2 protein was found to co-
elute with this complex from lysates prepared under either detergent condition.  
The levels of SNAP23 and VAMP2 in input lysates was comparable to that in FT, 
consistent with lack of co-precipitation with TAP-Munc18c-Syntaxin 4 complexes 
(Figure 2-2B, lanes 1-2 and 4-5).  In addition, elution using high salt conditions 
(450 mM NaCl) failed to yield SNAP23 or VAMP2; C-terminal TAP-tagged 
Munc18c results were identical to N-terminal TAP-Munc18c (Figure 2-2C).  
These data suggest that the Munc18c-SNARE complex is labile under conditions 
required to adequately solubilize endogenous SNARE proteins. 
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Figure 2-1 Munc18c Associates with the SNARE Complex In Vitro Depending 
On Which Protein is Tagged.  A) Bacterially expressed GST-SNAP-23 or GST 
proteins were purified and linked to beads for in vitro binding studies with 
bacterially-expressed His-Munc18c, and soluble forms of Syntaxin 4 and 
VAMP2.  The Syntaxin 4 and VAMP2 GST fragments were thrombin cleaved 
to remove the GST tag.  Bound Proteins were subjected to a 12% SDS-PAGE 
for immunoblotting (IB) with anti-Munc18c, anti-Syntaxin 4, and anti-VAMP2 
antibodies.  B) Bacterially expressed GST-Munc18c or GST proteins were 
purified and linked to beads for in vitro binding studies with bacterially-
expressed Syntaxin 4, SNAP-23, and VAMP2.  The Syntaxin 4, SNAP-23, and 
VAMP2 GST fragments were thrombin cleaved to remove the GST tag.  
Bound Proteins were subjected to a 12% SDS-PAGE for immunoblotting (IB) 
with anti-Munc18c, anti-Syntaxin 4, and anti-VAMP2 antibodies.  Ponceau S 
staining shows input of GST fusion proteins. 
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Figure 2-2 Munc18c Does Not Co-immunoprecipitate with VAMP2 in Detergent 
Solubilized MIN6 Cell Lysates.  A) MIN6 beta cells were incubated in MKRBB for 
2 hours and harvested in 1% NP40 containing lysis buffer.  Lysates were divided 
into two portions and ~2 mg protein used for immunoprecipitation (IP) with anti-
Munc18c or anti-VAMP2 antibodies.  Lysate (lane 1) and immunoprecipitated 
proteins (lanes 2-4) were subjected to a 12% SDS-PAGE for immunoblotting (IB).  
TrueBlot anti-Rabbit Ig IP beads were substituted in for Protein G plus agarose to 
facilitate detection of SNAP-23.  B) MIN6 cells were transduced with NTAP-
Munc18c adenovirus (MOI=100).  Lysates were subsequently prepared in buffer 
containing 0.1% Triton X-100 (lanes 1-3), or 1% Triton X-100 (lanes 4-6).  SBP-
CBP column eluates were subjected to 12% SDS-PAGE for immunoblotting (IB) 
and comparison with input lysate (50 μg/lane) with an equivalent volume of CBP 
column flow-through (FT).  C)  Same as B) but eluted with higher salt (450mM 
NaCl). 
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2.3.2 Doc2β Preferentially Associates with Tyrosine Phosphorylated 
Munc18c 
We have previously shown that treatment of MIN6 cells with the protein 
tyrosine phosphatase inhibitor pervanadate (pV) results in accumulation of 
tyrosine-phosphorylated Munc18c, which corresponds to a decrease in Munc18c-
Syntaxin 4 interaction (95).  The region of Munc18c bound by Doc2β contains a 
key stimulus-induced phosphorylation site, Y219 (146).  To determine if the 
binding of Doc2β was related to the phosphorylation state of Munc18c, cells were 
treated for 5 minutes with 0.1 mM freshly-prepared pervanadate and detergent 
(1% NP-40 unless otherwise specified) cell lysates prepared for use in co-
immunoprecipitation experiments.  Pervanadate treatment resulted in a ~1.5 ± 
0.06-fold increase in phospho-Munc18c (P<0.01) as detected by anti-Munc18c 
immunoprecipitation from detergent lysate followed by 4G10 antibody 
immunoblotting (Figure 2-3A, lanes 1-2), with a 60 ± 3% decrease in Syntaxin 4 
co-precipitation (P<0.01), consistent with previous results (95).  Interestingly, pV 
treatment resulted in a coordinate 1.8 ± 0.09-fold increase in co-precipitation of 
Doc2β compared to untreated cell lysates (P<0.01).  This pattern of binding with 
phospho-Munc18c was fully recapitulated using detergent-solubilized plasma 
membrane (PM) fractions (Figure 2-3A, lanes 3-4), implicating the PM as the 
principal cellular locale of these events (1.5 ± 0.06-fold increase in phospho-
Munc18c, P<0.01; 60 ± 5% decrease in Syntaxin 4 co-precipitation, P<0.01; and 
2.2 ± 0.2-fold increase in co-precipitation of Doc2β, P<0.01).  As an additional 
approach, detergent lysates prepared from MIN6 cells over-expressing 
recombinant flag-Munc18c treated with or without pV were immunoprecipitated 
using anti-flag antibody for subsequent immunodetection of tyrosine-
phosphorylated Munc18c and co-precipitation of Syntaxin 4 and Doc2β (Figure 2-
2B).  Nearly identical results were obtained (1.5 ± 0.04-fold increase in phospho-
Munc18c, P<0.01; 60 ± 8% decrease in Syntaxin 4 co-precipitation, P<0.01; and 
1.8 ± 0.09-fold increase in co-precipitation of Doc2β, P<0.01) suggesting that the 
selective binding of Doc2β to the region of Munc18c containing the pivotal Y219 
residue was enhanced by phosphorylation at this site.  
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Figure 2-3 An Inverse Correlation Between Syntaxin 4 and Doc2β Association 
withTyrosine Phosphorylated Munc18c.  A) MIN6 beta cells were incubated in 
MKRBB for 2 hours prior to 15 minutes treatment with or without freshly prepared 
0.1 mM pervanadate.  Detergent solubilized (1% NP40) cleared cell lysates or 
plasma membrane (PM) fractions were immunoprecipitated (IP) with anti-
Munc18c and proteins resolved on 12% SDS-PAGE for immunoblotting (IB).  B) 
Lysates were prepared from MIN6 cells transfected with pcDNA3-Flag-Munc18c 
and incubated 48 hours prior to pervanadate treatment.  Anti-flag antibody was 
used for immunoprecipitation, and proteins resolved on 12% SDS-PAGE for 
immunoblotting.  Band intensities were quantified using the BioRad Chemi-Doc 
system and normalized to untreated (no pV) bands in either Syntaxin 4 (Syn4) or 
Doc2β immunoblots; data represent the average of 3 experiments, P<0.05. 
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2.3.3 The Hc-linker Region of Syntaxin 4 (Amino Acids 118-194) Confers 
Binding to Munc18c 
Recent structural data have shown that the N-terminal 19 amino acids of 
Syntaxin 4 constitute an important contact region for Munc18c binding, but that 
other contacts must contribute to its specificity of binding to Munc18c (114).  To 
investigate additional contact regions that were both necessary and sufficient to 
confer binding to Munc18c, truncated forms of Syntaxin 4 were used in GST 
interaction assays in vitro.  First, GST-Syntaxin 4 truncation proteins were 
expressed in E. coli and purified by glutathione sepharose precipitation, and 
subsequently thrombin-cleaved from GST.  Pure Syntaxin 4 mutant proteins were 
captured for use in binding assays with GST-Munc18c linked to beads. As shown 
in Figure 2-4A, four C-terminal truncation mutants of Syntaxin 4 were generated, 
with sequential deletion of the H3 domain (containing residues 1-194), up to the 
Hb domain (containing residues 1-112), and up to the Ha domain (containing 
residues 1-70).  Removal of the H3 domain failed to eliminate Syntaxin 4 binding 
to GST-Munc18c compared with binding of the full-length soluble Syntaxin 4 (1-
273, no transmembrane domain) (Figure 2-4A, lanes 1-2).  However, further 
deletion of the Hc-linker and Hb domains eliminated all binding to GST-Munc18c 
(Figure 2-4A, lanes 3-4).  This lack of binding did not result from insufficient 
Syntaxin 4 protein input (Figure 2-4A, lanes 7-8).  Further increases in input of 
the 1-70 protein failed to permit detection of association with GST-Munc18c (data 
not shown). 
 To determine the requirement for the Hc-linker region of Syntaxin 4 in 
mediating contact with Munc18c, N-terminal deletions of Syntaxin 4 were made.  
GST-Syntaxin 4 N-terminal deletion mutants were expressed and purified as 
described above, but were retained on sepharose beads for interaction studies 
with recombinant His-Munc18c protein.  His-Munc18c protein was expressed in E. 
coli and purified for use as previously described (146).  As depicted in Figure 2-
4B, GST-Syntaxin 4 N-terminal deletions were generated by removal of the first 
38 residues (GST-39-273), deletion through the Ha domain (GST-71-273), 
deletion through the Hb domain (GST-113-273), or removal of all but the  
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Figure 2-4 The Region Containing the HC and Linker Domains (118-194) of 
Syntaxin 4 Binds Directly to Munc18c In Vitro.  A) Bacterially expressed GST-
Munc18c or GST proteins were purified and linked to beads for in vitro binding 
studies with bacterially-expressed full length or C-terminal truncations of soluble 
Syntaxin 4.  The Syntaxin 4 fragments (1-70, 1 -112, 1-194, and 1-273) were 
thrombin cleaved to remove the GST tag and were prepared at the concentration 
1 mg/ml.  Bound Proteins were subjected to 18% SDS-PAGE for immunoblotting 
(IB) with anti-Munc18c and anti-Syntaxin4 antibodies.  Asterisks denote band of 
expected MW.  B) Bacterially expressed N-terminal truncations GST-Syntaxin 4 
(1-273, 118-194, 71-273, 113-273, and 39-273) or GST proteins were purified 
and linked to beads for in vitro binding studies with bacterially-expressed full 
length His-Munc18c.  Bound proteins were subjected to 12% SDS-PAGE for 
immunoblotting with anti-Munc18c antibody.  Ponceau S staining shows input of 
GST-Syntaxin 4 truncation proteins. 
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Hc-linker region (GST-118-194).  All three Syntaxin 4 N-terminal deletion mutants 
bound to His-Munc18c, as did the isolated Hc-linker region, while GST alone 
failed to precipitate the His-Munc18c protein (Figure 2-4B, lanes 1-6).  Thus, 
these data delineated the minimal region of Syntaxin 4 that was both necessary 
and sufficient to confer binding to Munc18c. 
 Alignment of this Hc-linker region of Syntaxin 4 with other mammalian PM-
localized syntaxin isoforms was performed using ClustalW (http://ca.expasy.org).  
Syntaxin 4 and Syntaxin 1A share 53% and 37% identity in their Hc and linker 
regions, respectively (Figure 2-5). Residues 155-163 at the C-terminal end of the 
Hc domain are highly conserved, arguing against this region functioning in 
Syntaxin binding specificity for its cognate Munc18 protein. However the N-
terminal 6 residues of the linker region (amino acids 164-169) of Syntaxin 4 vary 
considerably from those of Syntaxins 1A, 2 and 3. These data suggest that non-
conserved residues present in the Hc-linker region of Syntaxin 4 may participate 
in conferring its specificity for binding to Munc18c. 
 
2.3.4 The Hc-Linker Region (118-194) of Syntaxin 4 Competitively Inhibits 
Munc18c-Syntaxin 4 Association 
Next we sought to determine whether the Hc-linker region of Syntaxin 4 
was capable of competing with full-length soluble Syntaxin 4 for binding to 
Munc18c.  Either GST alone or GST-Munc18c proteins linked to Sepharose 
beads were preincubated with recombinant purified Syntaxin 4 (residues 1-273) 
and centrifuged to eliminate unbound Syntaxin 4 protein.  Syntaxin 4 binding was 
dose-dependent and specific, as determined by lack of interaction with GST 
alone or GST-nSec1 (neuronal Sec1/Munc18-1) (Figure 2-6A, lane 2 and Figure 
2-6B lane 5). Subsequent addition of Hc-linker protein to reactions containing 
pre-bound GST-Munc18c-Syntaxin 4 complexes decreased Syntaxin 4 binding to 
the GST-Munc18c (Figure 2-6B, lanes 2-4).  Because of its small molecular 
weight (~8 kDa), the Hc-Linker region of Syntaxin 4 protein was difficult to 
visualize by Coomassie or Ponceau S staining, and lacks the epitope for 
Syntaxin 4 antibody  
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Figure 2-5 Sequence Alignment of Hc-Linker Regions Amongst Mammalian 
Plasma Membrane-localized Syntaxin Isoforms.  ClustalW was used to align 
sequences of different Syntaxin proteins relative to amino acids 118-240, Hc-
Linker domains of rat Syntaxin 4 (http://ca.expasy.org/tools/#align).  R, rat; m, 
mouse; h, human.  Boxed region amino acids 164-169 shows region of highest 
heterogeneity amongst syntaxin isoforms. 
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Figure 2-6 The Hc-linker Region of Syntaxin 4 Effectively Competes with Full 
Length Soluble Syntaxin 4 for Binding of Munc18c In Vitro.  A) Bacterially 
expressed GST-Munc18c or GST proteins were purified and linked to beads and 
incubated at 4°C for 2 hours with bacterially-expressed soluble Syntaxin 4 
(residues 1-273, 10 μg).  Bound proteins were subjected to 12% SDS-PAGE for 
immunoblotting.  Ponceau S staining shows input of GST fusion proteins.  B) 
Bacterially expressed GST-Munc18c or GST-nSec1 proteins were purified and 
linked to beads and incubated at 4°C for 2 hours with recombinant soluble 
Syntaxin 4 protein (10 μg).  The GST-Munc18c-Syntaxin 4 complex was pelleted 
for subsequent addition of thrombin-cleaved competitor protein (residues 118-
194 of Syntaxin 4) and incubated for an additional 2 hours.  Bound proteins were 
subjected to 12% SDS-PAGE for immunoblotting (IB).  Ponceau S staining 
shows input of GST fusion proteins. 
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recognition.  Thus, the Hc-linker region was fused to the C-terminus of EGFP for 
confirmation of its binding to Munc18c and use in cell studies (schematic in 
Figure 2-7A). 
 To determine if the Hc-Linker region bound to Munc18c in cells, pEGFP-
(118-194) or pEGFP-C2 vector were co-electroporated with pcDNA3-Flag-
Munc18c into CHO-K1 cells and detergent lysates were prepared for use in 
immunoprecipitation reactions.  CHO-K1 cells transfect with very high efficiency, 
as evidenced by EGFP and Flag immunoblotting of lysates in Figure 2-7B (lanes 
1-2), but fail to express detectable levels of endogenous Munc18c.  Anti-Flag 
immunoprecipitation specifically co-precipitated the EGFP-(118-194) and not 
EGFP alone (Figure 2-7B, lanes 3-4).  The pEGFP-(118-194) construct was then 
transfected into MIN6 cells to determine its ability to bind to endogenous 
Munc18c (Figure 2-7C).  Anti-Munc18c selectively co-immunoprecipitated EGFP-
(118-194) with endogenous Munc18c, similar to results obtained in CHO-K1 cells. 
These data indicated that the interaction of EGFP-(118-194) with Munc18c was 
specific, and that this region of Syntaxin 4 was sufficient to confer binding in a 
relevant cell type. 
 
2.3.5 Functional Impact of Hc-Linker Region (Amino Acids 118-194) 
Expression Upon Insulin Exocytosis 
Two types of proteins are known to interact with the N-termini of Syntaxin 
proteins:  Munc18 and Munc13 (80,151).  Of these, only Munc18c is known to 
bind to Syntaxin 4. Munc13-1 binds to the second helix, known as Hb, of 
Syntaxins 1-3, but it is not yet known whether it associates with Syntaxin 4.  
Given this selectivity of binding, we predicted that the EGFP-(118-194) could be 
used in MIN6 cells to determine the functional impact of dissociating endogenous 
Munc18c-Syntaxin 4 complexes.  Transfection of MIN6 cells with the pEGFP-
(118-194) or pEGFP constructs resulted in ~30-50% cells exhibiting EGFP 
fluorescence.  Expression of the EGFP-(118-194) protein reduced 
coimmunoprecipitation of Syntaxin 4 with Munc18c by 25 ± 5% (P<0.01) 
compared to EGFP expression alone (Figure 2-8A).  
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Figure 2-7 Residues 118-194 of Syntaxin 4 Bind to Munc18c in CHO-K1 and 
MIN6 Beta Cells.  A) Schematic of constructs used:  Full length Munc18c with a 
Flag tag at the N-terminus and the Hc-Linker region (118-194) of Syntaxin 4 with 
a GFP tag at the N-terminus.  B) pEGFP-118-194 and pcDNA3-flag-Munc18c 
were co-electroporated into CHO-K1 cells, and 48 hours later detergent lysates 
were prepared for immunoprecipitation (IP) with anti-Flag antibody.  Proteins 
were subjected to a 12% SDS-PAGE and immunoblotted (IB) with anti-flag and 
anti-EGFP antibodies.  Lysates (50 µg) were included to show expression and 
correct migration of each recombinant protein.  C) pEGFP-118-194 and pEGFP 
were transfected into MIN6 beta cells and resulting detergent lysates used for 
immunoprecipitation with anti-Munc18c.  Proteins were subjected to a 12% SDS-
PAGE and immunoblotted with anti-EGFP, and anti-Munc18c.  Lysates show 
expression of EGFP and EGFP-118-194 proteins. 
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Figure 2-8 The Hc-linker Region (118-194) of Syntaxin 4 Interacts with 
Endogenous Munc18c and is Important for Insulin Exocytosis.   A) Over-
expression of Syntaxin 4 (118-194) in MIN6 cells inhibits the association of 
endogenous Syntaxin 4 with Munc18c.  Detergent cell lysates prepared from 
MIN6 cells transiently transfected to express EGFP-Syntaxin 4 (118-194) or 
vector control were used in immunoprecipitation (IP) reactions with anti-munc18c 
antibody.  Immunoprecipitated proteins were resolved on a 12% SDS-PAGE and 
immunoblotted (IB) with anti-Munc18c and anti-Syntaxin 4.  Munc18c 
immunoblotting confirms equal precipitation in each reaction.  B) Detergent cell 
lysates (2.5 mg) from MIN6 cells were incubated with 500 ng of recombinant 
Syntaxin 4 (118-194) or Syntaxin 4 (2-23) peptides for 2 hours at 4°C and used in 
immunoprecipitation reactions with anti-Munc18c.  Immunoprecipitated proteins 
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were resolved on a 10% SDS-PAGE for immunoblotting.  C) MIN6 cells were 
transiently transfected with either EGFP vector or EGFP-(118-194) plus human 
pro-insulin DNA, which served as a reporter of secretion specifically from 
transfectable cells.  After 48 hours of incubation, cells were preincubated in 
MKRBB for 2 hours and were stimulated with 20 mM glucose.  Human C-peptide 
secreted into the media was measured by RIA and normalized for total cellular 
protein content.  D) Detergent cell lysates prepared from MIN6 cells transfected 
to express EGFP-Syntaxin 4 (118-194) or vector control were incubated with 
purified GST-VAMP2 linked to beads.  Bound proteins were subjected to 12% 
SDS-PAGE for immunoblotting.  Ponceau S staining shows input of GST fusion 
proteins.  E) Fifty μg MIN6 lysate prepared from EGFP- or EGFP-(118-194)-
expressing cells were resolved on 12% SDS-PAGE for immunoblotting to show 
lack of effect upon SNARE protein expression. 
 56
Using a second approach, recombinant peptide was added to anti-
Munc18c immunoprecipitation reactions to evaluate the ability of the free peptide 
to disrupt endogenous Munc18c-Syntaxin 4 protein complexes.  The advantages 
of this approach were the ability to control peptide input level as well as obviate 
concern over EGFP-peptide cellular localization or differential susceptibility to 
proteasomal degradation.  As seen in Figure 2-8B, the Hc-linker region (residues 
118-194) effectively disrupted endogenous Munc18c-Syntaxin 4 complexes by 
50 ± 1% (P<0.005), whereas an identical quantity of the N-terminal Syntaxin 4 
peptide (residues 2-23) had no significant impact (97 ± 6% of control).  Taken 
together, these assays indicated that the 118-194 residue region of Syntaxin 4 
had the capacity to function as a competitive inhibitor of endogenous Munc18c-
Syntaxin 4 association in MIN6 cells. 
To evaluate its effect upon glucose-stimulated secretion, EGFP-(118-194) 
was co-transfected with human proinsulin cDNA into MIN6 cells.  The human C-
peptide derived from expression of human pro-insulin is immunologically distinct 
from the mouse C-peptide produced by MIN6 cells, and thus serves as a reporter 
of secretion only from transfected cells.  In control EGFP-expressing MIN6 cells, 
glucose induced a 38% increase in human C-peptide secretion (Figure 2-8C), 
similar to that in other reports (190,191).  However, expression of the EGFP-
(118-194) significantly increased glucose-stimulated secretion to nearly 60%.  As 
seen in Figure 2-8D, this secretory increase paralleled a 67 ± 3% increase in the 
capacity of endogenous Syntaxin 4 to bind to exogenous GST-VAMP2, 
compared with EGFP expression alone (P<0.01).  Over-expression of EGFP-
(118-194) had no effect upon expression of endogenous cognate interacting 
proteins (Figure 2-8E).  These data are consistent with recent Doc2β over-
expression studies (146) showing that partial disruption of Munc18c binding to 
Syntaxin 4 results in enhanced glucose-stimulated insulin release via enhancing 
Syntaxin 4 accessibility for docking.   
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2.3.6 The 118-194 Region Does Not Associate with Phosphorylated 
Munc18c 
Having identified the 118-194 region of Syntaxin 4 as a functional binding 
site for Munc18c in a relevant cell system, we next focused upon determining the 
relationship between the complexation of Munc18c with Syntaxin 4 and the 
tyrosine-phosphorylation of Munc18c in MIN6 cells.  Cells transiently expressing 
EGFP control protein or EGFP-(118-194) were briefly treated with pV and 
cleared detergent lysates prepared for immunoprecipitation of tyrosine-
phosphorylated proteins using anti-4G10 antibody (Figure 2-9).  While the EGFP-
containing lysate showed typical phospho-Munc18c and Doc2β co-
immunoprecipitation, the EGFP-(118-194)-containing lysates revealed 50 ± 5% 
less phospho-Munc18c (P<0.01) associated and 75 ± 9% less Doc2β (P<0.01).  
Importantly, EGFP-(118-194) binding to Munc18c was fully abolished by the 
tyrosine-phosphorylation of Munc18c.  This was not due to reduced expression of 
EGFP-(118-194) or increased expression of endogenous Syntaxin 4, as 
expression levels of each were similar to that of EGFP (Figure 2-9, lysate panels).  
This suggests that the 118-194 fragment may trap Munc18c in a conformation 
which prevents Munc18c’s phosphorylation at Y219, and hence abolishes its 
ability to coprecipitate Doc2β. 
 
2.3.7 Modeling the Munc18c-Syntaxin 4 Complex Interaction Sites 
Although it is assumed that Munc18c will bind to Syntaxin 4 with high 
affinity, based upon similarity to Munc18-1 interaction with Syntaxin 1A (188), 
kinetic measurements of the Munc18c-Syntaxin 4 interaction are lacking.  To 
address this, Surface Plasmon Resonance (SPR) data was collected using 
recombinantly expressed and purified His-Munc18c, Syntaxin 4 (1-273), and 
Syntaxin 4 (118-194) proteins (Figure 2-10).  Analysis of SPR data revealed an 
association rate constant (ka) of 9.22 x 105 and a dissociation rate constant (kd) 
of 2.96 x 10-2 with Munc18c-Syntaxin 4 (1-273), as shown in Figure 2-9A. From 
these data, the calculated equilibrium dissociation constant (KD = kd/ka) was 32 
nM.  The fast association rate, which approaches the diffusion limit, is suggestive 
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of a small free energy barrier for association of Munc18c with Syntaxin 4.  The 
slow dissociation rate suggests a steeper barrier for the reverse process 
indicating that the complex formation is exergonic.  Munc18c binding to the 118-
194 region of Syntaxin 4 resulted in association and dissociation rate constants 
of 473 s-1 and 2.4 x 10-3 s-1, respectively (Figure 2-10B).  These values led to a 
dissociation equilibrium constant of 5 x 10-6 M-1, which is nearly three orders of 
magnitude lower than that of full-length soluble Syntaxin 4.  The lower affinity for 
the fragment is mostly attributed to its significantly slower association rate to 
Munc18c, suggesting a larger free energy barrier that the complex must 
overcome to bind.  While different from that of full-length soluble Syntaxin 4, 
these data clearly demonstrate the ability of the 118-194 region to confer 
Syntaxin 4 binding to Munc18c. 
To model this high-affinity interaction we used the three-dimensional 
crystal structures of Munc18c-Syntaxin 4 (114) and nSec1-Syntaxin 1A complex 
(110) to compile a structure of the Munc18c-Syntaxin 4 complex.  More 
specifically, the crystal structure of Munc18c was used and a homology model of 
Syntaxin 4 was constructed by using the crystal structure of Syntaxin 1A.  The 
structure is likely highly accurate in light of the high (80%) sequence identity 
between Syntaxin 4 and Syntaxin 1A (110).  We modeled the Munc18c-Syntaxin 
4 complex illustrating how Syntaxin 4 anchors it to the plasma membrane 
through a carboxyl-terminal transmembrane helix (Figure 2-11A).  Munc18c is 
shown in blue and the Doc2β binding site on Munc18c, the N-terminal region 
residues 173-255 (146), is in orange.  The short red region next to the Doc2β 
binding site corresponds to the first 19 amino acids of Syntaxin 4 that has been 
crystallized in complex with Munc18c (114).  Syntaxin 4 N-terminal domains Ha, 
Hb, Hc and linker (residues 39-193) regions are shown in red (right) and Syntaxin 
4 C-terminal domain H3 (residues 194-273), also known as the SNARE binding 
domain, is shown in yellow.  The absence of the region between residues 1-19 
and 39-273 of Syntaxin 4 suggests that this region is highly dynamic in solution.  
The N-terminal region of Syntaxin 4 (1-19) is remarkably close to the Doc2β and 
the Y219 residue of Munc18c known to undergo phosphorylation (95).  More  
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Figure 2-9 Syntaxin 4 (118-194) Does Not Bind to Phosphorylated Munc18c.  
MIN6 beta cells were transfected with pEGFP-118-194 and pEGFP, and 48 
hours later were incubated in MKRBB for 2 hours prior to 15 minutes treatment 
with freshly prepared 0.1 mM pervanadate.  Cleared detergent cell lysates were 
prepared for immunoprecipitation (IP) with anti-4G10 antibody.  Proteins were 
resolved on 10% SDS-PAGE and immunoblotted (IB) with anti-Munc18c, anti-
Doc2β, anti-EGFP, and anti-Syntaxin 4 antibodies. 
 60
 
Figure 2-10 Sensorgram Depicting the Kinetic Analysis of Munc18c Binding to 
Syntaxin 4.  Munc18c protein was injected at concentrations of 0, 1.7, 3.3, 6.7, 
13.3, 26.7, and 53.3 nm, respectively.  Dissociation was monitored for 3 minutes: 
A) soluble Syntaxin 4 (residues 1-273), B) region containing residues 118-194 of 
Syntaxin 4.  The association data and dissociation data were fit to a 1:1 binding 
model to determine kinetics of binding.  
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Figure 2-11 Ribbon Representation of the Munc18c-Syntaxin 4 Complex.  A) 
Overall illustration of Syntaxin 4 interacting with Munc18c in close proximity to 
the plasma membrane (PM).  Munc18c is shown in blue, Doc2β binding site on 
Munc18c in brown, and Syntaxin 4 N-terminus (amino acids 1-19) to the left in 
red.  To the right in red is Syntaxin 4 N-terminal domains Ha, Hb, and Hc.  The 
Syntaxin 4 C-terminal domain H3 (SNARE binding domain) is illustrated in yellow.  
B) A close up view illustrating Syntaxin 4 R2 interacting with full length Munc18c 
and Munc18c E223 interacting with a nitrogen in the backbone of Syntaxin 4 
which results in a strong hydrogen bond.  C) A close up illustration showing two 
contact sites between Munc18c (blue) and the Hc-Linker domain (green) of 
Syntaxin 4.  Arrows point to the two contact regions between Munc18c and 
Syntaxin 4 (118-194). 
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specifically, Figure 2-11B shows that interactions between Syntaxin 4 and 
Munc18c close to Y219 are mediated by R2 located on Syntaxin 4 and appears 
to be a water-mediated interaction with Munc18c.  Another interaction occurs 
between K17 and E223 on Munc18c that are found to interact with a backbone 
nitrogen in Syntaxin 4.  Collectively, these interactions would contribute to the 
introduction of sufficient stability to the Munc18c-Syntaxin 4 complexes so as to 
maintain Munc18c in the conformation where Y219 is buried and unable to be 
phosphorylated, and may underlie the binding preference of Syntaxin 4 for 
unphosphorylated Munc18c.  Furthermore, upon dissociation of Syntaxin 4 from 
Munc18c, a loop that holds the Y219 residue might more easily flip open to 
expose Y219 for phosphorylation and Doc2β binding. 
 The Hc-linker region of Syntaxin 4 (residues 118-194) shown in green 
interacts with Munc18c in two distinct areas as indicated by the arrows (Figure 2-
11C).  One interaction (right arrow) includes possible hydrophobic interactions 
between Syntaxin 4 residues V118, M122, Q126, V129, Q132, and Q133 and 
Munc18c.  This is intriguing given that M122, Q132 and Q133 are found only in 
the Syntaxin 4 isoform and not in Syntaxin isoforms 1-3, whereas Q126 is 
conserved amongst all isoforms.  The other hydrophobic interaction region of 
Syntaxin 4 contains a conserved R149.  Future crystallographic analyses of 
these regions or the entire soluble Syntaxin 4 protein will be required to validate 
these proposed contacts. 
 
2.4 DISCUSSION 
In an effort to reconcile discrepancies in models of Munc18c-Syntaxin 4 
complex dynamics derived primarily from in vitro data, we used the islet beta cell 
as model system of regulated exocytosis that is known to require Munc18c-
Syntaxin 4 interaction.  Herein, we demonstrate that the induction of Munc18c 
tyrosine phosphorylation is an important trigger for Munc18c to switch its binding 
specificity from Syntaxin 4 to Doc2β in the beta cell.  Modeling studies showed a 
putative role for the N-terminal peptide of Syntaxin 4 in this switch mechanism, 
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given its close proximity to the Y219 site lying within the Doc2β binding site on 
Munc18c.  However mutagenesis studies further revealed the necessity of the 
Hc-linker region of Syntaxin 4, which was also found to be sufficient to confer 
binding to Munc18c.  Binding of the novel Hc-linker binding site was confirmed by 
SPR, and its expression in MIN6 cells was found to effectively disrupt 
endogenous Munc18c-Syntaxin 4 complexes.  Functionally, this enhanced 
glucose-stimulated insulin exocytosis via increasing Syntaxin 4 accessibility to 
VAMP2.  Moreover, phosphorylation of Munc18c reduced its association with Hc-
linker, suggesting that the Hc-linker region is involved in the switching 
mechanism.  These data represent a new and important region of Syntaxin 4 on 
which to focus in our efforts to delineate the dynamic conformational changes 
and associated functional modes of the Munc18c-Syntaxin 4 complex as it 
pertains to regulated exocytosis.  
In contrast to some recent reports of preferential Munc18 interaction with 
Syntaxins engaged in SNARE core complex assembly using in vitro paradigms, 
our results were obtained using endogenous proteins present in MIN6 beta cell 
lysates, and demonstrate the predominance of binary Munc18c-Syntaxin 4 
complexes in cells, with no detection of Munc18c-SNARE complexes.  Although 
it is certainly possible that Munc18c-SNARE complexes might exist transiently, 
our data combined with the current literature suggest that in endocrine cells such 
as pancreatic beta cells and 3T3L1 adipocytes Munc18c mostly associates with 
monomeric Syntaxin 4 (114).  The rationale behind Munc18c binding to and 
facilitating formation of Syntaxin-SNARE complexes has been founded upon in 
vitro data.  However, we show here that the N-terminal peptide is dispensable for 
conferring Syntaxin 4 binding in cells, and rather that the association is conferred 
by the Hc-linker region.  Moreover, the N-terminal peptide failed to competitively 
inhibit endogenous Munc18c-Syntaxin 4 association, while Hc-linker was an 
effective competitor and SPR data supported its ability to stably interact with 
Munc18c.  Concomitant with these findings, other reports demonstrate that the 
99N-terminal peptide of Syntaxin 1A or Syntaxin 4 is insufficient to confer the 
binding interaction (115,116).  Most recently, Weis and Fasshauer (192) used 
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isothermal titration calorimetry and fluorescence spectroscopy to confirm that the 
binary interaction between Munc18-1 and Syntaxin 1A for the ‘closed 
conformation’ did require contact sites which included the N-terminal peptide, but 
show that removal of the first 24 residues of Syntaxin 1A only reduces the Kd 
from 1 nM to 8 nM, indicating that there is only a small contribution of the N-
peptide.  
 Our modeling studies indeed support the concept that the N-terminal 
peptide of Syntaxin 4 binds to Munc18c, but also expand upon this by further 
speculating that this peptide might actively participate in the dissociation 
mechanism involving exposure of Y219 of Munc18c, along with participation of 
the Hc-linker region of Syntaxin 4.  Evidence supportive of Hc-linker function in 
this phosphorylation-dissociation mechanism stems from the loss of Hc-linker 
binding to phosphorylated Munc18c, contrasting with its otherwise robust binding 
to Munc18c in vitro and in unstimulated MIN6 cells.  One possible explanation for 
this is that the 118-194 fragment held Munc18c in a conformation that is 
unfavorable for Munc18c to become phosphorylated.  Alternatively, Munc18c 
phosphorylation may have triggered dissociation of Hc-linker, as it does with full-
length endogenous Syntaxin 4.  However our data do not fully support this latter 
scenario, given the 50% loss of Munc18c phosphorylation detected in EGFP-
118-194-expressing cells.  Thus while the first explanation seems more plausible, 
future conformational studies of the phosphorylated form of Munc18c will be 
required to confirm or dispute this concept.  
A recent NMR study demonstrated that Munc18-1 binds to and prevents 
the opening of Syntaxin 1A, and that an additional factor helps to transition 
Syntaxin into the open conformation (193).  Doc2β would seem a suitable 
candidate for the ‘additional factor’, given our finding that it preferentially bound 
the tyrosine-phosphorylated form of Munc18c, and that the increase in binding to 
Doc2β was proportional to the decrease in Syntaxin 4 association.  Our modeling 
studies revealed a close proximity of the Syntaxin N-terminal peptide to a 
solvent-exposed Doc2β binding site on Munc18c which contains the Y219 
phosphorylation site.  Incorporation of Doc2β into the binding model with 
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Munc18c-Syntaxin 4 provides new insight into the mechanism by which Munc18c 
dissociates, whether partially or fully, from Syntaxin 4.  However, it is predicted 
that this protein triad is further impacted by proteins such as Munc-13 and 
Tomosyn, which like Doc2β have been shown to regulate and inhibit Munc18-
Syntaxin complexes.  Although Munc13-1 has not yet been shown to participate 
in Syntaxin 4-based complexes, the UNC-13 homolog from C. elegans was 
shown to displace Syntaxin from the Munc18-Syntaxin (UNC-18-Syntaxin) 
complex by competing for binding to Munc18 (194).  In addition, Munc13-1 can 
bind directly to an N-terminal region of Doc2β and also to the Hb domain of 
Syntaxin 1A, which was later shown to stabilize Syntaxin in its open conformation 
(195).  Tomosyn binds to Syntaxin 1A and Syntaxin 4 through their H3 domains, 
the same region bound by VAMP2 and SNAP25 (113,169).  Thus, it may be that 
the presence of these and other proteins in cell lysates in combination with 
stimulus-induced post-translational modifications such as the tyrosine-
phosphorylation of Munc18c is the reason for the discrepant results gained by in 
vitro studies as opposed to those conducted using mammalian cell systems. 
 Assigning a role to Munc18c as either a positive SNARE complex 
interacting protein as opposed to a negative closed Syntaxin 4 ‘clamping’ protein 
has also varied as a function of detergent conditions used.  For example, titration 
studies demonstrated the ability of Munc18 to displace SNAP-25 and VAMP2 
from Syntaxin 1, coordinate with the ability to co-immunoprecipitate only Syntaxin 
1 with anti-Munc18 antibody but not SNAP-25 or VAMP2 from detergent-
solubilized (1% Triton X-100) synaptosomal membranes (80,127,128).  However, 
more recent studies show that while the Munc18-Syntaxin binary complex does 
predominate, under in vitro conditions containing little (0.1% Triton X-100) or no 
detergent, SNARE complexes bound by Munc18 were detected 
(116,129,186,196).  Using a novel immunofluorescent approach, it was shown 
that Syntaxin 1 bound to Munc18-1 could also bind SNAP-25, but that addition of 
VAMP2 displaced Munc18-1 (130).  The current general consensus is therefore 
that Munc18-1-Syntaxin 1 complexes predominate and likely function in 
regulating vesicle docking (197).  The molecular mechanism of Munc18c function 
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is equally controversial.  For example, Munc18c reduced the binding of SNAP23 
to Syntaxin 4 in a concentration-dependent manner when evaluated in 1% Triton 
X-100 solubilized cell lysates (69), yet under low-stringency detergent conditions 
Munc18c binding to Syntaxin 4-bound SNARE core complexes was detected 
(129).  Indeed the benefit of using low-stringency buffers was the ability to detect 
the otherwise elusive transient docking complex.  However, biochemical 
validation of the formation of this complex by endogenous proteins in cells awaits 
further investigation.  
 In summary, the model presented in this paper provides a new 
base/scaffold for building in these additional Syntaxin4-Munc18c-Doc2β 
interacting proteins, and serves to explain in part the mechanistic role for 
Munc18c in stimulus-induced Syntaxin 4 engagement in exocytosis.  In addition 
to tyrosine phosphorylation, other modifications such as glycosylation and 
serine/threonine phosphorylation of Munc18c still need to be incorporated into 
this model.  Munc18c becomes O-linked glycosylated in 3T3L1 adipocytes to 
inhibit insulin-stimulated GLUT4 vesicle translocation (143).  Serine/threonine 
phosphorylation of Munc18c by PKC has been suggested to dissociate it from 
Syntaxin 4 and facilitate SNARE complex assembly in pancreatic acinar cells 
(136).  Very recently, S-nitrosylation of Syntaxin 1 was shown to alter affinity for 
Munc18-1 (142).  Therefore, further studies of various post-translational Munc18c 
modifications will be important for fully understanding its impact upon Syntaxin 4 
conformation and role in exocytosis in physiologically relevant exocytosis events. 
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CHAPTER 3: IDENTIFICATION OF AN INSULIN-STIMULATED MUNC18C 
TYROSINE KINASE IN ADIPOCYTES AND SKELETAL MUSCLE 
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Identification of an Insulin-stimulated Munc18c Tyrosine Kinase in Adipocytes 
and Muscle. 
Author Contributions:  Tagliabracci VS generated data for Figures 3-1B, 3-2B, 
and 3-6.  Oh E. assisted in the mice work, generation of the Munc18c Phospho-
Tyrosine 219 antibody, and microscopy.  The rest of the data and text was 
generated by Jewell JL. 
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3.1 INTRODUCTION 
Insulin-stimulated GLUT4 vesicle translocation is mediated by Syntaxin 4-
based SNARE protein complexes (reviewed in (7,198)).  The GLUT4 vesicle-
associated SNARE protein (VAMP2) complexes with the binary cognate receptor 
complex at the target membrane composed of SNAP23 and Syntaxin 4 proteins 
(t-SNAREs) to form a SNARE heterotrimeric complex (9,25,49,70,199,200).  The 
Munc18c isoform of the Sec1/Munc18 secretory protein family further regulates 
this SNARE core complex through its ability to directly bind to Syntaxin 4 at the 
plasma membrane in 3T3L1 adipocytes and skeletal muscle 
(1,26,53,55,81,93,95,146,157,201).  Reductions in the endogenous protein level 
of Munc18c in mice and humans are implicated in the incidence of insulin 
resistance and Type 2 diabetes, presumed to be necessary for facilitating 
Syntaxin 4 function in GLUT4 vesicle translocation and fusion, although the 
detailed molecular mechanistic action(s) of this regulatory protein are perplexing. 
It has recently been determined by our laboratory and others that 
Munc18c-Syntaxin 4 complexes undergo numerous phosphorylations in 
response to a variety of stimuli, leading to confusion as to its differing actions 
when compared across tissues.  For example, Syntaxin 4 becomes tyrosine 
phosphorylated in adipocytes upon stimulation by insulin (140), while in islet beta 
cells Syntaxin 4 does not undergo phosphorylation in response to glucose (95).  
However in adipocytes and islet beta cells, we and others have shown that the 
Munc18c isoform undergoes stimulus-induced phosphorylation at residues Tyr 
521 and Tyr 219 respectively.  The identification of a common mechanism, if 
targeted therapeutically, could simultaneously improve insulin release from the 
beta cell and glucose clearance from the muscle and adipose tissue, which 
would be of great value for the treatment of Type 2 diabetes.  However, the 
kinase(s) responsible for phosphorylating Munc18c are unknown. 
In the present study, we have identified the first known tyrosine kinase for 
Munc18c, the Insulin Receptor (IR).  Further investigations using 3T3L1 
adipocytes and skeletal muscle extracts indicate that Munc18c interacts with the 
IR tyrosine kinase in an insulin-dependent manner resulting in phosphorylation of 
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Munc18c, coordinate with the timing of its dissociation from Syntaxin 4.  Finally, 
knockdown of endogenous Munc18c decreased GLUT4 translocation to the 
plasma membrane in 3T3L1 adipocytes.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials  
Rabbit anti-Munc18c antibody was generated as previously described (81). 
Anti-phosphotyrosine monoclonal antibody (4G10) was obtained from Upstate 
Biotechnology.  Monoclonal PY20 and clathrin were purchased from BD 
Biosciences.  Rabbit polyclonal antibodies anti-phospho AKT (T308) and AKT 
(pan) were purchased from Cell Signaling.  Rabbit polyclonal anti-Syntaxin 4 was 
obtained from Chemicon (Temecula, CA), rabbit polyclonal anti-IR and anti-IR 
HRP from Santa Cruz Biotechnology, and monoclonal anti-IRS-1 from Millipore.  
The rabbit polyclonal Munc18c phosphotyrosine 219 peptide antibody was 
generated by PhosphoSolutions (Aurora, CO).  Mouse anti-Myc was from Santa 
Cruz Biotechnology and rabbit anti-Myc antibody was from Upstate.  Goat anti-
mouse and anti-rabbit horseradish peroxidase secondary antibodies were 
acquired from Bio-Rad (Hercules, CA).  Monoclonal Flag antibody, bovine serum 
albumin were purchased from Sigma (St. Louis, MO).  The insulin, insulin like 
growth factor (IGF-1), and wortmannin used in the cell culture studies were 
obtained from Sigma.  Protein G plus agarose was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Enhanced chemiluminescence (ECL) and 
SuperSignal West Femto reagents were obtained from Amersham Biosciences 
(Pittsburgh, PA) and Pierce (Rockford, IL), respectively.  The IR inhibitor 
HNMPA-(AM)3 used for these studies was from Biomol International. 
 
3.2.2 Plasmids  
The generation of pcDNA3.1-flag-Munc18c, pGEX4T1-Syn4 (1-273), 
pET28a(+)-His-Munc18c, pGEX-Munc18c, pSilencer 1.0-siControl, and pSilencer 
1.0-siMunc18c #2 plasmids has been previously described (56,81,146,157).  The 
siRNA resistant pcDNA3-Munc18c-WT, -Y219F and -Y521F constructs were 
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made using the Quick-Change II site-directed mutagenesis kit (Stratagene) 
according to the manufacturer's protocol, and DNA sequencing used for 
validation.   
 
3.2.3 Cell Culture and Transient Transfection  
Murine 3T3-L1 preadipocytes were cultured in DMEM that contained 25 
mM glucose, 10% calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 
and 292 μg/ml L-glutamine at 37°C in an 8% CO2 atmosphere. Confluent cultures 
were fully differentiated into adipocytes as previously described (143,202).  All 
studies used adipocytes that were between 8 and 12 days after differentiation, 
upon full differentiation.  Differentiated adipocytes were co-electroporated (0.16 
kV and 960 microfarads) with 50 μg of Myc-GLUT4-EGFP, 200 μg of additional 
plasmid DNA.  After electroporation the cells were allowed to adhere to 
coverslips in 35-mm tissue culture dishes for 48 hours and were used for 
confocal microscopy. 
 
3.2.4 Co-immunoprecipitation and Immunoblotting  
Adipocytes - Whole cell detergent extracts were prepared by solubilization 
in NP-40 lysis buffer (1 M HEPES, pH 7.4, 1% Nonidet P-40, 10% glycerol, 50 
mM sodium fluoride, 10 mM sodium pyrophosphate, 137 mM sodium chloride, 1 
mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 1 
μg/ml pepstatin, 5 μg/ml leupeptin) rotating for 10 minutes at 4°C.  Insoluble 
material was removed by microcentrifugation for 10 minutes at 4°C.  Cleared 
whole cell detergent lysate (2–4 mg) was combined with primary antibody for 2 
hours at 4°C followed by a second incubation with protein G Plus-agarose for 2 
hours.  The resultant immunoprecipitates were subjected to a 10% or 12% SDS-
PAGE followed by transfer to PVDF membranes for immunoblotting:  Munc18c 
and Syntaxin 4 antibodies were used at 1:5000, IRS-1, IR, Clathrin, 4g10, PY20, 
and AKT were used at 1:1000, and PAKT used at 1:500.  Secondary antibodies 
conjugated to horseradish peroxidase were diluted at 1:5,000 for visualization by 
ECL for detection using a Chemi-Doc documentation imaging system (Bio-Rad). 
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 Skeletal Muscle – Mice were fasted 8am-12pm (male, 3-4 months, 
C57BL/6J), then injected intraperitoneally with 10 U/kg of insulin (Humulin R, Eli 
Lilly Indianapolis IN, diluted in saline); control mice were injected with a similar 
volume of saline.  After 5 minutes mice were sacrificed by cervical dislocation 
and hind limb skeletal muscle was excised immediately and frozen in liquid 
nitrogen.  Frozen tissues were subsequently pulverized under liquid nitrogen and 
stored at -80°C until use.  All subsequent steps were performed at 4°C:  frozen 
powdered tissue samples were homogenized in 10 volumes (w/v) of a buffer 
containing 50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 2 mM EGTA, 1% Triton X-
100, 0.1 mM N-p-tosyl-L-lysine chloromethyl ketone, 2 mM benzamidine, 0.5 mM 
phenylmethylsulfonyl fluoride, 10 µ/mL leupeptin and 1mM Na3VO4 using a tissue 
tearer (Biospec Products Inc.).  Homogenates were then centrifuged at 3600 ×g 
for 10 minutes, and resultant supernatants used in anti-Munc18c 
immunoprecipitation reactions.  Briefly, 2-3 mg of skeletal muscle lysate was 
combined with anti-Munc18c antibody for 2 hours at 4oC followed by incubation 
with protein G Plus-agarose for 2 hours.  Beads were extensively washed using 
lysis buffer and co-immunoprecipitated proteins resolved on a 10% SDS-PAGE. 
     
3.2.5 In Vitro Kinase Assays 
 In vitro protein kinase activity assays were performed by quantifying the 
incorporation of [32P] phosphate from [32P] ATP into recombinantly expressed 
and purified His-Munc18c protein, using the activated β-subunit of the IR as the 
source of the kinase (Millipore).  The reaction contained 50 mM Tris HCl (pH 7.5), 
0.1 mM EGTA, 0.1 mM Na3VO4, 0.1% β-mercaptoethanol, 10 mM MnCl2, 50 μM 
[32P] ATP with a specific radioactivity of 2000 cpm/pmol, and of His-Munc18c 
protein substrate for the time points indicated.  Reactions were stopped by the 
addition of Laemmli sample buffer and boiling for 5 minutes.  Proteins were 
separated by 10% SDS-PAGE and gels then stained with Coomassie Blue, and 
dried.  The phospholabeled proteins were detected by autoradiography, and 
bands subsequently excised from gels and quantitation of γ32P incorporation by 
scintillation counting.  The IRS-1 (Y608) peptide substrate (Biomol International 
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Inc.) was incubated in the presence of [γ32P] ATP with or without the recombinant 
β-subunit of the IR in the same reaction buffer and spotted on filter paper.  The 
peptide was then precipitated with 1% phosphoric acid, washed with acetone, 
dried, and incorporation of radioactivity determined by scintillation counting. 
 In addition, in vitro kinase assays were performed with non-radiolabled [γ 
32P] ATP, using instead GST-Munc18c, GST-Munc18c-Y219F, or GST-Munc18c-
Y521F with or without the recombinant activated β-subunit of the IR in a reaction 
buffer (described above) for 30 minutes.  The reaction was stopped with Laemmli 
sample buffer and subjected to 10% SDS-PAGE followed by transfer to PVDF 
membrane for immunoblotting.  The phosphorylation of Munc18c was determined 
by the anti-phosphotyrosine monoclonal antibody 4G10.   
 
3.2.6 Computer Modeling 
 The three-dimensional crystal structure of the Munc18c complex (PDB 
code 2PJX) was used to illustrate the locations of 219 and 521.  This was carried 
out with the computer program PyMol.  
 
3.2.7 Myc-GLUT4-EGFP Translocation Analysis 
Forty-eight hrs following transfection, 3T3-L1 adipocytes were fixed with 
4% formaldehyde in phosphate-buffered saline (PBS, pH 7.4) on coverslips for 
20 minutes at RT, washed three times with PBS and permeabilized (only in cells 
co-transfected with pFlag-Munc18c DNA) in 0.2% Triton X-100 at RT for 15 
minutes.  Fixed cells were rinsed with PBS three times (if permeablized) and 
blocked (1% bovine serum albumin and 5% donkey serum in PBS) at 4°C 
overnight.  Coverslips were incubated with anti-Myc monoclonal or polyclonal 
antibody (1:50, when co-transfected with pFlag-Munc18c DNA) for 1 hour and 
the Alexa555-conjugated secondary (1:50) antibody for 1 hour.  Anti-Flag 
monoclonal antibody (1:50) was used to detect Flag Munc18c and Flag Munc18c 
mutants for 1 hour and the Alexa405-conjugated secondary antibody for 1 hour.   
 
 
 74
3.2.8 Confocal Microscopy 
Fully differentiated non-transfected 3T3L1 adipocytes were incubated in 
serum free media for 2 hours, treated with pervanadate (0.1 mM) for 15 minutes, 
followed by fixation with 4% formaldehyde in PBS on coverslips for 20 minutes at 
RT, washed three times with PBS and permeabilized in 0.2% Triton X-100 at RT 
for 15 minutes.  Fixed cells were rinsed with PBS three times (if permeablized) 
and blocked.  Coverslips were incubated with anti-Munc18c phospho-tyrosine 
219 primary antibody (1:50) for 1 hour with the addition of the peptide competitor 
(500 ng) in its non-phosphorylated or phosphorylated state.  FITC-conjugated 
anti-secondary antibody was then applied for 1 hour for subsequent confocal 
immunofluorescent microscopy analysis. 
 
3.2.9 Statistical Analysis 
 All data are expressed as mean ± S.E.  Data were evaluated for 
statistical significance using an unpaired two-tail Student's t test. 
 75
3.3 RESULTS 
3.3.1 Insulin Stimulates Munc18c-IR Association Concurrent with Munc18c 
Tyrosine Phosphorylation in Adipocytes and Skeletal Muscle. 
 We and others have previously reported the rapid tyrosine 
phosphorylation of Munc18c in 3T3L-1 adipocytes in response to insulin 
stimulation (95,140,141).  To better define the temporal pattern of Munc18c 
phosphorylation in fully differentiated 3T3L-1 adipocytes, the cells were 
stimulated with 100 nM insulin for 5, 15, or 30 minutes and the cell lysates were 
prepared (Figure 3-1A).  While unstimulated adipocytes contained a low but 
detectable level of tyrosine-phosphorylated Munc18c, within 5 minutes of insulin 
stimulation Munc18c tyrosine phosphorylation levels rose more than two-fold (2.1 
± 0.01-fold, p<0.05).  However, after 10 minutes of insulin stimulation, no 
detectable Munc18c tyrosine phosphorylation remained. 
In general the GLUT4 translocation mechanisms are conserved in skeletal 
muscle and adipocytes, but Munc18c tyrosine phosphorylation has yet to be 
reported for skeletal muscle.  Therefore, mouse hindlimb muscle homogenates 
were prepared for anti-Munc18c immunoprecipitation reactions (Figure 3-1B).  
Twelve C57BL/6J male mice, matched for body weight (3-4 months age), were 
fasted for four hours (8am-12pm) in clean feed-free cages, and injected 
intraperitoneally with 10 U/kg of insulin or with a similar volume of saline.  After a 
5 minutes incubation, mice were sacrificed and entire hindlimb muscles rapidly 
excised for preparation of cleared detergent extracts for use in 
immunoprecipitations and detection of insulin-stimulation of tyrosine 
phosphorylation.  Consistent with the adipocyte data, Munc18c tyrosine 
phosphorylation increased by nearly two-fold (1.82 ± 0.09-fold, p<0.05) in insulin 
stimulated skeletal muscle extracts.  As a positive control for the action of insulin, 
phospho-AKT detection was analyzed, clearly showing the expected downstream 
activation of AKT.  Taken together, these data show that the rapid insulin-
stimulation of Munc18c tyrosine phosphorylation is a conserved event in 
adipocytes and skeletal muscle. 
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Figure 3-1 Insulin Stimulation Increases Munc18c Tyrosine 
Phosphorylation.  A) Munc18c was immunoprecipitated (IP) from 3T3L1 
adipocytes with or without insulin (100nM) for the indicated time points.  Proteins 
were subjected to a 10% SDS-PAGE and immunoblotted (IB) with anti-Munc18c 
and striped for detection of P-Tyr Munc18c using the tyrosine antibody 4G10.  
Quantitation of 3 independent experiments below panel, *p<0.05 significance for 
Munc18c tyrosine phosphorylation under basal conditions vs. insulin stimulation. 
B) Munc18c was IP from mouse muscle hindlimb homogenates with or without 
insulin (10U/kg, for 5 min) stimulation for the indicated time points.  Proteins were 
subjected to a 10% SDS-PAGE and IB with anti-Munc18c and stripped for 
detection of P-Tyr Munc18c using the tyrosine antibody 4G10.  The 
phosphorylation of AKT (T301) in extracts was immunoblotted as validation of 
insulin activation using this protocol.  Quantitation of 12 mice (6 injected with 
saline and 6 injected with insulin) below panel, *p<0.005 significance for 
Munc18c tyrosine phosphorylation under basal conditions vs. insulin stimulation.   
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To initiate the identification of the Munc18c kinase, inspection of the Munc18c 
amino acid sequence by the ExPASy Proteomics Server (NetPhosk 1.0 Server, 
http://www.cbs.dtu.dk/services/NetPhosK/)  and Group-based Prediction System 
(203) revealed the presence of potential IR tyrosine phosphorylation consensus 
sites at tyrosine 219 (EKKLEDYYKIDEKGL) and tyrosine 521 
(RQKPRTNYLELDRKN).  To test this hypothesis, the potential Munc18c-IR 
interaction was examined in insulin-stimulated adipocytes and muscle (Figure 3-
2B and C).  Anti-Munc18c antibody effectively co-immunoprecipitated the IR from 
3T3L1 adipocytes stimulated with insulin (2 ± 0.1-fold, p<0.05) versus 
unstimulated cells (Figure 3-2B), and similar results were obtained using 
stimulated muscle extracts by 2.7 ± 0.03-fold (p<0.0005, versus unstimulated 
controls, Figure 3-2C).  Specificity for the action of insulin upon IR interaction 
was confirmed by demonstration of a 1.7-fold increase in the IR association with 
its well known substrate, the Insulin Receptor Substrate (IRS-1) under similar 
insulin-stimulated conditions (Figure 3-2A).  These data supported the prediction 
that the IR serves as an insulin-stimulated tyrosine kinase for Munc18c in both 
adipocytes and skeletal muscle, and suggest that the activated IR preferentially 
associates with Munc18c. 
 
3.3.2 Pervanadate Mimics the Effects of Insulin  
 We have previously shown that in β-cells the protein-tyrosine phosphatase 
inhibitor pervanadate (pV) increases the tyrosine phosphorylation of Munc18c, 
and correspondingly reduces its association with Syntaxin 4 (95,139).  To 
determine whether this mechanism is conserved in insulin-responsive cell types, 
3T3L1 adipocytes were treated with freshly prepared 0.1 mM pervanadate for 15 
minutes and resultant detergent lysates used for anti-Munc18c co-
immunoprecipitation experiments.  In the absence of insulin stimulation, 
pervanadate treatment resulted in a 1.6 ± 0.07-fold (p<0.005) increase in the 
abundance of tyrosine-phosphorylated Munc18c compared to untreated cells, as 
detected by 4G10 (P-Tyr) antibody immunoblotting (Figure 3-3A, bar graph).   
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Figure 3-2 Munc18c-IR Association Increases Upon Insulin Stimulation.  A) 
IRS-1 or B) Munc18c was co-immunoprecipitated (co-IP) from 3T3L1 adipocytes 
for 5 minutes with or without insulin (100nM).  C) Munc18c was co-IP from 
mouse muscle hindlimb homogenates with or without insulin (10U/kg, for 5 
minutes).  Proteins were subjected to a 10% SDS-PAGE and IB with anti-
Munc18c, anti-IRS-1, and anti-IR. 
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 Figure 3-3 IR-Munc18c Complexes Are Mutually Exclusive of Syntaxin 4-
Munc18c Complexes.  Lysates prepared from 3T3L1 adipocytes treated with or 
without freshly prepared pervanadate (pV, 0.1mM) were used for co-
immunoprecipitations (co-IP) with A) anti-Munc18c, B) anti-Syn4, or C) ant-IR.  
Co-IP proteins were resolved by a 10% SDS-PAGE and for immunoblotting (IB) 
with anti-Munc18c, anti-phospho tyrosine 4G10 (P-Tyr), anti-IR, and anti-Syn4. 
Data are representative of at least three independent cell studies. 
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Also similar to insulin stimulation, pervanadate treatment increased the amount 
of IR co-immunoprecipitating with Munc18c.  Concurrently, pervanadate-  
stimulated tyrosine phosphorylation of Munc18c resulted in a 59 ± 1% (p<0.005) 
decrease in Munc18c-Syn4 association (Figure 3-3B).  Strikingly, anti-Syntaxin 4 
failed to co-immunoprecipitate the IR from pervanadate treated or untreated 
lysates (Figure 3-3B).  Reciprocal IR co-immunoprecipitation experiments 
confirmed the absence of Syntaxin 4 from IR-Munc18c association complexes 
(Figure 3-3C).  However, IR co-immunoprecipitation experiments clearly showed 
the pervanadate-induced association of Munc18c with IR.  These data showed 
the pervanadate-induced tyrosine phosphorylation of Munc18c to be a conserved 
mechanism in adipocytes, to mimic the actions of insulin-stimulation, and suggest 
that Munc18c-IR complexes are mutually exclusive of its binding to Syntaxin 4. 
 
3.3.3 Inhibition of IR Activity Decreases its Association with and Tyrosine 
Phosphorylation of Munc18c 
 To determine whether IR kinase activity was indeed required for the 
tyrosine phosphorylation of Munc18c, the IR-specific inhibitor Hydroxy-2-
napthalenylmethylphosphoric acid tris-acetoxy-methyl ester (HNMPA-(AM)3) 
(204,205) was used.  Fully differentiated 3T3L1 adipocytes were pretreated with 
100 μM HNMPA-(AM)3 for 1 hour, stimulated with insulin for 5 minutes, and 
cleared detergent lysates prepared for immunoprecipitation using anti-Munc18c 
antibody  (Figure 3-4).  The phosphorylation of AKT (AKT T301) was monitored 
by immunoblotting to ensure that HNMPA-(AM)3 halted the insulin signaling 
pathway (Figure 3-4B).  Compared to the typical two-fold increase in Munc18c 
tyrosine phosphorylation triggered by 5 minutes of insulin stimulation (2.3 ± 3-fold, 
*p<0.01), the HNMPA-(AM)3 fully abolished insulin stimulated Munc18c 
phosphorylation (Figure 3.4A , bar 2 versus bar 4, **p<0.01).  Moreover, IR 
kinase activity was necessary for its interaction with Munc18c, since complexes 
were reduced by ~ 50 % (51± 2%, p<0.05) in lysates prepared from HNMPA-
(AM)3–treated insulin-stimulated adipocytes (Figure 3-4C).  This was specific to 
IR, since IGF-1 stimulation failed to trigger tyrosine phosphorylation of Munc18c  
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Figure 3-4 Munc18c Tyrosine Phosphorylation and Munc18c-IR Binding 
was Reduced Following Treatment with the IR Inhibitor HNMPA-(AM)3.  A) 
3T3L1 adipocytes were pre-incubated in serum free media with or without 100 
μM HNMPA-(AM)3 for 1 hour prior to insulin stimulation.  Munc18c was 
immunoprecipitated and co-immunoprecipitated proteins resolved by 10% SDS-
PAGE and immunoblotted with anti-Munc18c and anti-4G10 or PY20  B) The 
phosphorylation of AKT in lysates was IB as validation of the inhibitor working.  
C) Munc18c was immunoprecipitated and co-immunoprecipitated proteins 
resolved by 10% SDS-PAGE and immunoblotted with anti-Munc18c anti-IR.  D) 
3T3L1 adipocytes were pre-incubated in serum free media for 2 hours followed 
by IGF-1 (100nM) stimulation for 5 minutes.  Munc18c was immunoprecipitated, 
resolved by 10% SDS-PAGE, and immunoblotted with anti-Munc18c, and anti-
4G10 or PY20 antibodies.  The phosphorylation of AKT (T301) in was IB in 
lysates as validation of IGF-1 activation using this protocol. 
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(Figure 3-4D).  These results suggest that the tyrosine phosphorylation of 
Munc18c requires IR kinase activity, as does the Munc18c-IR interaction.   
  
3.3.4 Munc18c Becomes Tyrosine Phosphorylated Independent of PI3K 
Insulin-stimulated tyrosine phosphorylation of Munc18c occurred 
concurrently with that of AKT activation, and AKT phosphorylation occurs 
downstream of PI3K.  To determine whether the IR-kinase dependent 
phosphorylation of Munc18c occurred in a PI3K-dependent or independent 
manner, adipocytes were pretreated with or without the PI3K inhibitor 
wortmannin prior to stimulation with insulin for 5 minutes.  Interestingly, 
wortmannin treatment failed to reduce the level of tyrosine-phosphorylated 
Munc18c compared to vehicle control (Figure 3-5).  Wortmannin action was 
confirmed by detection of its inhibition of AKT phosphorylation at T301.  These 
data indicate that insulin-stimulated tyrosine phosphorylation of Munc18c 
occurred in parallel to that of PI3K, in an independent pathway. 
 
3.3.5 The IR Phosphorylates Munc18c at Tyrosine 521 In Vitro  
 To determine whether Munc18c could serve as a substrate for IR’s kinase 
activity, in vitro kinase assays were performed.  In vitro kinase assays used an 
active IR beta subunit, [32P] ATP, and recombinant His-tagged Munc18c as the 
substrate (Figure 3-6A).  Autoradiography of 32P incorporation revealed an 
increase in Munc18c tyrosine phosphorylation in a time-dependent manner.  An 
IRS-1 peptide was used as a positive control to ensure that the IR beta subunit 
was active (inclusive of Tyr-608, which is a well known substrate of the IR) and 
yielded the same increase in phosphate incorporation in a time dependent 
manner (Figure 3-6B). 
 The site of Munc18c modification was examined next using a modified in 
vitro kinase assay.  Site-directed mutations of tyrosines 219 and 521 of Munc18c 
to phenylalanine were made and in vitro kinase reactions were performed  
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Figure 3-5 Munc18c Becomes Tyrosine Phosphorylated Upstream of PI3K 
in the Insulin Signaling Pathway.  Adipocytes were incubated in serum free 
media for 2 hr with or without wortmannin (100 nM) before insulin stimulation 
(100 nM) for 5 minutes. Cleared detergent cell lysates were prepared for anti-
Munc18c immunoprecipitation reactions, resolved by 10% SDS-PAGE, and 
immunoblotted with anti-Munc18c, anti-4G10 or PY20 antibodies. The 
phosphorylation of AKT (T301) in lysates served as validation of insulin’s action 
and wortmannins inhibition of PI3K-dependent signaling.  Data represents three 
independent experiments. 
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Figure 3-6 The IR Phosphorylates Munc18c on Tyrosine 521 In Vitro.  A) 
Recombinant His-Munc18c was incubated in the presence of [γ32P] ATP with or 
without the active beta subunit of the IR.  The reaction was stopped at the 
indicated time points by addition of SDS loading buffer.  B) IRS-1 peptide was 
incubated in the presence of [γ32P] ATP with or without the active beta subunit of 
the IR.  The reaction was stopped at the indicated time points.  C) GST-Munc18c 
was incubated in the presence of ATP and the active beta subunit of the IR.  The 
reaction was stopped after 30 minutes by addition of Laemmli sample buffer.  
Phosphorylation was detected using the anti-tyrosine phosphorylation antibody 
4G10. 
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containing the recombinant active IR β subunit, non-labeled ATP, plus either 
GST-Munc18c-WT, -Munc18c-Y219F, or -Munc18c-Y521F (Figure 3-6C).  
Consistent with the first in vitro kinase assay data, GST-Munc18c-WT 
incorporated phosphate, as detected by anti-4G10 antibody.  Surprisingly, GST-
Munc18c-Y219 became phosphorylated similarly to GST-Munc18c-WT.  
However, Munc18c-Y521F failed to undergo phosphorylation, suggesting that 
Y521 was the target for the active IR β subunit.   
 
3.3.6 Munc18c Becomes Phosphorylated at Tyrosine 219 in Adipocytes  
 Having previously shown that Munc18c Y219 is a key phosphorylation site 
in MIN6 beta cells, we had generated a phosphospecific Munc18c Y219 antibody 
to detect the cellular localization of tyrosine phosphorylated Munc18c.  
Consistent with the phospho-tyrosine pattern of Munc18c in plasma membrane 
fractions of β-cells (95), phospho-Y219-Munc18c specific antibody labeling of 
pervanadate treated 3T3L1 adipocytes was detected at the plasma membrane 
(Figure 3-7, panel 1).  The specificity of the phospho Y219 antibody was verified 
by competition with the synthetic phosphorylated antigenic peptide, whereas 
competition with the non-phosphorylated form of the same peptide was without 
effect (Figure 3-7, panel 3 versus 1 and 2).  Panel 4 verified the presence of 
adipocytes on the coverslip used to image panel 3.  Thus, these data show that 
Munc18c could be phosphorylated in adipocytes at Y219 in response to 
pervanadate, in contrast to the in vitro kinase data. 
 
3.3.7. Depletion of Munc18c Decreases GLUT4 translocation to the Plasma 
Membrane   
Munc18c heterozygous knockout mice exhibit an impaired insulin-
stimulated GLUT4 vesicle translocation in the hindlimb skeletal muscle consistent 
with their insulin resistance (20).  In contrast, a line of MEF-derived differentiated 
adipocytes from an independent Munc18c (-/-) mouse model shows an increase 
in GLUT4 abundance in plasma membrane subcellular fractions (57).  To 
reconcile these data using the 3T3L1 adipocyte model, RNAi-mediated depletion 
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Figure 3-7 Munc18c Tyrosine 219 Becomes Phosphorylated in 3T3L1 
Adipocytes.  3T3L1 adipocytes were incubate in serum free media (2 hours) 
prior to pervanadate treatment (pV), 0.1mM, for 5 minutes followed by fixation 
and permeabilization and immunostaining with anti-PY219-Munc18c antibody 
with the addition of the peptide competitor (500 ng) in its non-phosphorylated 
(Non-phospho-Peptide) or phosphorylated (Phospho-Peptide) state for confocal 
immunofluorescent microscopy analysis. 
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Figure 3-8 The Knockdown of Munc18c Decreases Plasma Membrane 
GLUT4.  A) Munc18c shRNA and non-targeting control shRNA constructs were 
each electroporated into 3T3L1 adipocytes and detergent cell lysates prepared 
48 hours later to determine the efficiency of protein depletion achieved by each.  
Lysates were subjected to 10% SDS-PAGE for immunoblotting with anti-
Munc18c and anti-clathrin (loading control) antibodies.  Optical density scanning 
quantitation was used to derive the band density for each clathrin band, which 
was used to normalize Munc18c bands in each experiment, and the mean ± SE 
of at least six independent sets of experiments were determined (*P < 0.005).  B) 
3T3L1 adipocytes were transfected with Myc-GLUT4-EGFP plasmid with or 
without Munc18c shRNA construct.  Forty-eight hours later the cells were either 
left untreated or stimulated with insulin (100nM) for 30 minutes.  The cells were 
then assayed for the plasma membrane translocation of GLUT4 by single cell 
assays with the confocal microscopy.  Fifty cells were blindly counted for a Myc 
Rim in each condition in three independent experiments.   
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was carried out using our transient plasmid delivery system (pSilencer1.0-
siMunc18c), as previously described (39).  The efficiency of the siMunc18c 
depletion from siMunc18c-expressing adipocytes was 64 ± 6% (p<0.005, Figure 
3-8A).  Adipocytes were co-electroporated with shRNA plasmid and myc-GLUT4-
GFP as a reporter of fusion of GLUT4 with the plasma membrane selectively in 
control or Munc18c depleted cells.  Because the myc epitope is inserted into the 
first exofacial loop of GLUT4, it becomes externalized upon fusion of vesicles 
containing myc-GLUT4-GFP with the plasma membrane (PM), making it 
available for labeling with a myc antibody in non-permeabilized cells.  Under 
basal conditions, control-depleted (siCon) cells expressing myc-GLUT4-GFP 
were identified by their punctuate green fluorescence, with nearly undetectable 
myc staining, consistent with a low level of fused GLUT4 in the absence of 
stimulation (Figure 3-8B, panel 1 and 2).  In response to insulin, GLUT4 vesicles 
translocated to the PM to form a continuous GFP rim, concurrent with a rim of 
externalized myc (Figure 3-8B, panels 4-6), consistent with insulin-induced 
GLUT4 vesicle fusion with the PM.  Cells co-transfected with siMunc18c 
displayed ~ 40% less membrane localized GLUT4 translocation in response to 
insulin (Figure 3-8 panels 10-12).  The intracellular punctuate pattern of GLUT4 
under basal conditions was unaffected by Munc18c depletion (Figure 3-8, panels 
7-9).  Consistent with the general role of Munc18c as a positive effector of vesicle 
fusion, and with the role of Munc18c in skeletal muscle, these data indicate the 
requirement for Munc18c in insulin-stimulated GLUT4 translocation in 3T3L1 
adipocytes.   
 Preliminary studies reveal that in adipocytes co-electroporated with myc-
GLUT4-GFP, Munc18c shRNA, and shRNA resistant Flag-Munc18c, insulin-
stimulated GLUT4 translocation is rescued approximately 67% (Figure 3-9 A).  
Interestingly, similar studies using shRNA resistant Munc18c-Y219F and 
Munc18c-Y521F showed less rescue of GLUT4 translocation (Figure 3-9A and 
B).  Studies are now underway to confirm these results.    
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Figure 3-9 The Effect of Munc18c Tyrosines 219 and 521 in Insulin-
Stimulated GLUT4 Translocation.  A) 3T3L1 adipocytes were transfected with 
Myc-GLUT4-EGFP plasmid, Munc18c shRNA construct, and Flag Munc18c 
(Top), Flag Munc18c Y219F (Middle), or Flag Munc18c Y521F (Bottom).  Forty-
eight hours later the cells were stimulated with insulin (100nM) for 30 min.  The 
cells were then assayed for the plasma membrane translocation of GLUT4 by 
single cell analysis with confocal microscopy.  Thirty cells were blindly counted 
for a GFP Rim in one experiment.   
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3.4 DISCUSSION  
In this study, we found that in 3T3L1 adipocytes and mouse skeletal 
muscle, insulin triggers the tyrosine phosphorylation of Munc18c concomitant 
with its association with the IR, and disruption of Munc18c-Syntaxin 4 complexes.  
IR kinase activity is required for these events, further implicating the IR as a 
novel Munc18c tyrosine kinase.  In vitro kinase assays and Y219-phospho 
specific antibody labeling point to Y219 and Y521 as target sites for modification 
in adipocytes.  Moreover, these sites are in close proximity within the Munc18c 
crystal structure (Figure 3-10), suggesting that this region is of particular 
importance in the transient and stimulus-coupled regulation of Munc18c-Syntaxin 
4 complexation.  Importantly, our data support a model whereby insulin-
stimulated phosphorylation of one or both of these tyrosine residues is required 
for normal insulin-stimulated GLUT4 translocation. 
This is the first report of a tyrosine kinase that phosphorylates Munc18c, 
that being IR.  IR-Munc18c association and Munc18c tyrosine phosphorylation 
supports the existence of parallel pathways for IR-mediated Munc18c tyrosine 
phosphorylation and the classic IR-IRS-1-PI3K dependent signaling cascade.  In 
fact, IR has numerous substrates besides IRS-1, such as insulin receptor 
substrate proteins (IRS2–IRS4), Shc, Gab-1, Cbl, APS, and caveolin 1 (206,207).  
However, since SNARE-mediated GLUT4 vesicle translocation has usually been 
considered the most distal event of the insulin-signaling cascade in adipocytes 
and skeletal muscle, we and others had predicted that the kinase mediating the 
dissociation of Munc18c-Syntaxin 4 complexes was downstream of PI3K, and 
likely PI3K-dependent.  To the contrary, our data instead suggest a new model, 
in which IR orchestrates the preparation of Syntaxin 4 for subsequent incoming 
insulin-stimulated GLUT4 vesicles in parallel to its signaling to mobilize those 
vesicles.  Future studies are required to stringently test this model.   
Finally, studies are now underway to determine the importance of 
Munc18c tyrosine phosphorylation of 219 and 521 with regards to the regulation 
of insulin-stimulated glucose uptake.  Preliminary data suggest that the tyrosine 
phosphorylation of both of these sites is important for the translocation of GLUT4 
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to the plasma membrane.  This region on Munc18c containing Y219 and Y521 
may be a potential target not only for regulating the Munc18c-Syntaxin 4 
interaction but also vesicle exocytosis, insulin-stimulated GLUT4 translocation in 
the peripheral tissues and glucose-stimulated insulin secretion in the pancreatic 
beta cell.  
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Figure 3-10 Modeling of Munc18c Y219 and Y521 Residues.  A depiction of 
the Munc18c (orange) crystal structure illustrating the close proximity of Y219 
and Y521.  The Pink dash line represents the disordered and uncrystallized 
region in which Y521 resides. 
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CHAPTER 4: FILAMENTOUS ACTIN REGULATES INSULIN EXOCYTOSIS 
THROUGH DIRECT INTERACTION WITH SYNTAXIN 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some of the text in this Chapter is reproduced from: 
 
Jewell JL*, Luo W*, Oh E, Wang Z, and Thurmond DC. (2008). A Direct 
Association of Filamentous Actin with Syntaxin 4 Functionally Restricts Granule 
Accessibility to Regulate Insulin Exocytosis. J Biol Chem 283: 10716-10726. 
*Authors Contributed Equally  
Author Contributions:  Oh E generated data for Figure 4-1.  Wang Z produced 
data for Figure 4-7.  Luo W generated data for Figures 4-3, 4-4, and 4-5.  Jewell 
JL produced data for Figures 4-2A, 4-5, 4-6C, 4-8 and 4-9. 
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4.1 INTRODUCTION 
 Insulin granule exocytosis requires two syntaxin isoforms: Syntaxin 1A 
and Syntaxin 4. Syntaxin 1A null mouse islets show significantly fewer pre-
docked granules which support first-phase insulin release in response to calcium 
influx, although second-phase secretion is normal (19).  Syntaxin 4 heterozygous 
knockout mouse islets show decreased first-phase secretion and also a slight 
decrease in second phase secretion (26).  In addition, Syntaxin 4 over-
expressing transgenic mouse islets have enhanced second-phase secretion (26). 
Other cell systems that utilize multiple syntaxins show partitioning of interactions 
and localization to particular membrane compartments to achieve differential 
modes of vesicle targeting and fusion (208,209).  Characterization of unique 
properties of Syntaxin 1A and Syntaxin 4 will be required before a mechanistic 
understanding of their different roles in biphasic insulin release can be discerned. 
 We have previously demonstrated that, in rodent islet beta cells, glucose-
induced insulin exocytosis is coupled to the interaction of F-actin with t-SNARE 
proteins (29).  Here, we demonstrate the relevance of this to human islet function, 
and have expanded upon the underlying mechanism by showing that F-actin 
bound directly to a novel motif in the N-terminus of Syntaxin 4.  
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Rabbit polyclonal Syntaxin 4 and mouse monoclonal Syntaxin 1 antibodies 
were obtained from Chemicon (Temecula, CA) and Upstate Biotechnology (Lake 
Placid, NY), respectively.  The mouse anti-insulin and rabbit anti-actin antibodies 
were obtained from Sigma (St. Louis, MO).  Rabbit anti-GFP antibody was 
acquired from Abcam (Cambridge, MA).  Monoclonal anti-SNAP-25 and anti-GFP 
antibodies were purchased from BD Biosciences Clontech (San Jose, CA).  The 
mouse monoclonal anti-VAMP2 antibody and recombinant soluble Syntaxin 1A 
protein were obtained from Synaptic Systems (Gottingen, Germany).  Latrunculin 
B was purchased from Calbiochem (La Jolla, CA).  Texas-red conjugated 
secondary antibody and control mouse and rabbit IgG for immunoprecipitation 
were purchased from Jackson Immunoresearch Laboratories (West Grove, PA).  
Radioimmunoassay grade bovine serum albumin and D-glucose were purchased 
from Sigma.  The MIN6 cells were a gift from Dr. John Hutton (University of 
Colorado Health Sciences Center).  Goat anti-mouse and anti-rabbit horseradish 
peroxidase secondary antibodies and Transfectin lipid reagent were acquired 
from Bio-Rad (Hercules, CA).  ECL reagent was purchased from Amersham 
Biosciences (Piscataway, NJ).  The human C-peptide and rat insulin RIA kits 
were purchased from Linco Research Inc (St. Charles, MO).  The Actin binding 
spin-down assay (#BK001) and F/G-actin quantitation kits were purchased from 
Cytoskeleton (Denver, CO). 
 
4.2.2 Plasmids  
The pGEX-4T1-VAMP2-(1-94) was generated as previously described 
(210). The pGEX-4T1-Syntaxin 4-(1-193), -(1-112) and –(1-70) cDNA constructs 
were generated by subcloning PCR-generated rat Syntaxin 4 fragments into the 
SalI and XhoI sites of the pGEX-4T1 expression vector.  The pGEX-4T1-Syntaxin 
4-(1-273) and -(39-273) cDNA constructs were made by subcloning PCR-
generated fragments into the EcoRI and XhoI sites of the pGEX-4T1.  The 
pEGFP-Syntaxin 4-(39-112) cDNA construct was generated by subcloning the 
PCR-generated Syntaxin 4 fragment engineered with 5’EcoRI and 3’XhoI sites 
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into the 5’EcoRI and 3’SalI sites of the EGFP-C2 vector (Clontech).  All 
constructs were verified by DNA sequencing. 
 
4.2.3 Cell Culture, Transient Transfection and Secretion Assays  
MIN6 beta cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM with 25 mM glucose) supplemented with 15% fetal bovine serum, 100 
units/ml penicillin, 100 µg/ml streptomycin, 292 μg/ml L-glutamine, and 50 µM β-
mercaptoethanol as described previously (146).  MIN6 beta cells at ~60% 
confluence were transfected with 40 μg of plasmid DNA per 10 cm2 dish using 
Transfectin (Bio-Rad) to obtain ~30-50% transfection efficiency.  After 48 hours 
of incubation, cells were washed twice with and incubated for 2 h in freshly 
prepared modified Krebs-Ringer bicarbonate buffer (MKRBB; 5 mM KCl, 120 mM 
NaCl, 15 mM Hepes pH 7.4, 24 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2 and 1 
mg/ml RIA-grade BSA).  Cells were stimulated with 20 mM glucose for the times 
indicated in the figures, after which the buffer was collected, microcentrifuged for 
5 min at 4oC to pellet cell debris, and insulin secreted into buffer quantitated 
using a rat insulin immunoassay kit (Linco Research).  Cells were harvested in 
NP-40 lysis buffer (25 mM HEPES, pH 7.4, 1% NP-40, 10% glycerol, 50 mM 
sodium fluoride, 10 mM sodium pyrophosphate, 137 mM NaCl, 1 mM sodium 
vanadate, 1 mM PMSF, 10 μg/ml aprotinin, 1 μg/ml pepstatin and 5 μg/ml 
leupeptin) containing 60 mM n-octylglucoside and lysed for 10 minutes at 4oC, 
and lysates cleared of insoluble material by microcentrifugation for 10 minutes at 
4oC for subsequent use in co-immunoprecipitation experiments.  For 
measurement of human C-peptide release, MIN6 beta cells were transiently co-
transfected with each plasmid plus human proinsulin cDNA (kind gift from Dr. 
Chris Newgard, Duke University).  Forty-eight hours following transfection, cells 
were pre-incubated for 2 hours in MKRBB buffer and stimulated with 20 mM 
glucose for 1 hour.  MKRBB was collected for quantitation of human C-peptide 
released. 
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4.2.4 Immunofluorescence and Confocal Microscopy  
MIN6 cells at 40% confluency plated onto glass coverslips were 
preincubated in MKRBB in the absence or presence of Latrunculin (10 μM) or 
vehicle (DMSO) for 1-2 hours followed by stimulation with 20 mM glucose for 5 
minutes and immediately fixed and permeabilized in 4% paraformaldehyde and 
0.1% Triton X-100 for 10 minutes at 4oC.  Fixed cells were blocked in 1% BSA 
plus 5% donkey serum for 1 h at room temperature, followed by incubation with 
ant-insulin antibody (1:100) for 1 hour.  MIN6 cells were then washed with 
phosphate buffered saline (PBS, pH 7.4) and incubated with anti-mouse Texas 
Red secondary antibody for 1 hour.  All cells were washed again in PBS, overlaid 
with Vectashield mounting medium and mounted for confocal fluorescence 
microscopy using a Zeiss 510 confocal microscope.  EGFP and insulin-Texas 
Red fluorescing cells were imaged using single-channel scanning using a 100x 
objective. 
 
4.2.5 Electron Microscopy 
MIN6 beta cells were grown to ~80% confluence on Thermonox coverslips.  
Cells were washed twice with and incubated 2 hours in freshly prepared modified 
Krebs-Ringer bicarbonate buffer followed by addition of either Latrunculin B or 
DMSO vehicle for an additional 30 minutes.  Cells were fixed in a 0.1 M 
cacodylate buffered mixture of 2% glutaraldehyde and 2% paraformaldehyde for 
30 min at room temperature followed by overnight incubation at 4oC, and then 
post-fixed in 1% OsO4 in for 1 hour.  En bloc staining in 0.5% aqueous uranyl 
acetate was performed for 3 hours followed by a 10 minute water wash. 
Dehydration was done in the following sequence, 50% ethanol, 70% ethanol, 
95% ethanol, and 100% ethanol each 10 minutes.  Infiltration entailed ethanol 
and resin in the order of 3:1 (1 hour), 1:1 (overnight), 1:3 (1 hour), and 100% 
resin (2-3 changes each 30 minutes).  The Thermonox Coverslips were inverted 
over a 1.5 ml centrifuge tube filled with resin and polymerized for 48 hours at 
60°C.  Thick (0.5-2.0 µm) and thin (60-100 nm) sections were cut using the 
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microtome (Leica Ultracut).  The thin sections were stained with uranyl acetate 
and lead citrate and viewed on the FEI Tecnai G2 Biotwin.  
 
4.2.6 Subcellular Fractionation  
Subcellular fractions of beta cells were isolated as described previously 
(210).  Briefly, MIN6 beta cells at ~90% confluence were harvested into 1 ml of 
homogenization buffer (20 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 
250 mM sucrose, 1 mM DTT and 1 mM sodium orthovanadate containing 
protease inhibitors.  Cells were disrupted by 10 strokes through a 27 gauge 
needle and homogenates centrifuged at 900 x g for 10 minutes.  Postnuclear 
supernatants were centrifuged at 5,500 x g for 15 minutes and the subsequent 
supernatant centrifuged at 25,000 x g for 20 minutes to obtain the storage 
granule (SG) fraction in the pellet.  The supernatant was further centrifuged at 
100,000 x g for 1 hour to obtain the cytosolic fraction (Cyt).  Plasma membrane 
fractions (PM) were obtained by mixing the postnuclear pellet with 1 ml of Buffer 
A (0.25 M Sucrose, 1 mM MgCl2 and 10 mM Tris-HCl, pH 7.4) and 2 volumes of 
Buffer B (2 M sucrose, 1 mM MgCl2 and 10 mM Tris-HCl, pH 7.4).  The mixture 
was overlaid with Buffer A and centrifuged at 113,000 x g for 1 hour to obtain an 
interface containing the plasma membrane fraction.  The interface was collected 
and diluted to 2 ml with homogenization buffer for centrifugation at 6,000 x g for 
10 minutes, and the resulting pellet was collected as the plasma membrane 
fraction.  All pellets were resuspended in 1% NP-40 lysis buffer to ensure 
solubilization of membrane proteins. 
 
4.2.7 Co-immunoprecipitation and Immunoblotting  
 MIN6 beta cell cleared detergent homogenates (2-3 mg) were combined 
with rabbit anti-Syntaxin 4 or mouse anti-Syntaxin 1 antibodies for 2 hours at 4°C 
followed by a second incubation with protein G Plus-agarose for 2 hours.  The 
resultant immunoprecipitates were subjected to 12% SDS-PAGE followed by 
transfer to PVDF membranes for immunoblotting.  Membranes were blocked in 
5% milk/TBS-Tween for 1 hour at room temperature, followed by immunoblotting 
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(Syntaxin 1A, Syntaxin 4 and SNAP-25 antibodies were used at 1:1000; VAMP2 
antibody was used at 1:5000).  Proteins were visualized by enhanced 
chemiluminescence for quantitation using a Chemi-Doc gel documentation 
system (Bio-Rad). 
 
4.2.8 Recombinant Proteins and Interaction Assays 
GST-VAMP2 (1-94) fusion protein was expressed in Escherichia coli and 
purified by glutathione-agarose affinity chromatography as described (210).  
GST-VAMP2 was immobilized on sepharose beads and incubated with cleared 
detergent lysates (~3 mg) prepared from unstimulated cells for 2 hours at 4oC.  
Following 3 washes with 1% NP40 lysis buffer, proteins were eluted from the 
sepharose beads and subjected to electrophoresis on 12% SDS-PAGE followed 
by transfer to PVDF membrane for immunoblotting with anti-Syntaxin 4 antibody.  
For the F-actin spin-down assays, recombinant VAMP2 and Syntaxin 4 proteins 
were initially expressed and purified as GST-fusion proteins, after which the GST 
was removed by thrombin cleavage and remaining protein captured (Novagen 
kit).  Syntaxin 1A protein was purchased from Synaptic Systems.  Proteins were 
concentrated to ~20 μM and centrifuged at 150,000 x g for 1 hour at 4oC 
immediately prior to use of resulting supernatant in actin binding assay.  Purified 
F-actin stocks (23 μM) were prepared according to manufacturer’s instructions.  
Test proteins were incubated with F-actin stock in actin polymerization buffer at 
room temperature for 30 minutes.  BSA and α-actinin control proteins provided by 
the manufacturer were used as negative and positive F-actin binding control 
proteins, respectively, in each experiment for validation of binding.  All reactions 
were centrifuged at 150,000 x g for 1.5 hours at 24oC and supernatants removed 
into individually labeled new tubes on ice.  Both the supernatants and the pellets 
were subjected to 12-18% SDS-PAGE followed by transfer to PVDF membranes 
for Coomassie staining or immunoblotting analyses. 
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4.2.9 Statistical Analysis 
All data are expressed as mean ± S.E.  Data were evaluated for statistical 
significance using an unpaired two-tail Student's t test. 
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4.3 RESULTS 
4.3.1 F-actin Function is Conserved Between Human and Rodent Islet Beta 
Cells 
We previously reported that treatment of rat islets with Latrunculin B 
results in potentiation of glucose-stimulated insulin release (29).  Latrunculin is a 
potent actin monomer-binding and sequestering agent which converts cellular F-
actin to G-actin.  To establish continuity of function amongst islet model systems, 
the impact of Latrunculin upon secretion from mouse islets and human islets was 
evaluated.  Similar to rat islets, isolated mouse islets showed a robust response 
to 2 hours glucose stimulation, which was further potentiated by Latrunculin 
(Figure 4-1A).  Human islets were obtained from three independent non-diabetic 
human cadaver pancreases through the NIH/ICR/ABCC distribution program.  
Because of the fragility of these human islets following isolation and shipment, 
Latrunculin pre-treatment and stimulation time was limited to 1 hour, rather than 
the 2 hour period used with mouse islets, which cumulatively resulted in a lesser 
yet still significant secretory response to glucose stimulation (Figure 4-1B).  
Importantly, each batch of human islets showed the Latrunculin-potentiated effect 
upon glucose-stimulated insulin release, while basal secretion was comparable 
to the vehicle (DMSO)-treated islets (Figure 4-1B).  Since islets contain multiple 
cell types, 70-80% of which are insulin-containing beta cells, cultured MIN6 beta 
cells were used to further confirm that this potentiating effect of Latrunculin was 
transduced through the beta cells and not one of the other islet cell types.  This 
potentiating effect occurred very rapidly, evident within 5 minutes of stimulation 
with glucose (Figure 4-1C).  Latrunculin also potentiated insulin release from 
MIN6 cells in response to KCl and PMA, as well as calcium-stimulated secretion 
from Streptolysin-O-permeabilized cells (21).  Moreover, the actin-depolymerizing 
effect of Latrunculin was validated by analysis of the F:G-actin ratio, converting 
F-actin:G-actin ratio from ~20%:80% in unstimulated or vehicle-treated cells to 
~1%:99% (data not shown).  Thus the potentiating effect of Latrunculin was 
found to be conserved across species and relevant to human islet function.  
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Figure 4-1 Latrunculin Potentiates Insulin Secretion in Human Islets-
Conservation of Function with Rodent Islets and Cultured Beta Cells.  A) Mouse 
islets were handpicked for 2 hour pre-incubation in KRB with 2.8 mM glucose ± 
Latrunculin (10 μM LAT), then 2 hour more under basal or stimulated conditions 
(20 mM glucose), with 10 islets per condition.  Three independent sets of mouse 
islets were combined and data expressed as insulin secretion normalized to 
insulin content.  *P< 0.05, versus vehicle-basal condition.  B) Human islets were 
isolated from cadaver pancreas at the ICR and shipped for receipt within 48 
hours of isolation.  Islets were allowed to recover for 3 hours and then 
handpicked for pre-incubation for 1 hour in KRB containing 2 mM glucose ± 
 106
Latrunculin (10 μM LAT) followed by 1 hour incubation under basal (2.8 mM 
glucose) or stimulated conditions (20 mM).  Data represent the average of three 
independent batches of human islets, normalized for insulin content and 
expressed as % vehicle-basal secretion set equal to 100%; *P< 0.05, versus 
vehicle-basal condition.  C) MIN6 cells were pre-incubated in glucose-free 
MKRBB containing vehicle or LAT for 2 hour and then stimulated with 20 mM 
glucose for 5 minutes.  Data represent the average of 6 independent sets of 
MIN6 cells, normalized for protein content and expressed as % vehicle-basal 
secretion; *P< 0.02, versus vehicle-basal condition. 
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Moreover, the MIN6 beta cell line was found to be an appropriate model system 
in which to pursue mechanistic study of the role of F-actin in beta cell secretion. 
 To determine how Latrunculin facilitated this potentiation, insulin granule 
localization was examined.  Electron micrograph images of Latrunculin-treated 
MIN6 cells showed the prevalence of granules localized at the plasma membrane 
(Figure 4-2A, right panel).  In 10 images collected of Latrunculin-treated cells, 
greater than 90% exhibited this phenotype.  In contrast, vehicle-treated cells 
contained only a few granules at the cell periphery (Figure 4-2A, left panel, arrow 
denotes plasma membrane between neighboring cells) in all fields.  Insulin 
immunofluorescent confocal microscopy of vehicle- or Latrunculin-treated MIN6 
cells confirmed the identity of the granules localized at the PM as insulin-
containing (Figure 4-2B).  Punctate insulin staining was visible broadly across the 
expanse of the beta cells under basal conditions, with regrouping of granules 
closer to the cell periphery after only 5 minutes of glucose stimulation.  
Latrunculin treatment mimicked this glucose-induced redistribution of granules to 
the cell periphery, but did so in the absence of glucose.  Immunofluorescent 
images of more than 30 clusters of Latrunculin-treated cells showed the 
phenotype in Figure 4-2B.  In a third approach, subcellular fractions were 
prepared from MIN6 cells treated with vehicle or Latrunculin to quantify the extent 
of the granule redistribution induced by Latrunculin.  The fractionation procedure 
was validated in two ways:  1) demonstration of highest insulin content in insulin 
secretory granule (SG) fraction with lesser but significant levels in PM fraction 
and none in cytosolic fraction (210-212); 2) the presence of marker proteins in 
the PM (Syntaxin 4, Syntaxin 1A), in the SG (VAMP2, phogrin), and in the Cyto 
fraction (Cdc42, Munc18c).  In three independent sets of fractions, Latrunculin 
induced an ~2.5-fold increase in VAMP2-bound insulin granules localized to the 
PM, with a coordinate ~40% loss from the storage granule (SG) pool (Figure 4-
2C and D).  Ponceau S staining was used to validate equal loading in each 
experiment.  Thus, Latrunculin-induced F-actin depolymerization allowed flow of 
insulin granules to the PM in the absence of the glucose stimulus.  
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Figure 4-2 Latrunculin Causes Increased Granule Accumulation at the Plasma 
Membrane in the Absence of Glucose.  A) Electron microscopy (TEM) of MIN6 
cells treated with vehicle (VEH) or Latrunculin (LAT), bar=500 nm.  B) Latrunculin 
treatment mobilizes granules towards the plasma membrane compartment from 
the storage granule pool under basal conditions.  MIN6 cells were left 
unstimulated, stimulated with 20 mM glucose for 5 minutes or treated with 10 µM 
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Latrunculin (LAT) for 2hours, then fixed and permeabilized for anti-insulin 
immunofluorescent confocal microscopy.  Bar, 5μm.  C) MIN6 cells were treated 
with Latrunculin or the DMSO vehicle for 2hours, then subfractionated and 20 μg 
protein from of plasma membrane (PM) and storage granule (SG) fractions were 
resolved on 12% SDS-PAGE for immunoblotting.  Ponceau S staining used to 
verify equal loading; Syntaxin immunoblotting used to validate PM fraction 
integrity in each fractionation.  Data are representative of two independent 
experiments.  D) Optical density scanning quantitation (each set of fractions 
normalized to VEH control=100%) of VAMP2; data shown as average ± S.E. of 3 
independent sets of fractions.  Ponceau staining used to verify loading in SG and 
PM fractions each experiment. 
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4.3.2 Glucose-Induced Dissociation of F-actin from Syntaxin 4 
We have previously reported that F-actin is dynamically reorganized in 
response to glucose stimulation in islet beta cells, and that this phenomenon is 
coupled to Syntaxin 1 association (29,213).  F-actin associated in a specific 
manner, as IgG alone or VDCC primary antibodies failed to co-immunoprecipitate 
F-actin.  These studies also showed that Syntaxin 1 only associates with F-actin 
and not G-actin; treatment of cells with actin depolymerizing agents destroyed 
this association.  We have since demonstrated a requirement for a second 
syntaxin isoform in insulin granule exocytosis, Syntaxin 4 (26).  Here we show 
that like Syntaxin 1, Syntaxin 4 associated with F-actin under basal conditions 
(Figure 4-3A and B).  Also similar is the marked significant reduction of actin 
association with Syntaxin 4 after 10 minutes of glucose stimulation.  Following 30 
minutes of glucose stimulation actin re-associated with Syntaxin 4, albeit to a 
lesser extent than it did with Syntaxin 1.  Treatment of cells with Latrunculin 
abolished ~90% of actin interaction with Syntaxin 4 (Figure 4-3C), indicating that 
it was F-actin and not G-actin that interacted with Syntaxin 4.  These data 
expand upon the current notion of F-actin serving as a barrier by suggesting that 
the negative function of F-actin is mediated through its association with multiple 
plasma membrane-bound Syntaxins.  
 
4.3.3 F-actin Directly Associates with Only the Syntaxin 4 Isoform 
To determine how the SNARE proteins might confer interaction with F-
actin, sequence analyses of v- and t-SNARE proteins for potential homology with 
any known actin binding protein motifs were conducted (http://smart.embl-
heidelberg.de).  While no homologies were identified in VAMP2, SNAP-25 or 
Syntaxin 1A, Syntaxin 4 was found to have some homology to a motif known as 
“spectrin-like”.  To determine whether Syntaxin 4 might bind in a direct manner to 
F-actin, an in vitro actin sedimentation/spin-down assay was employed.  
Recombinant soluble forms of each SNARE protein (transmembrane domain 
deleted) were expressed in E. coli and purified were incubated with F-actin in a 
calcium-containing binding buffer and subsequently centrifuged to pellet F-actin  
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Figure 4-3 Glucose-Induced Dissociation of F-actin from Syntaxin 1A and 
Syntaxin 4.  MIN6 cells were pre-incubated in MKRBB for 2 hours and stimulated 
with 20 mM glucose for 10, 30 and 60 minutes.  Detergent cell lysates were 
prepared by harvesting in lysis buffer containing 1% NP40 and n-octylglucoside.  
Cleared detergent cell lysates (2 mg of protein) were immunoprecipitated with:  
A) mouse anti-Syntaxin 1, or B) rabbit anti-Syntaxin 4 for 2hours at 4°C. 
Immunoprecipitates were resolved on 12% SDS-PAGE, and proteins were 
transferred to PVDF for immunoblotting with mouse anti-Syntaxin 1A or Syntaxin 
4, anti-SNAP25 and rabbit anti-actin.  C) Lysates prepared from cells pre-treated 
for 2 hours with vehicle (DMSO, VEH) or Latrunculin (LAT) were used in 
immunoprecipitation reactions with anti-Syn4 antibody for subsequent 
immunoblotting for co-immunoprecipitation of actin.  Parallel reactions including 
IgG immunoprecipitation reactions were included to control for non-specific 
binding as demonstrated previously ((29) not shown here).  Data are 
representative of at least 5 independent co-immunoprecipitation experiments.  
Optical density scanning quantitation of actin association with Syntaxin is shown 
directly below each of the three immunoprecipitation studies (each set of lysates 
normalized to basal=1).  Bars represent the average ± S.E. of 3-5 independent 
experiments normalized to basal=1.0.  
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and associated proteins.  Proteins in each fraction were resolved on SDS-PAGE 
for detection by Coomassie blue staining.  The known F-actin binding protein α-
actinin, appropriately localized to the pellet (P) with F-actin (Figure 4-4A, lanes 7-
8), while BSA served as the negative control in this assay and localized to the 
supernatant (S, Figure 4-4A, lanes 5-6).  Recombinant Syntaxin 1A also 
remained strictly in the supernatant (Figure 4-4, lane 4), as did VAMP2 (data not 
shown).  Syntaxin 4 protein was present in both the pellet and supernatant 
fractions (Figure 4-4A, lanes 1-2).  These data indicated that Syntaxin 4 had the 
ability to interact directly with F-actin, while Syntaxin 1A associated exclusively 
via an indirect mechanism.  
 To determine which region of Syntaxin 4 conferred direct interaction with 
F-actin, a series of C- and N-terminal truncations (Figure 4-5A) were made in the 
context of GST-Syntaxin 4 (ΔTM, soluble form).  Coomassie blue staining 
showed that all GST-Syntaxin 4 truncation proteins migrated at the correct 
molecular weight and as single bands (Figure 4-5B).  GST was cleaved and 
remaining Syntaxin 4 fragments purified for use in the F-actin spin down assay.  
In each assay, recombinant Syntaxin 1A and Syntaxin 4 were used as negative 
and positive controls for F-actin interaction, respectively (data not shown).  C-
terminal deletion of domains H3, Hc, or the N-terminal deletion of residues 1-38 
failed to abolish Syntaxin 4 interaction with F-actin (Figure 4-5C).  Further 
delineation of the binding region was detected by immunoblotting instead of 
Coomassie, because of lesser sensitivity due to the small molecular weight of the 
protein.  Immunoblotting increased sensitivity to any interaction, taking 
advantage of the N-terminal epitope recognized by this particular antibody 
(epitope is residues 2-23 of Syntaxin 4).  Using this, we observed that the C-
terminal deletion through the Hb domain did eliminate binding to F-actin (Figure 
4-5D).  Subsequent truncations of the Ha and Hb domains in the full soluble 
Syntaxin 4 protein were constructed to determine further importance of the Ha 
and Hb domains individually, but unfortunately were labile upon cleavage from 
the GST protein. Since these binding data indicated that the N-terminal Ha-Hb 
region comprising residues 39-112 as the minimal region sufficient to confer  
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Figure 4-4 Syntaxin 4 but not Syntaxin 1A Binds Directly to F-actin In Vitro.  
Recombinant purified proteins were tested for direct F-actin binding in an in vitro 
sedimentation assay.  Following incubation and centrifugation, F-actin and 
associated binding proteins are recovered in the pellet (P) fraction while non-F-
actin binding proteins remain in the supernatant (S).  Proteins were resolved on 
10% SDS-PAGE and detected by Coomassie blue staining.  This reaction was 
determined to be at saturation for binding (data not shown).  Data representative 
of 6 independent experiments using 4 different preparations of proteins. 
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Figure 4-5 The Region Containing the Ha-Hb Domains of Syntaxin 4 is 
Necessary and Sufficient to Confer Direct Binding to F-actin.  A) Four C-terminal 
truncations and one N-terminal truncation of Syntaxin 4 were generated as GST 
fusion proteins for expression in E. coli and purification on glutathione sepharose.  
B) Coomassie blue staining showed the expression of GST fusion Syntaxin 4 
truncation proteins to be expressed, soluble fragments with high purity.  C) 
Thrombin cleaved Syntaxin 4 N-terminal and C-terminal truncated fragments 1-
194, 1-112 and 39-273 were prepared at the concentration 1 mg/ml for use in the 
in vitro actin sedimentation assay.  Both the supernatants (S) and the pellets (P) 
were subjected to 15% SDS-PAGE for Coomassie blue staining.  Syn4 and 
Syn1A reactions were used as positive and negative controls, respectively, in 
each experiment (see Figure 4).  D) Purified Syntaxin 4 C-terminal truncations 1-
112 and 1-70 were prepared and tested in the actin sedimentation assay.  Both 
the supernatants and the pellets were subjected to 18% SDS-PAGE followed by 
transfer to PVDF membranes for immunoblotting with rabbit anti-Syntaxin 4.  
Data are representative of 2-3 independent sets of proteins. 
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binding of Syntaxin 4 with F-actin, GST-(39-112) was constructed, but also was 
labile in vitro.  The importance of these far N-terminal residues in Syntaxin 4 
structure has been reported and likely explains the instability of our constructs 
lacking this region (114).  Thus, the in vitro assay data suggested the F-actin 
interacting region of Syntaxin 4 to be between amino acids 39-112.  Notably, this 
region also contains the predicted spectrin-like motif. 
 
4.3.4 Selective Separation of Syntaxin 4 from F-actin Enhances Granule 
Mobilization and Exocytosis 
To determine the requirement for Syntaxin 4 binding to F-actin in cells, the 
Syntaxin 4 actin binding region (residues 39-112) was used as a selective 
competitive inhibitor.  This small region was fused to the C-terminus of the EGFP 
protein as shown in Figure 4-6A, which enabled visualization of its localization 
within transfected cells and easier detection of its expression by 
immunodetection on SDS-PAGE (Figure 4-6B, IB: EGFP in lysate).  Plasmids 
encoding EGFP-(39-112) or EGFP vector alone were transfected into MIN6 cells 
and effects upon Syntaxin 4-F-actin association evaluated by 
immunoprecipitation with anti-Syntaxin 4 antibody and actin immunoblotting.  
Because the EGFP-(39-112) fragment did not contain the epitope recognized by 
the Syntaxin 4 antibody, only endogenous Syntaxin 4 was immunoprecipitated.  
Indeed, expression of the EGFP-(39-112) resulted in an ~30% decrease in co-
precipitation of endogenous Syntaxin 4-F-actin complexes.  EGFP-(39-112) 
action was not due to inadvertent binding to other Syntaxin 4 binding partners, 
since immunoprecipitation of this fusion protein failed to coprecipitate proteins 
such as Syntaxin 4, VAMP2, SNAP-25 or Munc18c (data not shown).  The 
analogous region of Syn1A was not used for comparison, since this region of 
Syntaxin 1A is known to directly interact with another important exocytotic protein, 
Munc13-1 (151).  Despite its ability to dissociate endogenous F-actin-Syntaxin 4 
complexes and to bind to F-actin in vitro, stable association of the peptide with 
endogenous F-actin could not be consistently detected.  Although EGFP-(39-
112) protein expression levels were substantial, conformational changes in 
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peptide structure due to its fusion to EGFP may have impaired its ability to stably 
interact with F-actin.  Unlike Latrunculin treatment, the EGFP-(39-112) 
expression had no substantial effect upon global cellular F-actin content (F:G-
actin ratio of both was ~25%:75%), such that the action of the inhibitory peptide 
was more likely through selective separation of F-actin from Syntaxin 4 and not 
via dispersal of the cortical F-actin network to allow granules to gain access to 
the plasma membrane. 
 The EGFP-(39-112) competitive inhibitory fragment was then used to 
evaluate the functional importance of the endogenous Syntaxin 4-F-actin 
association in glucose stimulated insulin secretion.  Because transfection 
efficiency was ~50%, the human C-peptide reporter assay was utilized as a 
means to measure secretion only from transfectable cells.  MIN6 cells were co-
transfected with EGFP-(39-112) or vector control together with human proinsulin 
cDNA.  Human C-peptide (derived from human proinsulin) is synthesized and 
packaged in an identical fashion to mouse C-peptide and insulin in granules, but 
is immunologically distinct from mouse C-peptide and serves as a reporter of 
secretion from transfectable cells.  MIN6 cells transfected with EGFP vector 
responded to glucose stimulation by a 26% increase in insulin release (Figure 4-
6C), similar to levels reported by others using this particular reporter assay 
(190,191).  However, expression of EGFP-(39-112) increased this to ~49%, 
suggesting that the selective disruption of F-actin binding to Syntaxin 4 enhanced 
insulin exocytosis.  Thus, the potentiating effect of Latrunculin could be 
recapitulated, at least in part, by competitive inhibition of F-actin binding to 
Syntaxin 4.  
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Figure 4-6 Expression of Syntaxin 4 residues 39-112 in MIN6 Cells Results in 
Dissociation of the Endogenous F-actin-Syn4 Association and Increased 
Glucose-stimulated Secretion.  A) The Ha-Hb region of Syntaxin 4 was fused to 
the C-terminus of EGFP for expression in mammalian cells. Schematic 
representation of EGFP and EGFP-(39-112) proteins.  B) MIN6 lysates 
expressing the ~37 kDa EGFP-(39-112) protein were used for 
immunoprecipitation with Syntaxin 4 antibody and immunoblotted for co-
precipitation of actin.  EGFP (29 kDa) in lysates served as control; the actin/Syn4 
ratio in EGFP-expressing lysates was set equal to 1 for normalization in each of 
4 immunoprecipitation experiments,*P< 0.05.  C) MIN6 cells were co-transfected 
with EGFP or EGFP-(39-112) with human proinsulin to report effects upon 
glucose-stimulated human C-peptide secretion only from transfected cells.  MIN6 
cells were pre-incubated in glucose-free MKRBB followed by stimulation with 20 
mM glucose for 30 min.  Data represent the mean ± S.E. from 5 independent 
experiments, normalized for total protein content.  Data normalized to 
unstimulated level for each construct to obtain stimulation index; *P< 0.05. 
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4.3.5 Disruption of F-actin Binding to Syntaxin 4 Enhances Granule 
Mobilization and Syntaxin 4 Accessibility 
Given the functional parallels between actions of EGFP-(39-112) with 
Latrunculin upon insulin secretion, we next sought to determine if the EGFP-(39-
112) inhibitor impacted granule localization.  MIN6 cells expressing either EGFP 
of EGFP-(39-112) were subfractionated and VAMP2 accumulation in PM and SG 
fractions assessed.  There was a ~1.6-fold increase in VAMP2 in the PM fraction 
of EGFP-(39-112) expressing cells compared to cells expressing EGFP alone 
(P< 0.0002, Figure 4-7).  This increase occurred under basal conditions, similar 
to that with Latrunculin treatment, and correlated with a ~30% decrease of 
VAMP2 from the SG fraction of EGFP-(39-112) cells relative to control (P< 
0.0001).  These data indicated that VAMP2-bound granules were inappropriately 
mobilized to the PM in the absence of the glucose stimulus.  
 In addition to increasing granule number at the PM, we speculated that the 
role of F-actin binding to Syntaxin 4 might be to negatively regulate Syntaxin 4 
accessibility by VAMP2.  To test this hypothesis, exogenous GST-VAMP2 
(soluble form, ΔTM) protein linked to sepharose beads was added to cell lysates 
to ‘probe’ for accessible Syntaxin 4, i.e. Syntaxin 4 that was available for binding.  
From unstimulated MIN6 cells left untreated or treated with vehicle (DMSO), the 
GST-VAMP2 was able to co-precipitate Syntaxin 4 protein (Figure 8A, lane 1). 
Interestingly however, GST-VAMP2 co-precipitated significantly more Syntaxin 4 
protein (2.4 ± 0.2, P< 0.0005) from lysates prepared from Latrunculin-treated 
cells (Figure 4-8A, lane 2).   
 However, even though Latrunculin-induced F-actin depolymerization 
rendered Syntaxin 4 more accessible to VAMP2 and also significantly increased 
the number of granules juxtaposed to the PM under basal conditions, the amount 
of endogenous VAMP2 co-immunoprecipitated with Syntaxin 4 was not 
coordinately increased in Latrunculin treated lysates when compare to vehicle-
treated lysates (Figure 4-8B, lanes 1-2).  This result argued against a simple 
inverse relationship between loss of F-actin binding corresponding to increased 
VAMP2 binding.  In addition, Syntaxin 4-VAMP2 association was similar between 
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EGFP-(39-112) and EGFP-expressing cell lysates (Figure 4-8B, lanes 3-4), even 
though F-actin binding to Syntaxin 4 was significantly reduced by expression of 
EGFP-(39-112).  Co-immunoprecipitation experiments were also conducted 
using PM fractions in place of whole cell lysates, similarly showing no increased 
association of VAMP2 with Latrunculin treatment of EGFP-(39-112) expression 
(Figure 4-8C).  This lack of impact upon VAMP2-Syntaxin 4 association 
correlates with lack of effect of Latrunculin or the EGFP-(39-112) fragment upon 
basal insulin release.  Thus, these data suggest that F-actin negatively regulates 
exocytosis via binding and blocking Syntaxin 4 accessibility, but also reveal the 
necessity for additional signals and/or steps required to trigger vesicle docking 
and fusion.  
 
4.4 DISCUSSION 
The importance of F-actin in insulin exocytosis has long been debated, yet 
the relevance of this to human insulin release has remained unknown.  Here we 
demonstrate for the first time that the potentiating effect of F-actin 
depolymerization upon glucose-stimulated insulin secretion is a conserved 
mechanism in human islets.  Syntaxin 4 was found to function as a novel actin 
binding protein, associating with F-actin via its N-terminal region containing the 
Ha-Hb domains.  This association was specific for Syntaxin 4 as Syntaxin 1A 
failed to directly bind to F-actin, which represents the first mechanistic evidence 
to support functionally distinct roles for these seemingly redundant isoforms in 
insulin granule exocytosis.  
 Our data show that Syntaxin 4-F-actin complexes were key to the 
mechanism by which F-actin regulates granule flow/mobilization.  One possible 
role for this complex might be that Syntaxin 4 serves as an attachment site of F-
actin to the plasma membrane, such that under basal conditions, Syntaxin 4 
might exist in two conformations (Figure 4-9 model, left panel):  1) ‘closed’ and 
bound by F-actin to block granule docking, consistent with data presented here 
showing that Syntaxin 4 was more accessible in cells treated with Latrunculin, 
and 2) ‘open’ and bound by a granule to support first-phase insulin release.   
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Figure 4-7 Like Latrunculin Treatment, Expression of EGFP-(39-112) Mobilizes 
Granules into the PM Compartment from the Storage Granule Pool Under Basal 
Conditions.  MIN6 cells were transfected with EGFP or EGFP-(39-112) DNA and 
48 h later were subfractionated and 20 μg protein from of each plasma 
membrane (PM) and storage granule (SG) fractions resolved on 12% SDS-
PAGE for immunoblotting.  Optical density scanning quantitation (each set of 
fractions normalized to EGFP control=100%) of VAMP2; data shown as average 
± S.E. of 4 independent sets of fractions.  β-catenin immunodetection was used 
to verify PM fraction integrity and equal protein loading in each set of PM 
fractions; Ponceau staining used to verify loading in SG and PM fractions in each 
experiment.  
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Figure 4-8 EGFP-Syntaxin4 (39-112) Expression Increases Syntaxin 4 
Accessibility but not VAMP2 Docking/Fusion at Syntaxin 4 Sites.  A) MIN6 cells 
were treated with vehicle (VEH) or Latrunculin (LAT) for 2 hours in glucose-free 
MKRBB for preparation of cleared detergent lysates for use in GST-VAMP2 
(soluble form) interaction assays.  Lysate protein (2-3 mg) was combined with 20 
μl GST-VAMP2 linked to beads, and precipitated proteins resolved on 10% SDS-
PAGE for Syntaxin 4 immunoblotting.  Data representative of 4 independent sets 
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of cell lysates.  B) MIN6 cells were left untransfected or were transfected with 
pEGFP or pEGFP-(39-112) DNA.  Forty-eight hours later cells were preincubated 
in glucose-free MKRBB for 2 hours and harvested for preparation of cleared 
detergent lysates.  Lysate protein (2 mg per reaction) was incubated with anti-
Syntaxin 4, co-immunoprecipitated proteins resolved on 12% SDS-PAGE for 
immunoblotting with anti-Syntaxin 4, anti-VAMP2 and anti-actin antibodies.  C) 
MIN6 cells were transfected with EGFP or EGFP-(39-112) DNA and 48 hours 
later were subfractionated and ~200 μg from the PM fraction was incubated with 
anti-Syntaxin 4, and co-immunoprecipitated proteins resolved on 12% SDS-
PAGE for immunoblotting with anti-Syntaxin 4 and anti-VAMP2.  Data 
representative of 3-6 independent experiments. 
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Upon glucose-stimulated actin reorganization (Figure 4-9, right panel), granules 
mobilize and may preferentially dock at ‘open’ Syntaxin 4 sites for subsequent 
fusion and insulin release.  The novel F-actin binding motif of Syntaxin 4 
functioned as a competitive inhibitor of the direct association between F-actin-
Syntaxin 4, mimicking actions of Latrunculin but without inducing global changes 
in cellular F-actin content.  This suggests that it may be through this interaction 
with Syntaxin 4 that F-actin exerts some of its “barrier” function in exocytosis. 
Whether this association also plays a role in the ‘positive’ role for F-actin in 
granule mobilization remains untested.  To date there is evidence to suggest that 
the positive role is mediated by vesicle-microfilament interactions (214-217).  
 However, VAMP2 association with Syntaxin was not increased upon 
release of F-actin binding from Syntaxin 4, which could be due to a requirement 
for additional stimulus-dependent/induced step(s) preceding the docking and 
fusion steps in exocytosis. It is known that VAMP2-Syntaxin binding occurs more 
efficiently in cells than in vitro, and this has been proposed to be due to a 
requirement for VAMP2 activation, Syntaxin accessibility, or both (5).  Thus, the 
reason that docking/fusion was not enhanced under conditions where Syntaxin 4 
accessibility and granule mobilization to the PM were both increased was 
because of a missing cellular signal triggered by glucose required for VAMP2 
activation.  The small Rho-family GTPase Cdc42 has been suggested as a 
possible candidate (5), based upon data showing:  1) Cdc42 binds directly to the 
N-terminal 28 residues of the VAMP2 protein on the insulin granule (210), 2) 
Cdc42 activation correlates with mobilization of VAMP2-bound granules to the 
PM, specifically in response to stimulation with glucose and not KCl (182,210), 3) 
de-regulation of Cdc42 activation via depletion of its GDI results in inappropriate 
fusion and release of insulin in the absence of the glucose stimulus (218), and 4) 
Cdc42 is required exclusively for the second phase/mobilization phase of insulin 
secretion from islets (182).  This would be a glucose-specific signal independent 
of the calcium signal that is thought to couple the calcium-sensitive Complexin 
protein in mediating Syntaxin 1A-dependent exocytosis in neurotransmitter 
release (219).  However, the specifics as to how glucose Cdc42 might activate  
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Figure 4-9 Model depicting potential mechanism of regulation of insulin 
exocytosis by F-actin-Syntaxin 4 complexes under basal and glucose stimulated 
conditions.  Left panel:  under basal conditions, F-actin binds to residues 39-112 
of Syntaxin 4 (Ha-Hb domains), decreasing Syntaxin 4 accessibility to VAMP2 
(consistent with Syntaxin 4 being in ‘closed’ conformation), and also restricting 
the flow of storage pool granules into the readily releasable pool at the plasma 
membrane.  However some Syntaxin 4 sites are occupied by granules, 
consistent with the requirement for Syntaxin 4 in first-phase insulin release (26). 
Right panel:  glucose stimulation results in the localized reorganization of actin 
which allows the storage pool of insulin granules to traffic to the plasma 
membrane, and increases accessibility of VAMP2 to Syntaxin 4 sites (‘open’ 
conformation) to facilitate granule fusion and insulin release. An additional step 
triggered by glucose to ‘activate’ VAMP2 docking is suggested (see question 
mark). 
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VAMP2 to promote granule targeting to particular Syntaxin-based active sites to 
facilitate second-phase secretion is unclear because the characterization of such 
active sites remains incomplete. 
 Our finding that Syntaxin 4 in particular associated directly with F-actin 
represents a step towards distinguishing the functions of Syntaxin 4 from 
Syntaxin 1A, and in characterizing the active site used for second-phase 
secretion.  Syntaxin 4 binding to F-actin was mediated via its N-terminal Ha-Hb 
region and not through its H3/SNARE domain, consistent with alignments 
showing lesser conservation in the N-terminus of these Syntaxin isoform (35% 
identical in Ha, 38% in Hb versus 56% in H3 domain).  Moreover, VAMP2 
contains the conserved SNARE domain and yet failed to bind.  Only very recently 
has another SNARE protein been reported to directly interact with actin, the R-
SNARE protein Ykt6p, although the binding motif remains to be identified (220).  
A second distinguishing characteristic was the slow and incomplete re-
association of F-actin with Syntaxin 4 after the initial glucose-induced disruption 
of binding in the co-immunoprecipitation studies, relative to the kinetics of F-actin 
and Syntaxin 1A association.  These kinetic differences are consistent with the 
notion that Syntaxin 4 docking sites are accessible and operative during second-
phase secretion, although this awaits further examination using primary beta 
cells.  
 Differential localization to caveolae may also mark distinct syntaxin-based 
active sites.  Data from multiple studies in divergent cell types show that Syntaxin 
1A is clustered into ‘active sites’ by caveolae (221-223).  A recent study used 
STED microscopy to show that the SNARE motifs of Syntaxin 1 and 4 mediate 
specific Syntaxin clustering by homoligomerization, thereby spatially separating 
sites for different biological activities (224).  Moreover, caveolar clustering can be 
induced by localized F-actin depolymerization (225).  Furthermore, L-type 
calcium channels have been localized in or nearby caveolae (226), and over-
expression studies performed in cultured beta cells showed that increased 
Syntaxin 1A protein inhibited L-type calcium channel activity, whereas over-
expression of Syntaxin 4 was without effect (227).  
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 The Syntaxin 4 fragment comprising the Ha-Hb domain markedly 
increased granule flow to the PM, mimicking the effects induced by Latrunculin in 
unstimulated cells, as well as mimicking the effect of acute glucose stimulation 
(210).  Like glucose stimulation, the 39-112 inhibitory fragment did not cause 
global changes in F-actin content, while Latrunculin is a global depolymerizing 
agent.  These data suggest then that Syntaxin 4-F-actin complexes may be a 
target of glucose-induced localized F-actin reorganization, and may be the 
means by which glucose coordinates the timing of increased Syntaxin 4 
accessibility with increased granule accumulation at the plasma membrane.  
Alternatively, it is possible that this 39-112 fragment interfered with Syntaxin 4 
binding to other factors involved in actin remodeling. Of the SNARE and SNARE 
accessory proteins, only n-Sec1/Munc18 and Munc13 proteins are known to 
interact with the N-terminal helices of Syntaxin proteins (113,151), yet we failed 
to see alteration in endogenous Syntaxin 4-Munc18c association in cells 
expressing the 39-112 fragment, and the Syntaxin 4 isoform has yet to be shown 
to interact with Munc13.  However Syntaxin 4 has been shown to directly bind the 
actin binding protein α-fodrin (228), and in 3T3L1 adipocytes the Syntaxin 4-
fodrin complex is functionally important in insulin-stimulated GLUT4 translocation 
(173).  In addition, the F-actin severing proteins such as Gelsolin and Scinderin 
have been shown to be important in stimulus-secretion coupling in cultured beta 
cells (175,229), and pilot data from our laboratory suggest that Syntaxin 4 may 
associate with both Scinderin and Gelsolin under unstimulated conditions (Kalwat 
and Thurmond, unpublished). 
 In summary, these studies support a new model whereby the negative 
‘barrier’ function of cortical F- actin is mediated in part by a discrete and direct 
interaction with Syntaxin 4 at the plasma membrane, and further reveal the 
existence of a new step in stimulus-induced granule exocytosis that precedes 
docking.  In islet beta cells this new step requires glucose as the stimulus. 
Although the Syntaxin 4-F-actin interaction will likely impact exocytosis events in 
many cells, given the ubiquitous expression pattern of these proteins, the kinetics 
of biphasic insulin release are quite distinct from events such as neurotransmitter 
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secretion or GLUT4 translocation.  Second-phase insulin release can occur over 
a long time period (hours), requiring the readily releasable pool at the plasma 
membrane to be refilled from the more intracellular storage pool in a carefully 
metered manner.  F-actin is well-suited to this task, since release and refill 
events must occur across the expanses of the cell, yet be coordinated to occur 
simultaneously to achieve the precisely-timed biphasic release of insulin.  Future 
studies will be required to determine whether the importance and specific 
utilization of the Syntaxin 4-F-actin complex in these other cell types.  
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CHAPTER 5: CONCLUDING REMARKS 
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Type 2 Diabetes results from defects in multiple organs, wherein the 
exocytosis mechanism of pancreatic insulin secretion and subsequent insulin-
stimulated glucose clearance by peripheral tissues are compromised.  Both 
pancreatic beta cell insulin secretion and skeletal muscle/adipose tissue glucose 
transport have been shown to utilize Syntaxin 4-Munc18c complexes, and with 
commonalities in molecular mechanism.  In this thesis, I have used 
complementary in vitro, cell-based approaches, and animal tissue extracts to 
detail protein modifications and protein-protein interactions that affect SNARE 
core complex assembly and vesicle exocytosis mechanisms.  Using biochemical, 
molecular and cellular biology techniques, I have been able to determine that 
Syntaxin 4-Munc18c complexes are regulated through tyrosine phosphorylation 
and interaction with factors such as Doc2β, the Insulin Receptor, and F-actin.  
More specifically, the tyrosine phosphorylation of Munc18c at residues Y219 and 
Y521, regulate its interaction with Syntaxin 4.  In the beta cell, stimulus induced 
Munc18c Y219 phosphorylation results in a 2-fold decrease in Syntaxin 4-
Munc18c association and a parallel 2-fold increase in Munc18c-Doc2β formation 
at the plasma membrane resulting in an increase in insulin secretion. We have 
termed this exchange “the switch mechanism.”  Similarly, Munc18c Y219 
phosphorylation is also seen in adipocytes, along with phosphorylation at a 
second site, Y521.  In response to insulin, the Insulin Receptor interacted with 
Munc18c with the same time course as observed for the stimulus-induced 
phosphorylation of Munc18c.  Further investigation identified the Insulin Receptor 
as the first example of a Munc18c tyrosine kinase, phosphorylating Munc18c at 
Y521.  Interestingly, Y521 resides in a disordered region, a type of region thought 
to be a “hot spot” for protein phosphorylation and protein-protein interaction sites 
(230-232).  Finally, it was found that stimulus-induced changes occurred also 
with Syntaxin 4, in the beta cells.  Syntaxin 4-mediated insulin release requires F-
actin remodeling to mobilize insulin granules to the plasma membrane.  Syntaxin 
4 was seen to directly associate with F-actin in MIN6 beta cells, and disruption of 
this complex correlates with an increase in glucose-stimulated insulin secretion. 
Altogether, this thesis demonstrates that modulating Syntaxin 4-Munc18c 
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complexes through post-translational modifications and through binding partners 
can regulate both insulin secretion and glucose uptake.   
My studies have also helped to clarify the Munc18c-Syntaxin 4 interaction 
in beta cells and mouse skeletal muscle, in terms of whether Munc18c interacts 
with Syntaxin 4 alone or with Syntaxin 4 when it is in the SNARE complex.  There 
are three models in the literature to date:  (1) Where Munc18c holds Syntaxin 4 
in a “closed” conformation exclusive of the SNARE complex (110-112); (2) 
Where Munc18c can interact with the Syntaxin 4-SNARE complex through an N-
terminal peptide of Syntaxin 4 (114,129,185-187); (3) And most recently, where 
Munc18 proteins can bind to the SNARE complex via the four alpha-helical 
bundle (116).  My data suggest that model one holds true in the beta cell, 
adipose and muscle.  This model is confirmed by my data in which I delineated 
the minimal binding domain of Syntaxin 4 that interacts with Munc18c to be its 
Hc-Linker Region (residues 118-194).  Model 3 is disputed based upon in vitro 
binding studies which failed to show that deletion of the SNARE interacting 
domain (H3) of Syntaxin 4 impairs its association with Munc18c.  Model 2 is 
undermined by failure of the Syntaxin 4 N-terminal peptide to function as an 
effective competitive inhibitor of endogenous Syntaxin 4-Munc18c complexes as 
well as its inability to suffice as a Munc18c binding peptide (115,139).  Molecular 
modeling studies support the the hypothesis that the Hc-Linker region as the 
critical contact region on Syntaxin 4, the region which also confers interaction 
with Munc18c, and has further unveiled new residues in which to examine for 
roles in Munc18c-Syntaxin 4 interaction.  Some of these residues exist 
exclusively in the Syntaxin 4 isoform, and may be critical specifiers of the 
Syntaxin 4-Munc18c interaction. 
A previous study from the laboratory has shown that Munc18c interacts 
with Doc2β through its second C2 domain (C2B), exclusive from formation of 
Syntaxin 4-Munc18c complexes at the plasma membrane in beta cells.  
Furthermore, I have shown that the phosphorylated form of Munc18c interacts 
with Doc2β at the plasma membrane.  Interestingly, the Doc2β binding site on 
Munc18c (residues 173-255) includes the regulatory Y219 site, suggesting that 
 134
Doc2β may have to dissociate before Munc18c can be dephosphorylated by a 
phosphatase.  Doc2β exerts positive effects on insulin granule and GLUT4 
vesicle exocytosis, and while the precise mechanisms are still not understood, 
one possibility is that by binding to phosphorylated Munc18c, Doc2β relieves the 
inhibition that Munc18c exerts on Syntaxin 4 (145,146).  Alternatively, a very 
recent report shows that Doc2β interacts directly with the SNARE complex (149).  
Doc2β may serve as a scaffold to capture transiently dissociating Munc18 
proteins, since it can dock Munc18-1 through its first C2 domain (C2A) and 
Munc18c through its second C2 domain (C2B), to facilitate SNARE-mediated 
exocytosis events (146,148) 
Insulin-stimulated Munc18c tyrosine phosphorylation and disruption of 
Munc18c-Syntaxin 4 complexes was observed to occur early in the time course 
of insulin signaling in adipocytes or skeletal muscle (within 5 minutes of insulin 
stimulation), yet occurred in a manner independent of PI3K, suggesting that IR 
signaling and preparation for SNARE-mediated GLUT4 vesicle docking occurs 
simultaneously in the adipose and skeletal muscle.  After 15 minutes of insulin 
stimulation, Munc18c tyrosine phosphorylation had returned to basal, implying 
the activation of a Munc18c phosphatase downstream in the insulin signaling 
cascade.  In my studies, the Insulin Receptor was identified as the first known 
Munc18c tyrosine kinase effectively utilizing Munc18c as a direct substrate in 
vitro kinase assays.  Interestingly, both tyrosines Y219 and Y521 are in the same 
3D structural vicinity, suggesting that this region of Munc18c may be key in 
regulating Munc18c-Syntaxin 4 and Munc18c-Doc2β interactions.  Furthermore, 
depletion of Munc18c decreased GLUT4 translocation in adipocytes, similar to 
the decrease in insulin granule localization in MIN6 beta cells (56), suggesting 
that Munc18c plays a conserved positive role in exocytosis.  Studies are now 
underway to determine the functional effect of Y219 and Y521 phosphorylation of 
Munc18c for GLUT4 translocation to the plasma membrane.  
Under non-glucose stimulated conditions, Syntaxin 4 (residues 39-112, 
Ha-Hb Domains), was found to directly bind to F-actin but not G-actin, and block 
granule localization to the plasma membrane and SNARE core complex 
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assembly.  The role of Munc18c in this process is unknown.  However, pilot data 
from our lab has revealed that Munc18c association with Syntaxin 4 was 
diminished in cells devoid of F-actin (depolymerized to G-actin by Latrunculin 
treatment) suggesting that this interaction is somehow linked to intact filaments.  
Moreover, depletion of Munc18c resulted in reduced Syntaxin 4 association with 
F-actin (unpublished data, Oh and Thurmond).  Future experiments will test how 
Munc18c associates with F-actin-Syntaxin 4 and why its participation is important 
for Syntaxin 4 function. 
Munc18c and Syntaxin 4 are clearly common links in the known 
mechanisms of insulin granule exocytosis and GLUT4 vesicle translocation, and 
yet the molecular details of their actions in these processes remain incomplete.  
With regards to Munc18c, significant progress has been made in its 
characterization as a positive effector of both processes, as well as the recent 
identifications of novel binding factors that implicate it in both Syntaxin 4-
dependent (vesicle docking/fusion at the plasma membrane) and Syntaxin 4-
independent (granule mobilization/localization) mechanisms.  The possibility that 
Munc18c functions in a Syntaxin 4-independent role in facilitating insulin granule 
delivery is particularly important, given that granule recruitment to the readily 
releasable pool of a β-cell is a rate-limiting component of insulin release.  
Pharmacological targeting of Munc18c function, directly or indirectly, via a 
binding partner implicated in that mechanism, could presumably exert profound 
effects upon the capacity of the β-cell to sustain insulin release beyond the first 
few minutes.  The ability to sustain insulin release in a regulated biphasic manner, 
as opposed to the constitutive release triggered by current popular oral 
medications which cause hypoglycemia and hasten beta cell failure, would be of 
tremendous advantage as it would allow for restoration of glucose homeostasis 
with lower resting insulin levels and hence less risk of hypoglycemic episodes.   
 In addition to gaining more insight into how Munc18c-Syntaxin 4 
complexes are regulated, it will be particularly important to determine how and 
why Syntaxin 4 and Munc18c protein levels decrease under conditions of obesity 
and Type 2 diabetes in humans and rodent models.  Interestingly, knockout and 
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transgenic mouse model studies suggest that Munc18c protein levels are 
controlled by Syntaxin 4.  Thus, future studies aimed towards gaining the ability 
to control Syntaxin 4 expression could be advantageous to improving whole body 
glucose homeostasis.   
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APPENDIX B: ADDITIONAL EXPERIMENTS 
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Insulin Signaling and Munc18c Tyrosine Phosphorylation in the Beta Cell.  A) 
MIN6 cells were pre-incubated in MKRBB with or without 100 μM HNMPA-(AM)3 
for 2 hour prior to glucose stimulation (20mM) for 5 min.  Munc18c was 
immunoprecipitated and co-immunoprecipitated proteins resolved by 10% SDS-
PAGE and immunoblotted with anti-Munc18c and anti-IR.  B) MIN6 beta cells 
were pre-incubated in MKRBB for two hours and stimulated with insulin (100nM) 
for 5 minutes.  Munc18c was immunoprecipitated and co-immunoprecipitated 
proteins resolved by 10% SDS-PAGE and immunoblotted with anti-Munc18c and 
anti-4G10 (P-Tyr).  C)  MIN6 cells were pre-incubated in MKRBB with or without 
100 μM HNMPA-(AM)3 for 2 hour prior to glucose stimulation (20mM) for the 
indicated times. Insulin secretion was measured by RIA.  
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